Phase 1b Safety Run -In Study   Pancreatic Cancer Action Network  
Confidential and Proprietary  1 PanCAN-SR1 Original Version: 22JUL2020 
  
A PHASE 1B  STUDY TO DETERMINE THE SAFETY 
AND TOLERABILITY AND CONFIRM THE DOSE OF 
CANAKINUMAB AND SPARTALIZUMAB IN 
COMBINATION WITH NAB -PACLITAXEL AND 
GEMCITABINE FOR PATIENTS WITH METASTATIC 
PANCREATIC CANCER  
 
 
DESCRIPTION/CATEGORY:  Phase 1b Safety Run -In Study  
DATE FINAL:  22 July 2020 
IND NUMBER:   
PROTOCOL NUMBER:  PanCAN- SR1 
PROTOCOL VERSION:  1.2 
PRINCIPAL INVESTIGATORS:    
  
  
  
  
  
SPONSOR NAME/ADDRESS:  Pancreatic Cancer Action Network  
 1500 Rosecrans Avenue, Suite 200  
 Manhattan Beach, CA 90266  
 
 
  CONFIDENTIAL  
This protocol is provided to you as an Investigator, potential Investigator, or consultant for 
review by you, your staff, and ethics committee/institutional review board. The information 
contained in this document is regarded as confidential and, except to the extent necessary to 
obtain informed consent, may not be disclosed to another party unless such disclosure is 
required by law or regulations. Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further disclosed by them.  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  2 PanCAN-SR1 Original Version: 22JUL2020 
 GLOSS ARY AND LIST OF ABBREVIATIONS  
 
AE   Adverse Event  
ALK  Anaplastic large cell lymphoma  
ALP   Alkaline phosphatase  
ALT (SGPT)  Alanine Aminotransferase  
ANC   Absolute neutrophil count  
AST (SGOT)  Aspartate aminotransferase  
β-hCG   β- human chorionic gonadotropin  
BUN   Blood urea nitrogen  
CANTOS  the Canakinumab Anti -Inflammatory Thrombosis Outcomes Study  
Ca  Cancer; carcinoma  
Ca  Calcium  
CAPS   Cryopyrin Associated Periodic Syndromes  
CA 19 -9 Carbohydrate antigen 19 -9 
CBC   Complete blood count  
CLIA   Clinical Laboratory Improvement Amendments  
CR  Complete remission / complete response  
CRP   C- reactive protein  
CRF/eCRF  Case Report Form/electronic Case Report Forms  
CRF   Chronic renal failure  
CRO   Clinical Research Organization  
CT  Computerized tomography (scan)  
CTCAE  Common Terminology Criteria for Adverse Events  
CTLA -4 Cytotoxic T -lymphocyte Antigen-4  
dL  Deciliter  
DSMB  Data and Safety Monitoring Board  
ECG   12- lead electrocardiogram (ECG)  
ECOG   Eastern Cooperative Oncology Group   
EDC   Electronic Data Collecti on tool  
EDTA   Lavender top tubes  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  3 PanCAN-SR1 Original Version: 22JUL2020 
 FMF   Familial Mediterranean Fever  
FDA   Food and Drug Administration  
FFPE   Formalin -fixed paraffin -embedded  
FSH  Follicle -stimulating hormone  
FWA   Federal -wide Assurance  
GA  Gemcitabine + nab -paclitaxel  
mGPS  modified Glasgow Prognostic Score  
GCP   Good Clinical Practice  
g  Gram (unit)  
Hgb  Hemoglobin 
HIDS   Hyperimmunoglobulin D Syndrome  
IgG1/κ  Immunoglobulin G1/ κ isotype subclass  
ICF   Informed Consent Form  
ICH GCP  International Conference on Harmonisation - Good Clinical Practice  
IL-1  Interleukin -1 cytokine 
IL-1α  Interle ukin-1α cytokine  
IL-1β  Interleukin -1β cytokine  
IL-1R  Interl eukin-1 Receptor  
IL-1Ra  Interleukin -1 Receptor agonist  
IL-6  Interl eukin-6 cytokine  
IB   Investigator Brochure 
IND   Investigational  New Drug  
IRB   Institutional Review Board  
IV  Intravenous  
LD  Longest diameter  
LLN   lower limit of normal  
mg  milligram 
m2  meter square 
mm  millimeter  
MRI   Magnetic Resonance Imaging  
MKD   Mevalonate Kinase Deficiency  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  4 PanCAN-SR1 Original Version: 22JUL2020 
 MMR -D Mismatch repai r deficient state  
MDSC s M yeloid -derived suppressor cells  
NCI   National Cancer Institute  
NGS   Next -generation sequencing  
NIH   National Institutes of Health  
ORR   Overall Response Rate 
OS  Overall Survival  
PanCAN  Pancreatic Cancer Action Network  
PD  Progressive disease  
PDAC   Pancreatic adenocarcinoma  
PET  Positron Emission Tomography  
PFS  Progression free Survival  
PI   Principal Investigator  
PK Pharmacokinetic  
PO  Oral administration/by mouth  
PR  Partial Response  
PD-1  Programmed cell D eath protein-1 
PD-L1  Programmed cell Death ligand -1 
PD-L2  Programmed cell Death ligand -2 
PT  Prothrombin time  
PTT  Partial thromboplastin time  
RBC   Red blood cell / red blood count  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE   Serious adverse event  
SJIA   Systemic  Juvenile Idiopathic Arthritis  
SD  Stable disease  
SOC   Standard of Care  
SOP   Standard operating procedures  
TLR   Toll-like receptors  
TGF β  Transforming  growth factor -β 
TRAPS  Tumor Necrosis Factor Receptor Associated Periodic Syndrome  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  5 PanCAN-SR1 Original Version: 22JUL2020 
 TAMs   Tumor associated microphages  
TAN   Tumor associated neutrophils  
ULN   Upper limit of normal  
WBC   White blood cell count  
WCC   White cell count  
WOCBP  Women of child -bearing potential
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  6 PanCAN-SR1 Orig Version: 22JUL2020 
 TABLE OF CONTENTS  
1.0 INTRODUCTION ............................................................................................................ 14  
1.1 Background ...................................................................................................................... 14  
1.1.1  Prevalence and outcomes in pancreatic adenocarcinoma  14 
1.1.2  Prognosis and staging  ....................................................................................................... 14  
1.1.3  Current treatment landscape  ............................................................................................. 14  
1.1.4  Challenges in pancreatic cancer drug development  ........................................................... 15  
1.2 Study overview ................................................................................................................. 15  
1.3  Overview of IL -1β ........................................................................................................... 16  
1.3.1  IL-1β in cancer  ................................................................................................................. 17  
1.3.2  IL-1β in pancreatic cancer  ................................................................................................ 18  
1.3.3  Anti-IL-1β therapy effect on cancer in CANTOS .............................................................. 19  
1.3.4  Immunotherapy in pancreatic cancer ................................................................................. 19  
1.3.5  Inflammation in pancreatic cancer and rationale to combine with a IL -1β inhibitor  ........... 21  
1.4 Overview of canakinumab  ................................................................................................ 21  
1.4.1  Non-clinical experience with canakinumab  ....................................................................... 22  
1.4.2  Clinical experience with canakinumab in cancer  ............................................................... 22  
1.5 Overview of spartalizumab  ............................................................................................... 23  
1.5.1  Non-clinical experience with spartalizumab  ...................................................................... 24  
1.5.2  Clinical experience with spartalizumab  ............................................................................. 24  
1.6 Rationale for the dosing regimen of canakinumab ............................................................. 26  
1.7 Rationale for the Study Regimen  ...................................................................................... 28  
2.0 OBJECTIVES AND ENDPOINTS ................................................................................... 29  
2.1 Overview  .......................................................................................................................... 29  
2.2 Study Design ....................................................................................................................... 31  
3.0 STUDY POPULATION ................................................................................................... 32  
3.1  Study Duration ................................................................................................................. 32  
3.2 Inclusion Criteria  ..............................................................................................................  33 
3.3 Exclus ion Criteria  ............................................................................................................. 34  
4.0 STUDY TREATMENT AND DOSE MODIFICATION  .................................................. 38  
4.1 Administration and Dosing ............................................................................................... 38  
4.1.1  Gemcitabine and nab -paclitaxel  ........................................................................................ 39  
4.1.2  Canakinumab  ................................................................................................................... 39  
4.1.3  Spartalizumab ................................................................................................................... 40  
4.1.4  Initial Dosing Schedule  40 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  7 PanCAN-SR1 Orig Version: 22JUL2020 
 4.1.5  Dose Recommendation Guideline for Study Cohort  41 
4.1.5.1  Definitions of Dose Limiting Toxicities (DLTs)  42 
4.2 Dose Modifications  44 
4.2.1  Dose Modifications of Gemcitabine and Nab -Paclitaxel  44 
4.2.2  Dose modification and dose interruption of spartalizumab and canakinumab  47  
4.2.3  Dose Modification Guidelines for Canakinumab  48 
4.2.4  Dose modification and Dose Interruption for spartalizumab  51 
4.2.4.1  General dose modification instructions for spartalizumab  52 
4.2.5  Dose modification and Management Requirements for Potential Immune -Mediated 
Adverse Events (irAEs)  52 
4.2.5.1  Guidance for Corticosteroids Tapering for Management of Immune -Related AEs  65  
4.2.6  Permanent discontinuation of spartalizumab  65 
4.3 Follow -up for toxicities  66 
4.3.1  Follow -up of Immune -Related AEs  66 
4.3.2  Follow -up of Potential Drug- Induced Liver Injury (DILI) Cases  66 
4.3.3  Follow -up for Infections  68 
4.4 Concomitant Medications  ................................................................................................. 68  
4.4.1  Permitted Concomitant Therapy  69 
4.4.2  Permitted concomitant therapy requiring caution and/or action  70 
4.4.3  Prohibited concomitant therapy  71 
4.4.3.1  Prohibited concomitant therapy for spartalizumab  72 
4.4.3.2  Prohibited concomitant therapy for canakinumab  72 
4.5 Overdose  .......................................................................................................................... 73  
4.6 Investigational Product Accountability and Disposal  ........................................................ 73  
4.7 Investigational Product Compliance  ................................................................................. 73  
5.0 STUDY ASSESSMENTS  ................................................................................................ 74  
5.1 Study Schedule  ................................................................................................................. 75  
5.2 Baseline P rocedures  ......................................................................................................... 79  
5.3 Treatment Procedures  ....................................................................................................... 81  
5.4 Study Treatments .............................................................................................................. 83  
5.4.1  Study Treatment Beyond Disease Progression  85 
5.4.2  Study Treatment Duration  ................................................................................................ 85  
5.5 End of Treatment Procedures  ............................................................................................ 86  
5.6 Pharmacokinetic (PK)  Blood Draw Schedules .......................... 88  
5.7 As Needed Assessments  ................................................................................................... 90  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  8 PanCAN-SR1 Orig Version: 22JUL2020 
 5.8 Safety Follow Up (30 -day, 60- day, 90- day, 120- day and 150- day As sessments)  ............... 91  
5.9 Post Treatment Efficacy Follow Up  .................................................................................. 92  
5.10  Survival Follow Up .......................................................................................................... 93  
5.11  Patie nt Discontinuations  ................................................................................................... 93  
 
 
  
 
7.0 SAFETY ASSESSMENTS ............................................................................................... 97  
7.1 Defini tion of Adverse Event  ............................................................................................. 97  
7.2 Definition of a Serious Adverse Event  .............................................................................. 98  
7.3 Monitoring ....................................................................................................................... 98  
7.4 Reporting  ......................................................................................................................... 99  
7.4.1  Adverse Events ................................................................................................................. 99  
7.4.2  Severity of AEs  .......................................................................................................... 100  
7.4.3  Causality of AEs  ............................................................................................................ 101  
7.4.4  Adverse Events of Special Interest  .................................................................................. 101  
7.4.5  Serious Adverse Events  .................................................................................................. 102  
7.4.6  Manufacturer Communications  ....................................................................................... 103  
7.4.7  End of Treatment safety Follow -up................................................................................. 103  
8.0 RESPONSE ASSESSMENT  .......................................................................................... 103  
8.1 Methods for Evaluation of Measurable Disease  .............................................................. 104  
8.1.1  Imaging Requirements  .................................................................................................... 104  
8.1.2  Tumor Marker Requirements  .......................................................................................... 104  
9.0 STATISTICAL CONSIDERATIONS  ............................................................................ 105  
9.1 Analysis Sets  .................................................................................................................. 105  
9.1.1  Full Analysis Set  ............................................................................................................ 105  
9.1.2  Safety Set  ....................................................................................................................... 105  
9.1.3  Dose -Deter mining Analysis Set (DDS)  ........................................................................... 105  
9.1.4  Pharmacokinetic Analysis Set  ......................................................................................... 105  
9.2 Subject Demographics and Other Baseline Characteristics .............................................. 106  
9.3 Study Treatment and Dose Exposure  .............................................................................. 106  
9.4 Study Primary Objective ................................................................................................. 106  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  10 PanCAN-SR1 Orig Version: 22JUL2020 
 12.0  RECORD KEEPING/QUALITY CONTROL  ................................................................ 121  
12.1   Inspection ...................................................................................................................... 121  
12.2  Record Retention  ............................................................................................................ 122  
13.0  CONFIDENTIALITY .................................................................................................... 123  
14.0  REFERENCES  ............................................................................................................... 124  
15.0  APPENDICES  ............................................................................................................... 132  
APPENDIX A ......................................................................................................................... 132  
APPENDIX B  ......................................................................................................................... 133  
1 Statistical model for triple combination  .......................................................................... 133  
1.1 Single agent parts  ........................................................................................................... 133  
1.2 Interaction  ...................................................................................................................... 133  
1.3 Meta -analytic  framework  ................................................................................................ 134  
1.3.1  Single agent part  134 
1.3.2  Interaction  134 
1.4 Reference doses for spartalizumab, canakinumab and chemotherapy  .............................. 134  
1.5 Prior specification  .......................................................................................................... 135  
1.5.1  Single agent  135 
1.6 Interactions between spartalizumab, canakinumab, and chemothereapy  .......................... 136  
1.7 Historical data  ................................................................................................................ 137  
1.8 Summary of prior distribution of DLT rates  .................................................................... 139  
APPENDIX C  ......................................................................................................................... 140  
 
  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  11 PanCAN-SR1 Orig Version: 22JUL2020 
 TABLES AND FIGURES  
 
Figure  1. Involvement of IL -1 in Cancer  ................................................................................... 17  
Table 1 -1. Steady State PK Parameters of canakinumab  ............................................................ 26  
Table 2 -1. Study Objectives and Endpoint Summary ................................................................. 29  
Table 4 -1. Initial Dose and Treatment Schedule  ........................................................................ 39 
Table  4-2. Provisional Dose Levels for canakinumab with fixed dosages of spartalizumab, 
gemcitabine and nab -paclitaxel  ......................................................................................... 41  
Table  4-3. Criteria for Defining Dose -Limiting Toxicities  ......................................................... 42  
Table 4-4. Dose Modifications for Gemcitabine and Nab -paclitaxel  .......................................... 44  
Table 4-5. Dose Modifications for Neutropenia and Thrombocytopenia at the Start of a Cycle or 
Within a Cycle  ................................................................................................................. 45  
Table  4-6. Dose Modifications for Other Clinically Significant Non -Hematological Toxicities  . 46 
Table 4 -7. Criteria for Dose Interruption and Re -Initiation of Canakinumab for Adverse Events 
at least possibly related to canakinumab treatment  ………………………………………..47  
Table 4 -8. Mandatory D ose Modification Requirements for Potential Immune -Related Diarrhea 
or Colitis  at least possibly related to spartalizumab treatment  ........................................... 53  
Table 4 -9. Mandatory Dose Modification Requirements for Immune -Related Liver Laboratory  
Alterations  at least possibly related to spartalizumab treatment  ......................................... 54  
Table 4 -10. Mandatory Dose Modification Requirements  for Immune -Related Skin Events  at 
least possibly related to spartalizumab treatment ............................................................... 57  
Table 4 -11. Mandatory Dose Modification Requirements  for Im mune -Related Nephritis  at least 
possibly related to spartalizumab treatment ....................................................................... 58  
Table 4 -12. Mandatory Dose Modification Requirements  for Immune -Related Pneumonitis  at 
least possibly related to spartalizumab treatment ............................................................... 59  
Table 4 -13. Mandatory Dose Modification Requirements  for Immune -Related Endocrine Event s 
at least possibly related to spartalizumab treatment  ........................................................... 60  
Table 4 -14. Mandatory Dose Modification Requirements  for “Other” Immune -Related Potential 
AEs at least possibly related to spartalizumab treatment  ................................................... 61  
Table 4 -15. Mandatory Dose Modification Requirements  for Immune -Related Infusion -Related 
Reactions  or Injection Site Reactions  at least possibly related to spartalizumab treatment  . 63 
Table 4 -16. Guidance for Specific Clinical and Diagnostic Assessments  ................................... 67  
Table 5-1. Schedule of Assessments  .......................................................................................... 74  
Table 5-2. ECOG Performance Status  ....................................................................................... 80  
Table 5-3. Pharma cokinetic and Blood Draw  Log for Canakinumab .................. 87  
Table 5-4. Pharmacokinetic and Blood Draw  Log for Spartalizumab  ................. 88  
Table 5-5. Pharmacokinetic Blood Draws for Gemcitabine  ....................................................... 88  
Table 5-6. Pharmacokinetic Blood Draws for Nab-paclitaxel  .................................................... 89  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  12 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 7 -1. AE Severity and Intensity  ....................................................................................... 100 
Table 7-2. AE Causeality  Assessments  .................................................................................... 100  
Table 9-1. Hypothetical Dose Escalation Scenarios  ................................................................. 107   
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  13 PanCAN-SR1 Orig Version: 22JUL2020 
 1.0 I NTRODUCTION  
1.1 Background 
1.1.1  Prevalence and outcomes in pancreatic adenocarcinoma  
Pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States 
and is projected to become the fourth leading cause of cancer death by 2020  (Siegal et al. 2020, 
Amer Cancer Society Facts and Figures 2017) . While the inciden ce and death rates from cancer 
are declining overall, these rates for pancreatic cancer are on the rise. Pancreatic cancer has the highest incidence -to-mortality ratio of any solid tumour (Bray et al. 2018).  An estimated 56,770 
people in the US will be diagnosed with pancreatic cancer in 201 9, and 45,750 are expected to 
die from their disease  (Howlander et al. 2017) . 
 
1.1.2  Prognosis and staging 
The majority of  patients (52%) are initially diagnosed with advanced disease that is inoperable. 
Median survival for untreated Stage IV disease (metastatic) is only  4.5 months with 5-year 
survival for these patients estimated  at  less than 3%  (Amer. Cancer Society Facts and Figures 
2017, Howlander et al. 2017, Malvezzi  et al. 2013) .
 
 
For 15 to 20% of newly diagnosed patients, long -term survival can be achieved with treatment by 
surgical resection followed by adjuvant therapy  (Bray et al. 2018) . However, recurrence is 
common, even in cases where optimal resection is achieved. For patients who present with locally 
advanced disease, treatment consists of chemotherapy with or without radiation.  For patients with more advanced disease, including metastatic disease, treatment usually consists of investigational 
agents, chemotherapy alone, and/or supportive care.  
 
1.1.3  Current  treatment landscape  
Gemcitabine monotherapy was considered a standard therapy in metastatic disease for many years 
but provided only a marginal improvement in survival.
 The addition of erlotinib or capecitabine 
to gemcitabine have shown small incremental improvements in survival  (Moore et al . 2007) . 
More recently, the use of combination therapies such as gemcitabine plus nab-paclitaxel  (Von 
Hoff et al.  2013) and FOLFIRINOX  regimen (5 -fluouracil, leucovorin, oxaliplatin and irinotecan)  
(Conroy  et al.  2011) have become standard -of-care for patients with PDAC ; however, impact on 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  14 PanCAN-SR1 Orig Version: 22JUL2020 
 survival remains modest with median overall sur vival less than 12 months and the 2 -year survival 
rate less than 7%.  
 
1.1.4 Challenges in pancreatic cancer drug development  
Drug development in pancreatic cancer has been challenged by a number of factors hindering 
pharmaceutical interest in this space. Advanced stage at diagnosis and high patient morbidity are 
major challenges in improving disease outcomes, specially within this naturally described older 
patient population.  
 
The desmoplastic tumor microenvironment is known to limit drug penetration and contributes to 
chemoresistance and, more recently described, immunoresistance (Clinical Dev Success Rates 
2006-2015, Mahadevan et al. 2007, Minchinton et al. 2006). T hough critical histopathologic 
aspects of the disease are defined, its molecular underpinnings require further elucidation 
(Whatcott et al. 2015) .  Driver mutations in KRAS, p53 and p16 are widely characterized, but 
large -scale “druggable” targets that effect response remain unknown  (Jones et al. 2008) . This 
leads to challenges in iden tifying rationale and biologically driven therapeutic combinations 
needed to have a greater impact on patients with advanced disease.  
  
1.2 Study overview  
This study combines canakinumab (ACZ885), a high -affinity human anti -interleukin -1β (IL -1β) 
monoclo nal antibody  (mAb) , and spartalizumab (PDR001), a mAb directed against human 
Programmed Death -1 (PD -1), with the chemotherapy combination of gemcitabine and nab -
paclitaxel. This study will confirm  for this 4-drug combination  the tolerable doses, the acceptable 
safety profile , and the  dose to be used for a Phase II combination treatment regimen. The 
description of the two investigational agents and their potential activity in pancreatic cancer are 
described in Section 1. 3 below.  
We hypothesize that blockade of IL -1β and PD -1 will result in alterations in myeloid, lymphoid, 
and fibroblast subsets within the pancreatic cancer microenvironment. We further predict that 
circulating monocytes and neutrophils, whose production and mobilization from the bone marrow 
is augmented in PDAC patients, will decline upon treatment with IL -1β and PD -1 blockade.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  15 PanCAN-SR1 Orig Version: 22JUL2020 
 This study offers a unique window to collect rich datasets on a small number of patients before 
and after perturbation of a biological pathway of interest. To this end, we propose to collect pre- 
and on treatment blood and tumor tissue from trial patients. These samples will be used to expand 
our knowledge of IL -1β signaling in human PDAC and will generate rich datasets for evaluation 
of biomarkers of response a nd understanding of immune regulatory pathways that may contribute 
to drug resistance.  A full description of the samples collected in this study for this analysis is 
described in Section 6.0  and is listed in the Schedule of Events Table in Section 5.0 . 
 1.3  Overview of IL -1β 
IL-1 (interleukin -1) is a pro -inflammatory cytokine secreted by a number of different cells, 
including monocytes and macrophages. The IL -1 gene family consists of cytokines IL -1α and IL -
1β, and the natural receptor antagonist (IL -1Ra).  Pro-IL-1α is functionally active and, because of 
a lack of the leader peptide, it remains in the cytoplasm. Pro -IL-1β is inactive and is secreted after 
cleavage by a specific intracellular protease abundant in hematopoietic cells. While IL -1β is most 
comm only found in circulation, detection of IL -1α is rare as it is released only in severe disease 
states as a consequence of cell death ( Dinarello  1996, Garlanda  et al 2013).  
IL-1β binds the IL -1 receptor (IL -1R) inducing a conformational change that allows binding of the 
accessory protein (IL -1RAcP) to the IL -1β/IL -1R complex. Activated IL -1R, which is found on 
almost all nucleated cell types, induces intracellular signaling cascade involving MAPK, JNK, 
ERK and NF -κB that control gene expression of multiple transcription factors, growth factors and 
cytokines involved in cell functional activation and cell survival responses ( Dinarello  1996,  
Arranz  et al 2017). When released as part of inflammatory reaction, IL -1β produces a range of 
biological effects , including through the induction of other inflammatory mediators such as 
corticotrophin, platelet factor -4, prostaglandins, IL -6, and IL -8. Circulating IL -1β and IL- 6 
promote synthesis of C -reactive protein (CRP) in hepatocytes. CRP has  a role in clearanc e of 
microorganisms and dead cells by the immune system and serves as a sensitive indicator of inflammation and IL -1β secretion. In addition, it is commonly used as a marker of IL -1β inhibition 
(Ridker 2016). IL -1β modulates hematopoietic stem cell function and contributes to bone marrow 
regeneration after myeloablatio n and transplantation. Inhibition of IL -1β signaling reduces bone 
marrow colony formation  in vivo  and suppresses cell cycle in bone marrow while reducing 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  16 PanCAN-SR1 Orig Version: 22JUL2020 
 numbers of leucocytes and platelets in peripheral blood ( Zhang  et al 2009). Being a pleiotropic 
cytokine, IL -1β has roles in other body systems, like bone and cartila ge, where it facilitates bone 
resorption and cartilage destruction ( Gowen  et al 1983); it promotes vasodilation and leucocytes 
migration ( Koch  et al 1992), elevates body core temperature and increases cortisol levels 
(Garlanda  et al 2013), and modulates sensitivity to pain via direct and indirect activation of pain 
nerve receptors ( Sommer  and Kress  2004). In addition, IL -1 orchestrates the differentiation and 
function of innate and adaptive lymphoid cells thus directly contributing to the immune response 
(Garlanda  et al 2013).  
1.3.1 IL-1β in cancer 
IL-1 expression is e levated in human pancreatic , skin , and other cancers. Patients  with IL -1 
producing tumors have poor prognosis ( Lewis  et al 2006). Due to the pleiotropic nature of IL -1, 
there are several likely mechanisms by which IL -1 promotes tumor growth and metastasis 
(Figure 1). Preclinical data has demonstrated that IL -1β is involved in all phases of the malignant 
process, including tumorigenesis, tumor invasiveness, angiogenesis, progression, as well as in 
activation/suppression of anti -tumor immunity ( Apte  et al 2006,  Becker  2006 , Lewis  et al 2006, 
Krelin  et al 2007, Zitvogel et al 2013,  Wu et al 2016). IL -1 β  i s  o n e  o f  t h e  m o s t  a b u n d a n t  a n d  
influential cytokines in the tumor microenvironment, and is produced by tumor cells, stromal cellular elements, and infiltrating leukocytes. Furthermore, IL -1β signaling induces a ca scade of 
several pro -metastatic proteins such as matrix metalloproteinases and endothelial adhesion 
molecules as well as VEGF, transforming growth factor -β  ( TG F β ), a n d  o th e r c h em oki n es  a n d 
growth factors thus creating microenvironment that promotes tumor i nitiation, growth and 
progression. IL -1β plays major role in later stages of tumor progression by driving angiogenesis, 
promoting cancer “stemness” and “epithelial to mesenchymal transition” 
(Mora  and Weigert  2016 ). In addition, IL -1β is capable of suppressing local anti- tumor immunity 
by promoting the infiltration of immunosuppressive cells into the tumor, including myeloid -
derived suppressor cells (MDSCs) and tumor associated microphages (TAMs) ( Guo et al 2016).  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  17 PanCAN-SR1 Orig Version: 22JUL2020 
 Figure 1. Involvement of IL -1 in cancer   
 
Based on  [Mantovani et al 2018].   
Abbreviations: MDSC – myeloid -derived suppressor cells ; TAM – tumor -associated 
macrophages ; TAN - tumor -associated neutrophils; TLR – toll-like receptors  
 
1.3.2 IL-1β in pancreatic cancer 
IL-1β play s an important role in pancreatic cancer development and progression. High IL -1β 
concentration in serum and in the tumor correlate with tumor fibrosis, resistance to chemotherapy 
and poor survival (Maker et al 2011; Zhang et al 2018). In mouse models, IL-1β  was shown to 
promote obesity -induced (a well -established risk factor  for pancreatic cancer) pancreatic 
carcinogenesis and drug resistance (Incio et al 2016). In addition, NLRP3 pathway that controls IL-1β production was shown to support pancreatic cancer progression by increasing population of 
intratumoral immune -suppressi ve macrophages and Treg and thus promoting intratumoral 
immune tolerance (Daley et al 2017). Das et al showed that IL -1β expression is upregulated in 
patients -derived pancreatic cancer tumors relative to normal pancreatic tissue both in ductal 
epithelium a nd in the stroma. This group also showed in the tumor mice model that tumor -derived 
IL-1β promoted activation of dormant pancreatic stellate cells  (important step for carcinogenesis 
and progression)  and induced immunosuppressive tumor microenvironment thro ugh increase in 
immunosuppressive M2 macrophages, MDSC and other cell populations . Elimination of tumor 
IL-1β signaling was associated with increase in cytotoxic T -cells, attenuat ion of tumor growth 
which resulted improved survival of mice (Das et al 2020) . All these support the role of IL -1β in 
pancreatic cancer and identify it as an attractive target for future development.   

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  18 PanCAN-SR1 Orig Version: 22JUL2020 
 1.3.3 Anti -IL-1β therapy effect on cancer in CANTOS  
The Canakinumab Anti -inflammatory Thrombosis Outcomes Study (CANTOS) was a 
randomized, double blind, placebo -controlled phase III trial of 10,061 subjects who were stable 
after a myocardial infarction ( Ridker et al 2017). The study was designed primarily to assess 
whether canakinumab, a human mAb targeting IL -1β, can prevent recurrent cardio vascular events 
among men and women who have a persistent proinflammatory response defined by the presence 
of high -sensitivity CRP (hs -CRP) ≥2 mg/L.  Subjects were randomized to three canakinumab doses 
(50 mg, 150 mg, and 300 mg administered subcutaneously every 3 months), or placebo.  The 
primary endpoi nt was reducing the risk of recurrent major cardiovascular events .  All participants 
in CANTOS had to be free of previously diagnosed cancer at trial entry , and  subjects were 
followed prospectively for incident AEs (including cancer, except for basal cell carcinoma ) for up 
to 5 years. During the median follow -up of 3.7 years, canakinumab administration was associated 
with dose -dependent reductions in concentrations of hs -CRP and IL -6 vs placebo. Total cancer 
mortality (n=196) was lower in the pooled canakin umab group than in the placebo group, the 
incidence rate of cancer mortality per 100 person -years was 0.64 in the placebo group, 0.55 in the 
50 mg group, 0.50 in the 150 mg, and 0.31 in the 300 mg group. The association of  canakinumab 
with a dose -dependent reduction of the incidence cancer mortality rate was  prominent with lung 
cancers . Incidence of fatal non- lung cancers showed a reduction with canakinumab, although the 
number of these cancers in general was low ( Ridker et al 2017).  Taken together, these hypothesis -
generating data from  pre- specified safety  analysis of CANTOS  suggest the possibility that 
inhibition of the IL -1β pathway may have a role in the treatment of cancer s charac terized by an 
activated IL -1β pathway. 
1.3.4 Immunotherapy in pancreatic cancer 
Immunotherapy and the use of immune checkpoint inhibitors such as anti -Programmed cell Death 
protein 1 (PD -1), PD ligand 1 (PDL -1) or cytotoxic T -lymphocyte Antigen 4 (CTLA -4), have been 
demonstrated to be effective agents for treatment of several key soli d tumors. PD-1 is a critical co -
inhibitory receptor that is upregulated on T cells upon activation (Freeman et al. 2008). It is also 
expressed by B cells, NK cells, dendritic cells, and activated monocytes. The ligands for PD -1, 
programmed death -ligand 1 ( PD-L1) and programmed death -ligand 2 (PD -L2), are expressed by 
macrophages and monocytes, and can be induced on numerous cell types (T cells, endothelial cells, 
and tumor cells) during inflammation (Keir et al. 2008). Engagement of PD -1 by its ligands 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  19 PanCAN-SR1 Orig Version: 22JUL2020 
 transduces a signal that inhibits T -cell proliferation, cytokine production, and cytolytic function 
(Pu et al. 2019). During tumorigenesis, cancer cells from a wide range of tumor types exploit 
immune checkpoint pathways, such as PD -1, to avoid detection by th e adaptive immune system 
(Fox et al. 2011). Blockade of the PD -1 pathway has been shown to lead to both accumulation and 
increased activity of antitumor effector T cells and reduced numbers of regulatory T cells (Tregs) 
at the tumor site (Wang et al. 2009;  Mangsbo et al. 2010; Mkrtichyan et al. 2011; Rosenblatt et al. 2011).  Results of a phase I/II study of pembrolizumab with gemcitabine + nab -paclitaxel in 
PDAC  showed 3 partial responses (27%) and 100% disease control rate among 11 evaluable 
chemotherapy  naive patients with an overall survival of 15 months (Weiss et al. 2018).  
Unfortunately, for the majority of patients, single agent immune checkpoint inhibitors have failed to improve survival in PDAC (Brahmer et al. 2012; Royal et al. 2010). A putative e xplanation is 
that PDACs have a low mutation burden and have an immune suppressive tumor microenvironment in comparison to other solid cancers, leading to a less immunogenic profile (Biankin et al. 2012). Strategies to overcome this problem include combina tions with other 
checkpoint inhibitors, vaccines, or cytotoxic therapy. Nonetheless, there is a small subgroup of 
patients with a mismatch repair deficient (MMR -D) state, which represent approximately 1- 3% of 
PDACs (Hu et al. 2018). These patients typicall y occur in the setting of Lynch syndrome in PDAC, 
where there is a rationale to use checkpoint inhibitors. These patients present with a significantly 
higher burden of mutations that may encode proteins recognized by the immune system. This 
hypothesis was validated in a phase II study of MMR proficient and deficient solid tumors, as 
significant response to pembrolizumab was seen only in MMR -D patients (Le et al. 2 015). Of the 
8 patients with metastatic pancreatic  cancer enrolled, there were 5 responders (2 complete 
response, 3 partial response) for an overall response rate of 62%. Median PFS and OS had not been reached (Le et al. 2017). These results have recently led to the FDA approval of pembrolizumab 
in MMR -D patients with solid tumors agnostic of the sp ecific underlying malignancy  (please refer 
to the Keytruda USPI : 
https://www.accessdata.fda.gov/ 
drugsatfda_docs/label/2019/125514Orig1s054lbl.pdf ).  
Adding chemotherapy to immunotherapy and canakinumab may contribute to increased efficacy of immunotherapy by improving immunogenicity of the tumor by causing tumor cells to emit 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  20 PanCAN-SR1 Orig Version: 22JUL2020 
 “danger” signal, by stimulating anticancer immune effector cells and  suppres sing 
immunosuppressive cells ( Zitvogel et al. 2013, Zitvogel et al. 2011).   
1.3.5 Inflammation in pancreatic cancer and rationale to combine with a IL -1β 
inhibitor  
The presence of stromal desmoplasia is a characteristic of pancreatic cancer that leads to  a unique 
tumor microenvironment that comprises of several cell types that includes fibroblasts that deposit 
fibronectin and collagen and inflammatory cells and macrophages that releases cytokines. These 
proinflammatory cytokines such as IL1 β and IL -6 have  been implicated for the adverse outcomes 
of pancreatic cancer (Lesina et al . 2011; Ebrahimi et al 2004) . This systemic inflammatory 
response has been associated with a more pronounced symptom burden, including cachexia 
syndrome, and poorer survival outcomes (Tan CR et.al.  2014). Consequently, elevated levels of 
CRP, weight loss and low serum albumin concentrations (hypoalbuminemia) are recognized as poor prognostic markers which is thought to be part of the systemic inflammatory response 
(Salmiheimo A et al 2016). The modified Glasgow Prognostic Score (mGPS) is a risk -stratification 
tool that evaluates systemic inflammation by incorporating CRP and albumin values into a score 
to predict clinical outcomes in patients with cancer (McMillan DC . 2013) and is extensively 
reported in retrospective analyses of pancreatic cancer. Moreover, preclinical models have 
demonstrated that enhancing IL -1 signaling in pancreatic cancer cells leads to enhanced 
proliferation of the tumor cells.  
It is therefore hypothesized that addition of a IL -1β inhibitor to the combination of inhibitors of 
immune checkpoint blockade and standard of care chemotherapy would lead to salutary effect on 
the efficacy of pancreatic cancer by altering the tumor microenvironment as described in  Section 
1.3.2  to facilitate the activity of the antitumor immune cells and inhibition of the cancer . Recent 
preclinical data (Das et al 2020) demonstrated an improved tumor growth suppression when blocking antibodies against IL -1β and PD- 1 were combined i n the KPC pancreatic cancer mouse 
model, which is supportive of this hypothesis.  
1.4 Overview of canakinumab 
Canakinumab (ACZ885) is a high -affinity human anti -interleukin -1β (IL -1β) monoclonal antibody 
that belongs to the Immunoglobulin G1 (IgG1)/κ isotype subclass. Canakinumab is manufactured in a murine SP2/0 cell line. Currently canakinumab is approved and ma rketed as Ilaris
® in more 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  21 PanCAN-SR1 Orig Version: 22JUL2020 
 than 70 countries for the treatment of IL -1β driven auto -inflammatory diseases: gouty arthritis, 
Still's disease, Cryopyrin Associated Periodic Syndromes (CAPS), Systemic Juvenile Idiopathic 
Arthritis (SJIA), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), 
Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), Familial Mediterranean Fever (FMF). For additional details please refer to the canakinumab Investigator ’s 
Brochure .  
1.4.1  Non-clinical experience with canakinumab 
Canakinumab neutralizes the bioactivity of human IL -1β by preventing its binding to the IL- 1β 
receptor. Canakinumab specifically binds human IL -1β with a Kd  of 40 -60 picomolar and has no 
cross- reactivity with other members of the IL -1 family (e.g. IL -1
α IL-1Ra etc). Canakinumab is 
selective for human and marmoset IL -1β but does not bind to mouse, rat, rabbit, rhesus, or 
cynomolgus monkey IL -1β. An extensive p rogram of toxicology studies was performed with 
canakinumab. The marmoset monkey was characterized as an appropriate model to predict human safety. Following IV or SC administration, canakinumab was well tolerated in marmosets at all 
dose levels without any relevant adverse findings. No anti -drug antibodies were detected. No 
significant treatment -related effects were observed with respect to male or female fertility in a 
mouse model using a murine analog of canakinumab. For further details, please refer to the 
canakinumab Investigator’s Brochure.  
1.4.2 C linical experience with canakinumab in cancer 
As of June 2019, approximately  13,111 patients were exposed to canakinumab in Novartis -
sponsored clinical studies  at various doses. Canakinumab is being studied in NSCLC in a number 
of settings: as single -agent adjuvant therapy (CACZ885T2301) , in combination with 
chemotherapy and immunotherapy in the first line setting  (CACZ885U2301 and 
CPDR001C2101) , and in combinat ion with chemotherapy in the second -line treatment setting  
(CACZ885V2301) . These trials are ongoing . 
In the open- label safety run -in part of a phase 3 study CACZ885U2301 (CANOPY -1), 
canakinumab (200 mg SC Q3W) was administered to 30 patients with Stage III B/C/IV NSCLC in 
combination with pembrolizumab and chemotherapy regimens : carboplatin+ pemetrexed  (Cohort 
A; 10 patients) , cisplatin+pemetrexed  (Cohort B; 11 patients) , or carboplatin+paclitaxel  (Cohort 
C; 9 patients) . Only 1 dose -limiting toxicity  (DLT)  was reported with these combinations (in 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  22 PanCAN-SR1 Orig Version: 22JUL2020 
 Cohort C only ; hepatitis , considered to be related to pembrolizumab ), and 12 SAEs reported in 8 
patients, none considered to be related to canakinumab by the investigators. There was no common 
pattern for SAEs except for infections (two events of pneumonia in two patients, urinary tract 
infection, lower respiratory tract infection). The dose level review team meeting concluded that 
the regimen evaluated in all three cohorts in the safety run -in (canakinumab 200 mg Q 3W) is 
tolerable and considered safe to be used in combination with pembrolizumab and chemotherapy 
in the randomized phase 3 part of the study . The phase 3 part of the study is ongoing.  
Study CACZ885T2301 (CANOPY- A) is a phase III randomized double-blind placebo -controlled 
study exploring canakinumab (200 mg SC every three weeks, up to 18 cycles) as adjuvant therapy 
in patients with completely resected Stages II -IIIA/IIIB (T>5cmN2) NSCLC. The safety of study 
treatment in first 56 subjects has been reviewied by DMC that recommended to continue the study.   
Study CACZ885T2301 (CANOPY -2) is a phase III randomized double -blind placebo -controlled 
study exploring canakinumab (200 mg SC every three weeks, up to 18 cycles) evaluating 
canakinumab (200 mg SC every three weeks) with docetaxel (75 mg/m2 every three weeks) in 
patients with metastatic NSCLC previously treated with PD -1 or PD -L1 inhibitors and platinum -
based chemotherapy. In the open- label safety run -in part of the study  in 8 patients, one DLT of 
pneumococo ccal pneumonia was reported (considered by the investigator related to combination 
of canakinumab and docetaxel) in the DLT observation period of the first 42 days of study treatment and 6 SAEs in 3 patients. None of these SAEs were considered  related to canakinumab 
per investigators assessment. The dose level review team concluded that the regimen evaluated in 
the safety run -in is tolerable and is safe to be used in combination with docetaxel in the randomized 
phase 3 part of the study. The randomized part  of the study is ongoing.  
For additional information on studies of canakinumab in patients with oncology indications  
(including studies in metastatic melanoma, triple -negative breast and colorectal cancer)  refer to 
the last  canakinumab Investigator’s Broc hure.  Information on studies exploring canakinumab in 
combination with PD -1 inhibitor spartalizumab (PDR001) is provided in Section 1.5 
1.5 Overview of spartalizumab  
Spartalizumab (PDR001) is a mAb  directed against human Programmed Death -1 (PD -1). PD -1 is 
a critical immune- checkpoint receptor that is expressed on CD4 and CD8 T cells upon activation.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  23 PanCAN-SR1 Orig Version: 22JUL2020 
 Engagement of PD -1 by its ligands, PD -L1 and PD -L2, transduces a signal that inhibits T -cell 
prolife ration, cytokine production, and cytolytic function. During tumorigenesis, cancer cells from 
a wide range of tumor types exploit immune checkpoint pathways, such as P D-1/PD- L1, to avoid 
detection by the adaptive immune system.  Inhibitors of immunological c heckpoints, including PD -
1 and PD -L1 mAb’s, have demonstrated significant antitumor activity in patients with various 
solid tumors.  
1.5.1 Non-clinical experience with spartalizumab  
Spartalizumab  binds specifically and with high affinity to human PD -1 and enhances IL -2 
production in lymphocyte stimulation assays in vitro. Spartalizumab  does not cross react with 
rodent PD -1. However, toxicology studies performed in cynomolgus monkeys showed acceptable 
cross reactivity with monkey PD -1. Repeat administration of spartalizumab to cynomolgus 
monkeys was tolerated at all doses tested up to 100 mg/kg/week for 5 weeks in the GLP toxicology 
single -agent study. No drug- related changes  in life, mortality, organ weight changes, or 
macroscopic findings were noted.  For further details, please refer to the spartalizumab 
Investigator’s Brochure.  
 
1.5.2 Clinical experience with spartalizumab 
As of 26-March -2020, a total of 1702 patients  have received spartalizumab in  Novartis -sponsored 
clinical studies  as a single agent ( 562 patients) , or in combination with other agents ( 1140 patients) 
in multiple tumor types. In these studies spartalizumab was administered every two weeks (Q2W), 
Q3W or every four weeks (Q4W).  
Safety profile s of spartalizumab in clinical studies across different tumor types and regimen/dose 
groups were similar  and consistent with and characteristic of other agents that inhibit the PD -1 
receptor. Severe immune- related adverse events (irAEs) were rare and typically manageable with 
dose interruption and use of immunosuppressive treatment or other supportive therap y as clinically 
indicated; discontinuations due to irAEs were rare. For additional details on safety of 
spartalizumab please refer to the spartalizumab I nvestigator ’s Brochure . 
Based on the available PK and safety data, two recommended phase two doses (RP2D) for spartalizumab single -agent have been declared: spartalizumab 400 mg Q4W or 300 mg 
spartalizumab Q3W.   
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  24 PanCAN-SR1 Orig Version: 22JUL2020 
 Clinical experience of administering spartalizumab with chemotherapy  or canakinumab include  
phase I /II studies CPDR001C2101, CPDR001X2103 and CPDR001J2201.  
- In CPDR001C2101, spartalizumab  (300 mg Q3W)  was administered  in combination with 
platinum -based regiments (gemcitabine + cisplatin; pemetrexed + cisplatin; paclitaxel + 
carboplatin) to patients with advanced  and metastatic NSCLC. As of January 2019, a total  
of 33 adults were treated in this study. The safety profile observed was characterized mostly 
by toxicities  attributed  to chemotherapy regimens (e.g. bone marrow suppression, nausea, 
and asthenia/fatigue). AEs attributed to spartalizumab were manageable and in -line with 
the existing safety profile of spartalizumab.  In addition, t he study confirmed spartalizumab 
recommended dose for subsequent NSCLC trials  as 300 mg IV Q3W.  
- In CPDR001X2103, spartalizumab was administered to patients with advanced/metastatic  
colorectal cancer, triple- negative breast cancer or NSCLC in combinations with 
canakinumab  or other immunomodulatory agents  or tyrosine kinases inhibito rs. One 
hundred and seven patients were treated with spartalizumab (400 mg Q4W) and 
canakinumab  combination  at doses 100 mg (6 patients), 300 mg (13 patients)  and 600 mg 
(88 patients)  (all Q8W  SC). In the spartalizumab  + canakinumab group, 104 patients (97.2 
%) had permanently discontinued study treatment, 3 (2.8 %) due to an AE, 93 (86.9 %) 
due to progression of disease, 5 (4.7 %) due to physician decision and 3 (2.8 %) due to subject/guardian decision.  The most freque nt AEs (≥20%) in this group regardless of 
relationship to study drug, were dyspnoea (30.8%), decreased appetite (28.0%), fatigue and nausea (24.3% each) and vomiting (22.4%).  
- In CPDR 001J2201, spartalizumab was administered to patients with previously treated 
unresectable or metastatic melanoma in combinations with canakinumab or other 
immunomodulatory agents or small molecules. As of interim analysis data cutoff date of 
07-Oct-2019, 36 patients have been administered spartalizumab 400 mg every 4 weeks and 
canakinumab 300 mg every 4 weeks. The most frequent AEs (>10%) in the spartalizumab + canakinumab group, regardless of relationship to study drug, were dyspnoea (17.1%), 
constipation (14.3%), abdominal pain (14.3%), decreased appetite (14.3%), anemia (14.3%), asthenia (14.3%), fatigue (11.4%) and weight decreased (11.4%). Grade >3 AEs reported more than once include anemia (three), fatigue, decreased appetite, tumour pain, lipase and amylase increased (twice each). The most frequent treatment -related AEs, 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  25 PanCAN-SR1 Orig Version: 22JUL2020 
 reported in at least 3 (>8%) subjects include pruritus (8.6%) and eosinophilia (8.6%). 
Treatment related events were grade >3 gastrointestinal pain, gastroesophageal reflux, 
lipase increased and peripheral ischaemia (once each). At the interim analysis with  a cutoff 
date of 07 -Oct-2019, spartalizumab + canakinumab arm  crossed the efficacy futility 
threshold and will not be further expanded.  
For additional details on CPDR001X2103, CPDR001C2101 and CPDR001J2201 please refer to 
the last edition of the spartalizumab Investigator ’s Brochure.   
1.6 Rationale for the dosing regimen of canakinumab  
 As described in Section 1.3.3 , adminis tration of canakinumab (50 mg, 150 mg, and 300 mg SC 
every three months) in CANTOS resulted in a dose dependent decrease in hs -CRP and was 
associated with a reduction of  lung cancer  cumulative  incidence  and mortality , compared to 
placebo , in a dose -dependent manner  and with no plateau observed at the highest dose 
adminis tered (300 mg every 3 months ), suggesting that higher doses of canakinumab could be 
associated with a greater decrease in risk of lung cancer incidence rate and mortality  (Ridker et al 
2017a). Important ly, the median hs -CRP at baseline in subjects who were subsequently diagnosed 
with cancer was higher compared to those patients who were not diagnosed with cancer (median 6.0 mg/L versus 4.2 mg/L).  Moreover , for subjects with higher baseline hs -CRP, the proportion of 
subjects whose hs- CRP normalized to a post -treatment target level of 2.3 mg/L was less than in 
subjec ts with lower baseline hs -CRP. All these  suggest that increasing the exposure of 
canakinumab beyond the maximal dose explored in CANTOS may result in  an improved control 
of inflammation in subjects with higher baseline hs -CRP which may lead to a greater an titumor 
efficacy of canakinumab. Based on this assumption, a dose of canakinumab 200 mg administered 
SC every 3 weeks (Q3W) , which results in higher steady -state exposure compared to the maximal 
exposure achieved in CANTOS, was selected for studies explori ng anti -tumor effect of 
canakinumab in NSCLC  (Section 1.4.2) . In these studies canakinumab is being explored in patients 
with NSCLC as monotherapy, or in combination with chemotherapy, or with chemotherapy and PD-1 blockers. Rationale for this dose was based on the PK properties of canakinumab, the drug’s 
ability to suppress hs -CRP for at least 1 month across a wide range of doses and indications, 
efficacy observed in the CANTOS study, safety considerations, and schedule of administration of 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  26 PanCAN-SR1 Orig Version: 22JUL2020 
 a standard of care backbone treatment (i.e. chemotherapy)  in NSCLC . Ability of Q3W dosing 
schedule of canakinumab to suppress hs-CRP for at least 1 month was also demonstrated in two 
single -dose phase II studies with dose ranges of 0.03 to 10 mg/kg IV ([CACZ885A2213] in 
diabetes) and 25 to 300 mg SC ([CACZ885H2251] in gouty arthritis).  
In this study, the backbone regimen of chemotherapy of gemcitabine and nab- paclitaxel is 
administered as 4 -weeks cycles. To align with the dosing regimen of chemotherapy, the every four 
week regimen of 250 mg canakinumab  SC as starting dose was selected . This decision was based 
on population PK analysis, where a 250 mg Q4W SC dosing schedule result ed in comparable PK 
at steady state to the 200 mg Q3W SC, the regimen used in NSCLC studies (Table 1 -1). This 
dosing is also supported by a long, 26-day s half -life of canakinumab .  
 
 
Table 1 -1: Steady State PK parameters of canakinumab  
 
Dose Regimen  Cmin  ug/mL  
(95% PI) Cmax ug/mL  
(95% PI) 
 
 AUC0-tau 
ug*day/mL  
(95% PI) Cave ug/mL  
(95% PI) 
 
 
200 mg Q3W S.C.  22.44 (9.16, 50.31)  35.21 (16.03, 75.42)  
 AUC21 -24week  
625.67 
(278.36, 
1334.69)  29.79 (13.26, 
63.56)  
 
 
250 mg Q4W S.C.  18.28 (7.50, 43.51)  35.65  
(16.31, 76.64)  
 
 AUC20 -24week  
771.81 
(348.12, 
1705.89)  27.56  
(12.43, 60.92)  
 
 
 
As described in the canakinumab I nvestigator’s Brochure,  safety of canakinumab doses equivalent 
to or higher than selected for this study dose (250 mg Q4W) has been confirmed in several 
completed and ongoing studies exploring canakinumab, including in combinations with 
chemotherapy and/or immunotherapy.  In Study CACZ885A2204, canakinumab was given at a 
dose of 600 mg IV Q4W along with methotrexate. In studies  CACZ885G2301 and 
CACZ885G2301E1 (extension of the former study) , canakinumab was administered at a dose of 
4 mg/kg up to maximum  300 mg SC Q4W to patients with  systemic juvenile idiopathic arthritis 
for a total median duration of exposure of more than 2 y ears.  As described in Section 1.4.2 , 
canakinumab dose of 200 mg SC Q 3W is being explored currently as monotherapy or in 
combination with chemotherapy or  chemoimmunotherapy in multiple studies in NSCLC. In a 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  27 PanCAN-SR1 Orig Version: 22JUL2020 
 phase 1b study CADPT01A12101C, 600 mg Q8W canak inumab was adminsitered in combination 
with spartalizumab and LAG25 to patients with metastatic triple negative breast cancer.  
In summary, based on evidence of efficacy from the CANTOS, PK and PD properties of 
canakinumab and the well -established safety p rofile of canakinumab at wide dose ranges, a dose 
of 250 mg SC Q4W has been selected for this study.   
 
 
1.7 Rationale for the Study Regimen 
As described in Section 1. 3.4, checkpoint inhibitor  monotherapy  has not demonstrate d outstanding 
efficacy in pancreatic cancer . This is possibly due to the immune suppressive tumor 
microenvironment with stromal infiltration of myeloid -derived suppressor cells  (MDSC) , tumor -
associated macrophages and /or overall low mutational load . IL-1β p lays an important role in 
pancreatic cancer development and progression via activation of dormant pancreatic stellate cells 
and increasing population of intratumoral immune -suppressive macrophages M2, Treg and MDSC 
(Section 1. 3.2). Recent preclinical data in pancreas cancer animal models showed improved tumor 
growth suppression with concurrent blockage of antibodies against IL -1β and PD- 1 (Das et al 
2020). Similarly, in an animal model of breast cancer, treatment with antibodies against IL -1β 
caused regression of the tumor due to decrease in intratumoral immunosuppressive macrophages 
and improvement of antitumor immunity via an increase in dendritic cell function and activated 
cytotoxic CD8+ lymphocytes  (Kaplanov et al 2019) . In the same model, where treatment with anti -
PD-1 had moderate effect on tumor growth, combination of anti-IL1β and anti -PD-1 abrogated the 
tumors completely. Combined, this data provide a strong preclinical rationale for a clinical trial 
investigating a combination of anti -IL1β and anti- PD-1 agents in the treatment of advanced 
pancreatic cancer.  
In this trial, anti- IL-1β antibody canakinumab will be combined with an anti -PD-1 antibody 
spartalizumab and chemotherapy regimen of gemcitabine and nab-paclitaxel. As described in 
Section 1.1.3 , gemcitabine and nab -paclitaxel is a standard treatment regimen for metastatic 
pancreatic cancer. It is expected, that combin ing anti-IL1β and anti -PD-1 agents with standard 
chemotherapy will have more than an additive effect : chemotherapy may increase the amount of 
neoantigens in the tumor and contribute to improved  response to immune checkpoint inhibit ion. 
As an evidence, it  was shown in preclinical models of pancreatic cancer  that combining 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  28 PanCAN-SR1 Orig Version: 22JUL2020 
 gemcitabine with e ither anti -PD-1 or anti -PD-L1 antibody enhanced tumor infiltration with CD8+ 
T cells and resulted  in complete responses  (uncommon in pancreatric cancer models)  in the treated 
animals (Nomi et al 2007) . In this trial, approved doses of gemcitabine and nab -paclitaxel will be 
used (Section 4 .1.1).  
Spartalizumab will be administered at  the recommended dose  for phase II  of 400 mg Q4W  
(Section 1.5.2 ). As described in Section 1. 5.2, the combination of chemotherapy and 
spartalizumab  is feasible, with the safety profile mostly attributed to chemotherapy regimens; AEs 
attributed to spartalizumab were manageable and in -line with the existing safety profile of 
spartalizumab.  
The first dose level explored of canakinumab will be 250 mg Q4W (Section 1.6 ), that  is expected 
to be equivalent to the dose explored in multiple ongoing phase III clinical trials in NSCLC  and 
phase I/II clinical trials in other cancers where no outsta nding safety signals  as a result of 
combination with chemotherapy administered in approved doses (and checkpoint inhibitors, where 
applicable) with canakinumab have  been observed , and the combination was feasible and tolerable, 
no overlapping toxicities were observed  (Canakinumab IB).  
Canakinumab and spartalizumab are m onoclonal antibodies and not metabolized by Cytochrome 
P450 (CYP450) enzymes or transported by P -glycoprotein (PgP) or related ABC membrane 
transporters. Therefore, the risk of DDI between canakinumab , spartalizumab  and chemotherapy 
agents is expected to b e low. However, as canakinumab is a cytokine modulator, the risk of DDI 
between canakinumab  and chemotherap y agents  that are metabolized by CYP enzymes  (e.g. 
paclitaxel)  cannot be completely excluded. In addition, when canakinumab was administered 
together  with paclitaxel in the safety run -in of study CACZ885U2301, no additional toxicities or 
DLT were observed ( Section 1.4.2). Therefore, t he PK of chemotherapy agent  that is metabolized 
by CYP enzymes (nab- paclitaxel) will also be characterized in this study to explore the DDI 
between canakinumab and spartalizumab  and nab -paclitaxel, if any.  
 
2.0 OBJECTIVES  AND END POINTS  
2.1 Overview  
This is an open -label  multi- center  phase Ib study to confirm the recommended phase II/III dose  of 
canakinumab and spartalizumab in combination with nab -paclitaxel and gemcitabine  as first -line 
therapy for patients with metastatic pancreatic cancer.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  31 PanCAN-SR1 Orig Version: 22JUL2020 
 The Bayesian analysis incorporates  prior toxicity data of single agent and drugs combinations 
together with the currently available data to  predict the probability of DLT and excessive toxicity 
of a dose level of interest.   
The Bayesian method is  be based on a Meta- Analytical -Combined (MAC) approach (Spiegelhalter 
2004, Neuenschwander 2016) to combine all historical and concurrent data. Prior toxicity 
information included in the BLRM model was obtained from three studies with canakinumab as a single agent and combination of canakinumab and spartalizumab (PDR001X2101,  ACZ885I2202, 
PRD001X2103) and from a phase I/II study of  nab -paclitaxel + gemcitabine (Von Hoff D, et.al., 
2011) .  Simulation was used to illustrate the recommendation from BLRM under a set of 
hypothetical scenarios with assumed number of evaulable patients and DLTs (See Table 9 -1). Full 
details on the model, prior toxicity information  from clinical trials in patients and assessment of 
DLT probability using the BLRM model are provided in Section 9.4 and Appendix B . 
The decisions on a recommended dose will be  made by the Investigators and the Sponsor  in a 
Safety Review  meeting  when at least 6 DLT evaluable patients per dose level will be observed for 
DLTs for a minimum duration of 56 days (8 weeks) . Safety review will be  based upon the review 
of all relevant data available including treatment  tolerability and safety information together  with  
the BLRM summaries of DLT probability,  PK, PD, and preliminary activity information (if 
available ) at the  time of the meeting ( Section 4.1.5).  
 
3.0 STUDY POPULATION 
The study population is treatment naïve metastatic pancreatic ductal adenocarcinoma patients.  
 
3.1  Study Duration 
Patient s will be treated until disease progression  per RECIST 1.1 , unacceptable toxicity, or until 
the patient or treating physician decides to stop treatment.  
All patient s must be followed for safety up to 150 days after the last dose of spartalizumab  or 
canakinumab , or 30 days after the last dose of the combination chemotherapy,  whichever the later . 
After the end of safety follow -up, patient s will be followed for disease progression if 
discontinuation of treatment is due to reason other than progression, and for survival (via 
telephone call or onsite visit if  a patient  happens to be visiting the site) until the end of study   
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  32 PanCAN-SR1 Orig Version: 22JUL2020 
 The study completion is defined as when the last patient  has completed the study treatment, safety 
follow up,  and completed survival follow up period up to 1 year from first treat ment , whichever 
is later  or in the event of an early study termination decision, the date of that decision .  
  
3.2 Inclusion  Criteria  
A patient  will be eligible to participate in this study if all of the inclusion criteria below are met:  
• Age > 18 years at the time of informed consent  
• Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC)  
(determined by a local laboratory)  with metastatic spread of disease (adenosquamous is 
also allowed) .  
• Patients  must have not received previous anti -cancer therapy for the treatment of metastatic 
pancreatic ductal adenocarcinoma.  
• Patient s who received previous neo -/adjuvant systemic therapy for non -metastatic PDAC 
≥12 months  from the last treatment to study enrollment date  are allowed  unless this therapy 
included immunotherapy and/or IL -1 inhibitors .   
• Radiographically measurable disease of at least one site by computed tomography (CT) 
scan (or magnetic resonance imaging, if allergic to CT contrast media) as defined by Resp onse Evaluation Criteria In Solid Tumors (RECIST 1.1 ). Primary lesion is allowed as 
long as it is measurable (per RECIST 1.1) and has not be en previously irradiated. Imaging 
results must be obtained within the 28-day screening window.   
• Eastern Cooperative Oncology Group (ECOG) performance status of 0- 1.  
• Adequate organ function ( laboratory results must be obtained within the 28 -day screening 
window)  
o Absolute neutrophil count > 1500/mm3 
o Hemoglobin > 9 g/dL  
o Platelets > 100,000/mm3 
o Serum creatinine < 1.5 x upper limit normal (ULN), or calculated creatinine 
clearance > 60 mL/min (Cockcroft Gault)  
o Albumin > 3.0 g/dL  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  33 PanCAN-SR1 Orig Version: 22JUL2020 
 o Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase 
(SGOT) and/or alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) < 3.0 x ULN ( < 5 x ULN in presence of liver metastasis).   
In patients with elevated ALT or AST, the values must be stable for at least 2 weeks   
and with no evidence of biliary obstruction on imaging   
o Total bilirubin ≤ 1.5 X ULN 
o INR ≤ 1.5 x ULN  
• Consent to provide protocol -mandated tissue  and blood samples for diagnostic, PK, and 
research purposes  
• Able to adhere to study visit schedule and other protocol requirements  
 
3.3 Exclusion Criteria  
A patient  will not be eligible to participate in this study if any of the following criteria below are 
met: 
• Diagnosis of pancreatic neuroendocrine carcinoma  or pancreatic acinar cell carcinoma  
• Previous immunotherapy (e.g. anti -PD-1, anti -PD-L1, anti -PD-L2, anti -CTL A-4 antibody, 
or any other antibody or drug specifically targeting T -cell co -stimulation or immune 
checkpoint pathways).  
• Known microsatellite instability -high (MSI -H) or mismatch repair -deficient  pancreatic 
cancer   
• Prior treatment with canakinumab or drugs  of a similar mechanism of action (IL -1 
inhibitor).  
• History of known hypersensitivity to any of the drugs used in this study  or any of their 
excipients, or patient has contraindication to any of the study drugs as outlined in the local prescribing informat ion (e.g. United States Prescribing Information [USPI])  
• Active autoimmune disease that has required systemic treatment in the past 2 years prior  
to enrollment i.e. with use of disease modifying agents, corticosteroids or  
immunosuppressive drugs. Control o f the disorder with replacement therapy (e.g.,  
thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or  
pituitary insufficiency, etc. ) is permitted.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  34 PanCAN-SR1 Orig Version: 22JUL2020 
 • Patient  with suspected or proven immunocompromised state or infections, including:  
- Evidence of active or latent tuberculosis (TB) as determined by locally approved 
screening methods. If the results of the screening per local treatment guidelines or clinical practice require treatment, then the patient is not eligible.  
- Chronic or active hepatitis B or C  
- Known history of testing positive for Human Immunodeficiency Virus (HIV) infections.  
- Any other medical condition (such as active infection, treated or untreated), which in the opinion of the investigator places the patient at an  unacceptable risk for 
participation in immunomodulatory therapy.  
Note:  Patient s with localized condition unlikely to lead to a systemic infection e.g. chronic 
nail fungal infection are eligible.  
• Allogeneic bone marrow or solid organ transplant  
• Treatment w ith any immune modulating agent in doses with systemic effects e.g.:  
- Systemic treatment with prednisone > 10 mg (or equivalent) for >14 days within 4 
weeks prior to the first dose of study treatment.    
- Equivalent dose of methotrexate > 15 mg weekly  
- Patient  receiving any biologic drugs targeting the immune system (for example, TNF 
blockers, anakinra, rituximab, abatacept, or tocilizumab).  
- Note:  Daily glucocorticoid -replacement for conditions such as adrenal or pituitary 
insufficiency is allowed.  
- Note:  Topica l, inhaled, or local steroid use in doses that are not considered to cause 
systemic effects are permitted  (based on investigator’s discretion and consultation with 
the Medical Monitor if needed) . 
• Patient has concurrent malignancy other than the disease und er investigation , with 
exception of malignancy that was treated curatively and has not recurred within 2 years prior to the date of  screening . Fully resected basal or squamous cell skin cancers , and any 
carcinoma in situ  are eligible.   
• Uncontrolled or severe cardiac disease (history of unstable angina, myocardial infarction, coronary stenting, or bypass surgery within the prior 6 months), symptomatic congestive 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  35 PanCAN-SR1 Orig Version: 22JUL2020 
 heart failure, serious uncontrolled cardiac arrhythmia [including atrial flut ter/fibrillation], 
requirement for inotropic support or use of devices for cardiac conditions 
[pacemakers/defibrillators]), uncontrolled hypertension defined by a systolic blood 
pressure =>160 mg and/or diastolic blood pressure =>100 mg Hg  
• Pre-existing p eripheral neuropathy > Grade 1  (CTCAE V 5.0)   
• Receipt of live vaccines within 3 months prior to the first dose of study treatment or while 
on active treatment within the trial (examples of live vaccines include, but are not limited to, the following : measles , mumps, rubella, chicken pox, yellow fever, rabies, BCG, and 
typhoid (oral vaccine). Seasonal influenza vaccines for injection are generally killed virus vaccines and are permitted. However, intranasal influenza vaccines (e.g. Flu -mist) are live 
attenuated vaccines and are not permitted.  
• Patient  has had major surgery within 14 days prior to enrollment  
• Patient  has symptomatic brain metastases, or brain metastases that require directed therapy 
(such as focal radiotherapy or surgery). Patients with treated brain metastases have to be 
neurologically stable and not using systemic steroids for at least 4 weeks prior to the study drug administration.  
• Women of child -bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they  are willing to use highly effective methods of 
contraception during treatment with study drugs (canakinumab, spartalizumab, 
gemcitabine and nab -paclitaxel).  
• Highly effective contraception methods are required while on treatment and for 150 days 
after stop ping spartalizumab. No contraception is required after treatment with 
canakinumab is stopped. Contraception use after chemotherapy is stopped should be followed per the local drug label requirements.  
 
Highly effective contraception methods include:  
- Total abstinence (when this is in line with the preferred and usual lifestyle of the patient . 
Periodic abstinence (i.e., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception  
- Female sterilizat ion (have had bilateral surgical oophorectomy (with or without 
hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  36 PanCAN-SR1 Orig Version: 22JUL2020 
 taking study treatment. In case of oophorectomy alone, only when the reproductive 
status of the woman has  been confirmed by follow up hormone level assessment.  
- Male sterilization (at least 6 m onths  prior to screening). The vasectomized male partner 
should be the sole partner for that patient.   
- Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception  
In case  of use of oral contraception women should have been stable on the same pill for a 
minimum of 3 months before taking study treatment.  
Note: Women of non -childbearing potential is defined as women who are physiologically 
and/or anatomically incapable of becoming pregnant, as now further described:  
- They are post -menopausal as evidenced by 12 months of natural (spontaneous) 
amenorrhea with an appropriate clinical profile (i.e., age appropriate history of 
vasomotor symptoms).  
- They have had bilateral surgical oo phorectomy (with or without hysterectomy), 
total hysterectomy or bilateral tubal ligation at least six weeks prior. In the case of oophorectomy alone, only when the reproductive status of the woman has been 
confirmed by follow up hormone level assessment i s she considered not of 
childbearing  potential. 
Note : Sexually active male patients and their partners who are women of childbearing  
potential should follow the contraception recommendations and any other precautionary measures as required by the local prescribing information for the SOC anti -cancer.  
• Any significant medical condition, laboratory abnormality or psychiatric condition that would 
constitute unacceptable safety risks to the patients, contraindicate patient  participation in the 
clinical study,  limit the patient ’s ability to comply with study requirements, or compromise 
patient ’s compliance with the protocol and all requirements of the study as stated in the 
Informed Consent Form. Significant medical conditions include but are not limited to kno wn 
history or current interstitial lung disease or non -infectious pneumonitis, medical history or 
current diagnosis of myocarditis, chronic active hepatitis, liver cirrhosis or any other 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  37 PanCAN-SR1 Orig Version: 22JUL2020 
 significant liver disease with moderate to severe hepatic impairment (Child -Pugh B or C), 
serious non -healing wound/ulcer/bone fracture, uncompensated/symptomatic hypothyroidism, 
or requirement for hemodialysis or peritoneal dialysis.  
• Unwillingness or unable to comply with all requirement of the study as stated in the Infor med 
Consent Form  
 
 
 
4.0 STUDY TREATMENT AND DOSE MODIFICATION  
4.1 Administration and Dosing  
For this study, the investigational drugs (INDs) are spartalizumab (PDR001) and canakinumab 
(ACZ885) . The study treatment is defined as spartalizumab  with canakinumab in combination with 
gemcitabine and nab -paclitaxel. Below are details of the dosing regimen and administration 
instructions for the four -drug combination . On days of combination therapy canakinumab  will be 
administered first, followed by  30 min observation period. After the end of the observation period , 
spartalizumab  will be administered . After spartalizumab infusion, patient s should be closely 
observed for potential infusion -related reactions for at least 2 hours after the first two 
spartalizumab infusions (before administration of chemotherapy). The same may apply for the 
subsequent spartalizumab infusions if medically indicated. Observation for a specific period of 
time after for the 3rd and subsequent infusion s is not necessary (unless  medically indicated)  but 
subjects should be provided instructions to notify the study personnel if symptoms of infusion 
reaction occur after any spartlizumab  infusion . Any pre -medication for the chemotherapies should 
be administered at least 30 minutes after the end of the infusion of spartalizumab  (for additional 
detials see Section 5.4 ).  
For the non-investigational drugs (gemcitabine and nab -paclitaxel), prescribing information and 
local institutional practice are to be followed. All dosages prescribed and dispensed to the patient  
and all dose changes during the study must be recorded on the appr opriate eCRF page.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  38 PanCAN-SR1 Orig Version: 22JUL2020 
 4.1.1  Gemcitabine and nab-paclitaxel  
Gemcitabine and nab -paclitaxel are FDA approved therapies for metastatic pancreatic cancer and 
will be supplied or obtained according to local clinical study agreements and in accordance with 
local gu idelines.  Additional information may be included on the label as needed or applicable.  
The following are recommended parameters for infusion timing and sequence of gem citabine and 
nab-paclitaxel , although institutional variation in the administration of t he regimen are permitted 
as long as drug dosing and modification guidelines are followed.  
• Nab-paclitaxel is infused at an initial dose of 125 mg/m2 over 30 -40 min on days 1, 8, 15 
of each 28 -day cycle.  
• Gemcitabine is infused at an initial dose of 1000 mg/m2 over 30 min, immediately after 
completion of nab -paclitaxel infusion, on days 1, 8, 15 of each 28- day cycle 
Doses should be re -adjusted if the patient ’s BSA changes by +/ - >10%. If the patient ’s BSA 
changes by <10%, no adjustment is necessary  unless the site has a standard procedure to adjust 
doses based upon current BSA according to institutional guidelines.  
Specifics on dosing and toxicity modifications for gemcitabine and nab -paclitaxel can be found in 
their Package Inserts (Appendix A).  
 
4.1.2 Canakinumab 
Canakinumab is provided as ready -to use pre -filled syringes to be administered by study center 
personnel.  Two strengths of solution for injection will be supplied:  
• Canakinumab 50 mg/ 0.5 mL  
• Canakinumab 200 mg/ 1.33 mL  
 
The starting dose of canakinumab will be 250 mg, administer subcutaneously (SC) in the abdomen, 
upper outer thigh or upper outer arm once every 4 weeks. To administer a target dose of 
canakinumab of 250 mg, two separate subcutaneous injections  (one of 200 mg and one of 50 mg)   
must be administered to the patient at a visit. Pre-medication to prevent in jection  reaction before 
the first administration of canakinumab is not re commended . For additional guidance refer to 
canakinumab (ACZ885) Instructions for Use / and to the canakinumab Investigat ors Brochure .  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  39 PanCAN-SR1 Orig Version: 22JUL2020 
 4.1.3 Spartalizumab 
Spartalizumab will be supplied in a liquid solution. The starting dose of spartalizumab  is 400 mg 
(prepared by reconstituting four vials with sterile water for injection (SWFI) and diluted in a 5% 
dextrose infusion bag before use) administered via intravenous infusion over 30 minutes (up to 2 
hours, if clinically indicated) once every 4 weeks. Infusion of spartalizumab must take place in a 
facility with appropriate resuscitation equipment available at the bedside and a physician readily available during the period of drug administration.   
Patient s should be closely observed for potential infu sion-related reactions including rigors, chills, 
wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever, and vital signs monitored more frequently if clinically indicated, during and for at least 2 hours after the first two spartalizumab inf usions  (before administration of chemotherapy ).  Observation for a specified 
period of time for the 3
rd and subsequent infusions is not necessary (unless medically indicated) 
but subjects should be provided instructions to notify the study personnel if symptoms of infusion reaction occur after any spartalizumab infusion. Patients shou ld not receive pre- medication to 
prevent infusion reaction before the first infusion of study treatment. If a patient experiences an infusion reaction, he/she may receive premedication on subsequent dosing days. The pre -
medication should be chosen per institutional standard of care, at the discretion of the investigator. Please refer to Table 4 -15 below  for additional details .  The same may apply for the subsequent 
spartalizumab  infusions if medically indicated.  
For additional guidance refer to Spartalizumab (PDR001) Pharmacy Manual  and to the 
spartalizumab Investigat or’s Brochure . 
4.1.4 Initial Dosing Schedule  
Table 4-1. Initial Dose and Treatment Schedule   
Study 
treatments  
Pharmaceutical 
form and route of 
administration Strength  Starting Frequency and/or 
Regimen  Dose 
Administered  
Spartalizumab 
(PDR001) Concentrate for 
solution for IV 
infusion   4 x 100 mg 
vials  Day 1 of each 28-
day cycle 
 400 mg  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  40 PanCAN-SR1 Orig Version: 22JUL2020 
 Study 
treatments  Pharmaceutical 
form and route of 
administration Strength  Starting Frequency and/or Regimen  Dose Administered  
Canakinumab (ACZ885) Solution for s.c. 
injection   
in prefilled syringe  200 mg/1 .33 
mL AND 1 x       
50 mg/0.5 mL  Day 1 of each 28-
day cycle   250 mg  
Gemcitabine IV  Days 1, 8, 15 of  
each 28-day cycle                     1000 mg/m2 
Nab-paclitaxel  IV  Days 1, 8, 15 of  each 28-
day cycle                     125 mg/m2  
 
 
4.1.5 Dose Recommendation G uideline  for Study Cohort  
Approximately t en patient s will be enrolled initially to have at least 6 evaluable patients per dose 
level  (additional patients maybe enrolled as needed in order to have 6 evaluable patients) . The 
evaluable criteria are defined in Dose Determining Set (DDS) , and the evaluable patients will be 
included in the Dose -Determining set. Patients must complete a minimum of 56 days (8 weeks) of 
dosing of study treatment with the minimum safety evaluation and drug exposure or have had a 
DLT within the first 56 days of study treatment to be considered evaluable for recommended dose 
decisions (Please refer to Section 9.1 .3 for further details). Additional approximately ten patients  
(to have at least 6 additional evaluable patients) may be enrolled at lower  dose level in case a dose 
de-escalation is necessary.    
 
Table 4 -1 defines the starting dose level.  In case of unaccepatable toxicility  of the starting dose 
devel,  the enrollment to the curre nt dose level will be stopped and a lower dose ( -1 dose level) 
will be used.  At the -1 dose level,  canakinumab is adminstered at 250 mg s.c Q8W while other 
components of the combination stay the sa me as the starting dose level.  Table 4 -2 below describes 
the starting dose and the -1 dose level in case the starting dose has unacceptable toxicity.   
  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  41 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 4 -2: Provisional dose levels for the canakimumab with fixed dosage of spartalizumab, 
Gemcitabin e and nab- paclitaxel  
Dose level  Proposed dose  of canakinumab   
   
1 (starting dose)  250 mg s.c. Q4W Canakinumab   
-1* 250 mg s.c Q8W  Canakinumab   
Spartlizumab:  400 mg s.c. Q4W;  Gemcitabine: 1000 mg/m2+ nab-paclitaxel 125 mg/m2 (on day 1, 8, and 15 of  
every cycle).  
  
*Dose level -1 represents the treatment dose for patients requiring a dose reduction from the starting dose level.  
 
As the starting dose is the highest provisional dose level, this dose may be declared  the 
recommended dose. This could occur if a minimum of 6 evaluable patients has been treated and 
deemed evaluable at this dose , and the dose is considered safe by BLRM  and it is the dose 
recommended for patient s after the review of all clinical databy investigators and Novartis . At t he 
Dose Confirmation Meeting the Safety Review Team (composed at least of a clinician, patient 
safety representative and biostatistician)  would review all available toxicity information (including 
adverse events and laboratory abnormalities that are not DLTs) and the available PK information.  
 The decision on dose tolerability will be based on all relevant data from the ongoing study and a review of safety data from the first 8 weeks. A Bayesian logistic regression model (BLRM) for 
combinations using the escalation with overdose control (EWOC) criterion to evaluate the risk of 
DLT will guide the decision.  The details of the BLRM are provided in Section 9.4  and Appendix 
B.   The adaptive Bayesian methodology provides an estimate of all dose levels of the combination 
and incorporates all DLT information at all dose levels for this estimation. To limit the patient  
exposure to DLT,  if 2 or more patients in the starting dose level (or -1 dose level) experience d a 
DLT, Novartis should be notified and the BLRM will be updated with this new information . 
Additional patients may be continued  into the current dose cohort only if the combination still  
meets the EWOC criteria and as agreed by Investigators and Novartis personnel.  
 
4.1.5 .1 Definitions of Dose Limiting Toxicities (DLTs)  
A dose -limiting toxicity (DLT) is defined as an adverse event (AE) or abnormal laboratory value 
assessed as unrelated to disease, disease progression, inter -current illness, or concomitant 
medications that occurs within the first 8 weeks of study treatment  and at least po ssibly related to 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  42 PanCAN-SR1 Orig Version: 22JUL2020 
 the study drugs . The investigator must notify the sponsor immediately (within 24 hours of the 
treating physician’s knowledge) o f  a n y  u n e x p e c t e d  C T C A E  g r a d e  ≥  3  A E s  o r  l a b o r a t o r y  
abnormalities.  NCI CTCAE v5.0 will be used for all grading.  
Table 4-3:   Criteria for Defining D ose-Limiting Toxicities  
TOXICITY  DLT CRITERIA  (NCI CTCAE v5.0 will be used for grading)  
Cardiac  • Grade ≥ 3 cardiac events  
Cutaneous 
reactions  • Grade ≥ 3  
Gastrointestinal  • Grade 3 nausea and vomiting for > 3 days despite optimal anti -emetic 
therapy  
• Grade 3 diarrhea for > 5 days despite optimal antidiarrheal treatment 
(which could include steroids)  
• Grade 4 vomiting or diarrhea  
Hematological  • Grade 4 neutropenia for > 7 consecutive days, or grade 4 febrile 
neutropenia 
• Grade 4 anemia  
• Grade 3 thrombocytopenia with clinically significant bleeding (i.e. life threatening and invasive intervention indicated) regardless of duration or requirement for transfusion, or grade 4 thrombocytopenia 
(<25,000/mm3)  
Hepatobiliary  • Grade 4 bilirubin elevation  
• For patient s with normal baseline AST, ALT and bilirubin values:  
- AST or ALT > 8.0 × ULN; OR  
- AST or ALT > 5.0 × ULN for more than 2 weeks; OR  
- AST or ALT > 3.0 × ULN combined with total bilirubin > 2.0 × ULN without evidence of cholestasi s 
• For patient s with abnormal baseline AST or ALT or abnormal baseline 
bilirubin value:  
- ALT or AST > 3.0 x baseline value; OR  
- ALT or AST > 3.0 x baseline (or > 8.0 x ULN), whichever is lower, combined with total bilirubin > 2.0 x baseline and > 2.0 x ULN 
without evidence of cholestasis   
Immune -related 
toxicities 
(except 
pneumonitis)  • Grade 3 immune -related toxicities that persist > 14 days with same 
severity despite treatment with corticosteroids.  
• Grade 4 immune related toxicities of any duration  
• Grade ≥ 3  infusion related reaction  
Infections  • Grade 4  
Hypertension  • Grade 3 hypertension if it persists > 7 days despite optimal anti -
hypertensive treatment  
• Grade 4 hypertension of any duration  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  43 PanCAN-SR1 Orig Version: 22JUL2020 
 Pancreatitis  • Symptomatic serum amylase or lipase elevation, medical intervention 
required  
• Grade ≥ 3 pancreatitis  
Peripheral 
neuropathy  • Grade ≥ 3  
Pneumonitis  • Grade 2 pneumonitis if it persists > 7 days despite treatment with 
corticosteroids  
• Grade ≥ 3 pneumonitis of any duration  
Other AEs  Other clinically significant AEs:  
• grade ≥ 3 AEs that have not been previously identified for canakinumab 
or spartalizumab or grade 4 AEs that have not been previously identified 
for gemcitabine and nab -paclitaxel  
• grade ≥ 3 AEs that are known to occur with canakinumab or 
spartalizumab,  or grade 4 AEs that are known to occur with gemcitabine 
and nab- paclitaxel, but cannot be controlled using the recommended 
product- specific management guidelines (per local prescribing 
information), or leads to ˂50% of planned exposure of study medication s 
• Other clinically -significant AEs, including a single event or multiple 
occurrences of the same event that lead to a dosing delay of > 8 weeks 
should be considered as DLTs by the Investigators and the sponsor, 
even if not grade 3 or higher  
 
Events which will NOT be considered as DLT for the purpose of this protocol:  
• Clinically insignificant laboratory values ≤ grade 2.  
• For electrolyte abnormalities ≥ grade 3, the maximum allowable time limit for correction  
to ≤ grade 1 is 72 hours. 
 
4.2 Dose Modifications 
4.2.1 Dose Modifications of Gemcitabine and Nab-P aclitaxel  
Toxicities for gemcitabine and nab -pacli taxel are graded based on Tables 4 -4 and 4 -5 below  
(according to CTCAE v 5.0). Dose adjustments are to be made according to the system showing 
the greatest degree o f toxicity. Please refer to the gemcitabine and nab -paclitaxel package inserts  
(Appendix A) .  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  47 PanCAN-SR1 Orig Version: 22JUL2020 
 please see Section 4.2.3  and Tables 4 -6 and 4-7  below.   For dose modifications of spartalizumab 
please see Section s 4.2.4 and 4.2.5  below.  
If canakinumab is interrupted for more than 12 weeks or a subject misses more than two doses of 
canakinumab due to canakinumab -related toxicities (whichever is longer), canakinumab must be 
permanently discontinued. If the chemotherapy drugs need to be interr upted due to chemotherapy -
related toxicity, canakinumab and spartalizumab  can be continued if a patient is clinically 
benefitting  from the treatment until disease progression per RECIST 1.1, intolerable toxicity, or 
any other conditions specified in Section 5.4.2.  
If spartalizumab and chemotherapy drugs are permanently discontinued due to toxicity, the 
investigator can continue canakinumab until disease progression per RECIST 1.1 or any other conditions for treatment discontinuation  as defined Section  5.4.2 , whichever is earlier.  
4.2.3 Dose Modification Guidelines for Canakinumab 
For patient s who do not tolerate the protocol -specified dosing schedule, dose interruptions are 
permitted in order to allow patients  to continue the study treatment. There are no canakinumab 
dose reductions allowed. However, if required, dose regimen modification by adjusting the interval 
between doses can be allowed  (from Q4W to Q8W) . 
Table 4 -7.  Criteria for Dose Interruption and Re -Initiation of Canakinumab for Adverse 
Events  at least possibly related to canakinumab treatment  
 
Worst toxicity  
(CTCAE v5.0) during a 
cycle of therapy  Mandatory dose schedule modifications for canakinumab  
General guidance for adverse drug reaction (to be followed whenever no other specific guidance  is 
described in this table)  
Grade 1/ Grade 2  Maintain dose level  
Grade 3 Interrupt dose until resolved to ≤ grade 2, then increase canakinumab 
dosing intervala 
Grade 4  Permanently discontinue canakinumab  
Exceptions to the above general guidanceb 
Infections  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  48 PanCAN-SR1 Orig Version: 22JUL2020 
 Worst toxicity  
(CTCAE v5.0) during a 
cycle of therapy  Mandatory dose schedule modifications for canakinumab  
Grade 2 Maintain dose level.  
For an infection that requires medical intervention, if it persists for >14  
days despite appropriate treatment, then interrupt dose until  infection 
resolves  to <grade 2 ; then resume treatment and maintain dose  
Grade 3  Omit dose until resolved to <grade 2, then maintain dose and schedule  
Neutropenia (ANC)  
Grade 2  Interrupt until ≤ grade 1, then maintain dose  
Grade 3  Interrupt until resolved to ≤ grade 1, then:  
• For subjects receiving chemotherapy, maintain canakinumab dosing 
interval, only delay canakinumab dose to match chemotherapy dosing 
• After permanent discontinuation of chemotherapy, increase 
canakinumab dosing intervala 
Grade 4  • If ≤7 consecutive days, omit dose until resolved to ≤ grade 1, then 
maintain dose and schedule  
• If >7 consecutive days,  permanently discontinue canakinumab  
Febrile neutropenia  
Grade 3  Omit dose until resolved, then maintain dose and schedule  
Grade 4  Permanently discontinue canakinumab  
Thrombocytopenia  
Grade 3 Interrupt dose until resolved to ≤ grade 1, then:  
• If resolved in ≤ 7 days, then maintain dose level 
• If resolved in > 7 - increase canakinumab dosing intervala 
• With clinically significant bleeding (i.e. life threatening or invasive 
intervention indicated) - increase canakinumab dosing intervala 
Serum creatinine  
Grade 2 • Maintain dose level; monitor other renal functions (e.g. creatinine 
clearance, glomerular filtration rate/GFR, blood urea nitrogen/BUN, urinalysis).  
• If elevated creatinine level persists at  grade 2 for >14 days despite 
appropriate management for other underlying contributing factors, interrupt the dose until resolved to < grade 2 or baseline, then resume 
treatment and increase dosing interval of canakinumab   
Grade 3  • 1st occurrence: Omit dose until resolved to ≤ grade 1 or baseline, then 
maintain dose and schedule  
• 2nd occurrence: Permanently discontinue treatment  
Isolated total bilirubin elevation*  
Any elevation > ULN  
 Fractionate bilirubin, evaluate for cholestatic liver injury (ALP) or alternative causes of bilirubin elevation (e.g. disease progression 
[imaging]) . 
Treat alternative causes according to local institutional 
guidelines  
Grade 2: > 1.5 - 3.0 x ULN • Maintain treatment.  
• Repeat LFTs within 48-72 hours, then monitor LFTs weekly until 
resolution to ≤ grade 1 or to baseline  
• If isolated bilirubin remains stable at grade 2, continue treatment with 
canakinumab at the same dos ing interval   
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  49 PanCAN-SR1 Orig Version: 22JUL2020 
 Worst toxicity  
(CTCAE v5.0) during a 
cycle of therapy  Mandatory dose schedule modifications for canakinumab  
Grade 3: >3.0 – 10 ULN  Interrupt  treatment.   
Repeat LFTs within 48-72 hours, monitor LFTs weekl y until resolution to 
≤ grade 1 or to baseline.  
 
If resolved in ≤ 14 days, maintain dose regimen; if not resolved in 14 
days, permanently discontinue canakinumab. (Please see foot -note 
regarding alternative cause/s of bilirubin elevation).  
Grade 4: > 10 x  ULN See footnote* - otherwise permanently discontinue treatment  
 
If alternative cause/s is identified and managed, and bilirubin resolves to ≤ grade 1 or to baseline, resume canakinumab at the same dose 
regimen.  
* An isolated bilirubin elevation is not typical for DILI. Bilirubin can be elevated either as part of a “Hy’s law” 
constellation with a preceding elevation of ALT/AST, or as part of a cholestatic reaction with simultaneous elevation 
of other cholestatic parameters (ALP, GGT). Isolated bilirubin can be seen in conjunction with drugs that inhibit bilirubin conjugation or excretion, but both scenarios do not typically represent liver injury. Alternative causes of bilirubin elevation should therefore, be ruled out before basing dose modification decisions on bilirubin values alone.
 
Isolated AST or ALT elevation  
Grade 1, 2  May continue canakinumab treatment  
Grade 3: >5 - 20 x ULN*   
With normal baseline:   
AST or ALT >5.0 –  10.0 x 
ULN Interrupt treatment. Repeat LFTs within 48-72 hours, then monitor LFTs 
weekly until recovery to grade ≤1 or to baseline.  
If resolved in ≤ 14 days, maintain dose level; if resolved in > 14 days, 
reduce by 1 dose level.  
AST or ALT >10.0 – 20.0 x 
ULN Interrupt treatment. Repeat LFTs within 48-72 hours, then monitor LFTs 
weekly until recovery to grade ≤1 or to baseline.  
Then reduce by 1 dose level.  
With abnormal baseline ALT/AST (up to grade 2: ≤  5.0 ULN):  
ALT/AST > 2.0 x baseline AND > 5.0 x ULN  
 Interrupt treatment. Repeat LFTs within 48-72 hours, then monitor LFTs 
weekly until recovery to baseline. If resolved in ≤ 14 days, maintain dose level; if resolved in > 14 days, reduce by 1 dose level 
ALT/AST > 3.0 x baseline 
AND >10 x ULN  Interrupt treatment. Repeat LFTs within 48 -72 hours, then monitor weekly 
until resolved to baseline, then reduce by 1 dose level  
Grade 4: >20 x ULN*  Permanently discontinue treatment  
Combined elevations of AST or ALT and total bilirubin  
With normal baseline LFTs:  
Grade 2 ALT/AST ( >3.0 x ULN)  
with bilirubin > 2.0 x ULN  
(unless Gilbert's syndrome)  Interrupt study treatment. Assess if case is true DILI.*     
• If DILI confirmed  - Permanently discontinue.  
• If Not DILI – interrupt treatment. Treat the identified                                                               
cause according to institutional guidelines. Repeat LFTs within 48-72 hours, then monitor weekly, till enzyme levels resolve to ≤Grade 1 or 
Baseline.                                                                                                                                                  
With abnormal baseline LFTs:  
ALT or AST >3.0  x baseline  After recovery, re -administration of study  treatment could be considered 
only if Investigator assesses benefit to outwei gh the risk. Any decision 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  50 PanCAN-SR1 Orig Version: 22JUL2020 
 Worst toxicity  
(CTCAE v5.0) during a 
cycle of therapy  Mandatory dose schedule modifications for canakinumab  
OR  ALT or AST >8.0 x ULN 
[which ever is lower)  
combined with total 
bilirubin >2.0 x baseline 
AND >2.0 x ULN                                                                            regarding re -administration of study drug/s and dose regimen should be 
discussed with the Sponsor.                                                                                                                     
* For addition al information on follow -up of potential drug induced liver injury cases, refer to section 4.3.2  
Pancreatitis  
Grade 3  Permanently discontinue canakinumab  
Hypertension  
Grade 3 • Interrupt dose until resolved ≤ grade 1, if resolved within ≤7 days then 
maintain dose level 
• if it persists > 7 days despite optimal anti -hypertensive treatment -  
then increase canakinumab dosing interval  
Diarrhea  - institute appropriate anti -diarrheal treatment and follow general guidelines  
Rash/photosensitivity  - initiate/institute appropriate skin toxicity therapy (such as antihistamines and/or 
topical corticosteroids) and follow general guidelines.  
Grade 3  Omit dose until resolved to grade ≤1  
• if resolved ≤7 days – increase canakinumab dosing interval 
• if resolved >7 days despite optimal therapy – permanently discontinue 
canakinumab  
Steven Johnson Syndrome, Toxic epidermal necrolysis  
• Permanently discontinue canakinumab  
Tuberculosis or reactivation of hepatitis  
• Permanently discontinue canakinumab  
Asymptomatic laboratory abnormalities -   
• If clinically significant, follow general guidelines  
DILI – drug-induced liver injury; LFTs - Liver function Tests  
a Canakinumab dosing interval can be increased from Q4W to Q8W.  
b If relatedness to canakinumab can be excluded with certainty and there is no risk for the patient, the dose 
modification for canakinumab is not mandatory 
 
4.2.4 Dose modification and Dose Interruption for spartalizumab  
The following sections address the specific instructions for mandatory and recommended dose 
modifications and recommended management for adverse events considered suspected to be 
related to spartalizumab. These modifications/interruptions must be recorded on the Dosage 
Administration Record CRF.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  51 PanCAN-SR1 Orig Version: 22JUL2020 
 4.2.4.1  General dose modification instructions for spartalizumab  
No dose  reductions of spartalizumab are allowed. Dose interruption for spartalizumab includes 
delaying or withholding the treatment for any reason as well as an interruption of treatment. All 
dose interruptions and the reason for the dose interruption must be documented in the eCRF.  
Overall, patient s with AEs suspected to be related to spartalizumab including those of potential 
immune -mediated etiology (irAE) may need to interrupt or permanently discontinue study 
treatment as outlined in Section 4.2.5 below .  
 
4.2.5 Dose modification and Management Requirements for Potential Immune -
Mediated Adverse Events (irAEs)  
Adverse events of a potential immune- mediated etiology  (irAE) can be associated with 
spartalizumab treatment. Investigators must be vigilant and carefully identify AEs that may be 
suggestive of potential irAEs as their appearance may be sub -clinical and early diagnosis is critical 
for its adequate management and resolution. Collaboration with disease -specific subspecialties is 
encouraged; corticosteroids are the mainstay of treatment for most irAEs.  
An irAE may be of low grade and self -limited, most frequently involving the GI tract (e.g. 
diarrhea/colitis), s kin (e.g. rashes, pruritus), liver (e.g. hepatitis), lung (e.g. pneumonitis), kidneys 
(e.g. nephritis) and endocrine systems (e.g. hypothyroidism, hyperthyroidism, type I diabetes, 
hypophysitis including hypopituitarism and adrenal insufficiency). Other im mune -mediated AEs 
may rarely include the nervous system (e.g. encephalitis, Guillain -Barre syndrome, myasthenia 
gravis), eye (e.g. uveitis, vision changes), musculo -skeletal system (e.g. myositis, arthritis), 
pancreas (e.g. pancreatitis), cardio -vascular s ystem (e.g. vasculitis, myocarditis) or blood system 
(e.g. anemia, cytopenias), and severe skin reactions such as toxic epiderm al necrolysis  (TEN)  or 
Steven Johnson syndrome  (SJS) . Furthermore, complications in patient s with bone marrow or solid 
organ transplant have been reported (e.g. organ rejection, severe graft -versus -host disease). 
However, nearly all organs can be affected by immune- mediated toxicities. irAEs often occur 
relatively early (mostly within weeks to 3  months after treatment initiation), however, may develop 
at any time during treatment (even after several months), and may also occur after the treatment 
discontinuation.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  52 PanCAN-SR1 Orig Version: 22JUL2020 
 Serological, immunological and histological assessments should be performed as deem ed 
appropriate by the investigator, to verify the potential immune- related nature of the AE, and 
exclude a neoplastic, infectious or metabolic origin of the AE.  
Severe grade or persistent lower grade irAEs typically require interrupting or permanently 
discontinuing treatment and administration of systemic steroids, and sometimes other 
immunosuppressive medications (i.e. tumor necrosis factor alpha (TNFα) antagonists, mycophenolate or tacrolimus, etc.). Early recognition and work -up of irAEs and initiation of 
treatment are critical to reduce the risk of complications, since the majority of irAEs are reversible with the use of steroids and other immuno suppressants. Some events like endocrinopathies may 
require life -long hormonal replacement.  
Tapering of steroids should not be too rapid (i.e. >4 weeks) to avoid recurrence or worsening of irAEs. The management of irAEs may further include initiation of antibiotics for prophylaxis 
against opportunistic infections.  
Patient s should be instructed to return to the study site as soon as possible (instead of waiting for 
their next scheduled visit) if they experience symptoms consistent with an irAE. Patient s who 
experience a new or worsening irAE should be contacted and/or evaluated by the study site more 
frequently.  
Based on clinical experience and published guidelines on the management of irAEs in patients treated with immune checkpoint inhibitors (Brahmer et al, 2018, Haanen et al, 2017, NCCN 2018), 
instructions have been developed how to manage irAEs that may occur  in patient s receiving 
spartalizumab with canakinumab. Dose modification requirements and AE management guidelines for the potential irAEs are provided in the following tables: diarrhea/colitis ( Table 4-
8), hepatitis (liver laboratory alterations) ( Table 4-9),  skin toxicity ( Table 4-10) , nephritis ( Table 
4-11) , pneumonitis (Table 4-12), endocrinopathies ( Table 4-13),  and other potential immune -
related AEs ( Table 4-14) . In addition, guidance for management of spartalizumab  infusion -related 
reactions is provided in ( Table 4-15).  
Investigators are encouraged to contact the Medical Monitor/ Sponsor as needed to discuss cases 
that warrant separate discussion outside of the scope of the current instructions.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  53 PanCAN-SR1 Orig Version: 22JUL2020 
 The dosing modification requirements are mandatory or recommended depending on AE, 
however, the AE management guidelines are recommendations and can be modified according to 
the local practices.   
 
Table 4-8. Mandatory dose modification requirements and recommended clinical 
management guidelines for potential immune -related diarrhea/colitis  at least 
possibly related to spartalizumab treatment  
 
 
Diarrhea and/or Colitis  
Grade  Recommended adverse event 
management guidelines Mandatory dose 
modification 
requirements (u nless 
specified otherwise)  
Grade 1 diarrhea: < 4 stools per day over baseline  
 
Grade 1 colitis: asymptomatic; clinical or diagnostic observations only; 
intervention not indicated  • Symptomatic treatment  (hydration, diet)  
• Monitor closely  May continue treatment 
(recommendation)  
Grade 2 diarrhea: 4-6 stools per day over baseline  
 
Grade 2 colitis: abdominal 
pain; mucus or blood in stool • Consult with GI specialist  
• Stool evaluation, imaging and endoscopy as clinically indicated  
• Symptomatic treatment (hydration, diet)  
• Commence steroids (0.5-1 mg/kg/d prednisone or IV equivalent) until recovery to grade 1, particularly in case 
of persisting/worsening symptoms, 
ulcerations or bleeding seen on endoscopy, or blood in stool. If no improvement within few days, manage as per Grade 3.  
• Slowly taper steroids once symptoms 
improve to Grade 1 (i.e. over 4 -6 weeks)  • Interrupt treatment until diarrhea/colitis 
recover to grade ≤1 
or baseline 
Grade 3 diarrhea: increase of ≥7 stools per day over baseline; incontinence; hospitalization indicated; limiting self -care ADL 
 
Grade 3 colitis: severe 
abdominal pain; peritoneal signs  
 • Consider hospitalization; rule out bowel perforation and initiate IV hydration as needed  
• Consultation with GI specialist; consider endoscopy and biopsy  
• In addition to symptomatic treatment, initiate treatment with IV steroids (1 to 2 mg/kg/d of methylprednisolone or equivalent)  
• Consider antibiotics as appropriate  • Interrupt treatment until diarrhea/colitis recover to grade ≤1 or baseline 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  54 PanCAN-SR1 Orig Version: 22JUL2020 
 Diarrhea and/or Colitis  
Grade  Recommended adverse event 
management guidelines Mandatory dose 
modification 
requirements (u nless 
specified otherwise)  
• If no improvement in 2 -3 days : consider 
initiating infliximab 5 mg/kg and continue steroids. (infliximab is contraindicated in patient s with sepsis/perforation)  
• Slowly taper steroids once symptoms improve to grade 1 (4 to 6 weeks)  
• If symptoms worsen during steroid reduction, re-escalate as needed followed by more prolonged taper and 
consider infliximab  
Grade 4 diarrhea or colitis: 
life-threatening 
consequences; urgent 
intervention indicated  Same as for grade 3  Permanently 
discontinue treatment  
 
  
Table 4-9. Mandatory dose modification requirements and recommended clinical 
management guidelines for potential immune -related liver laboratory alterations  
at least possibly related to spartalizumab treatment  
  
 Abnormal liver function tests  
Severity  Recommended 
adverse event 
management 
guidelines  Mandatory dose modification requirements  
Isolated AST and/or ALT elevation  
With normal AST and ALT at baseline:  
Grade 3: AST or ALT (>5.0 – 20.0) x ULN:  
AST or ALT >5.0 –  10.0 
x ULN Start oral prednisolone 
1 mg/kg  
 
 Interrupt treatment.  
Repeat LFTs within 48-72 hours, then monitor 
LFTs weekly until recovery to grade ≤1 or to 
baseline; then resume same dose  
AST or ALT >10.0 – 20.0 
x ULN Start I.V. (methyl) 
prednisolone 1-2 
mg/kg Permanently   discontinue study treatment. 
Monitor LFTs within 48-72 hours, then monitor 
LFTs weekly until recovery to grade ≤1 or to 
baseline.  
Grade 4: AST or ALT (>20 x ULN)  Start I.V. (methyl) prednisolone 2 mg/kg
 
 Permanently discontinue treatment  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  55 PanCAN-SR1 Orig Version: 22JUL2020 
  Abnormal liver function tests  
Severity  Recommended 
adverse event 
management 
guidelines  Mandatory dose modification requirements  
Isolated AST and/or ALT elevation  
With abnormal ALT/AST (up to grade 2 -  ≤ 5.0 x ULN) at baseline:  
ALT/AST > 2.0 x baseline AND > 5.0 x ULN  If rising ALT/AST when re-checked, start oral prednisolone 1 mg/kg  Interrupt treatment.  
Repeat LFTs within 48-72 hours, then monitor LFTs weekly until recovery to baseline; then 
resume same dose.  
•  
ALT/AST > 3.0 x baseline 
AND >10 x ULN Start oral prednisone/ prednisolone 1-2 mg/kg Interrupt treatment.  
Repeat LFTs within 48-72 hours, then monitor 
weekly until resolved to baseline, then resume 
same dose.  
 
AST or ALT >20 x ULN 
(grade 4) Start I.V. (methyl) 
prednisolone 1 -2 mg/kg  Permanently discontinue treatment.  
Concomitant elevation of AST and/or ALT and total bilirubin  
With normal AST/ALT and bilirubin at baseline:  
Grade 2 ALT and/or 
AST elevation ( >3.0 x ULN)
 with bilirubin > 
2.0 x ULN  (unless 
Gilbert's syndrome)                                 Start I.V. (methyl) 
prednisolone 1-2 
mg/kg Interrupt treatment. Assess if case is drug induced 
liver injury (DILI) -      
• If DILI confirmed, permanently discontinue study 
treatment. For additional information on follow -up 
of potential drug induced liver injury cases, refer 
to section 4.3.2. If no DILI confirmed, interrupt treatment, treat the identified cause according to institutional                                                 guidelines.  
Repeat LFTs within 48-72 hours, then monitor weekly, till enzyme levels resolve to ≤grade 1 or 
baseline.                                                                                                                                                  
After recovery, re -administration of study treatment 
could be considered only if Investigator assesses benefit to outweigh the risk. Any decision regarding re-administration of study drugs and dose regimen 
should be discussed with the Medical Monitor.                                                  
With abnormal ALT/AST at baseline:  
ALT or AST >3.0  x  
baseline OR  ALT or 
AST >8.0 x ULN                                                       
[whichever is lower]                                        
combined with total bilirubin >2.0 x baseline AND >2.0 x 
ULN                                             Start oral 
prednisone/ prednisolone 1-2 mg/kg
f Same as above  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  56 PanCAN-SR1 Orig Version: 22JUL2020 
  
  Isolated total bilirubin elevation  
Any elevation > ULN   Fractionate bilirubin, evaluate for cholestatic liver 
injury (e.g. by testing ALP) or alternative causes of bilirubin elevation (e.g. disease progression [imaging]). Treat alternative causes according to 
institutional guidelines  
Grade 2 ( >1.5 - 3.0 
ULN)  Maintain treatment.  
Repeat LFTs within 48-72 hours, then monitor LFTs weekly until resolution to ≤ grade 1 or to baseline.  
If isolated bilirubin remains stable at Grade 2, continue treatment with spartalizumab at the same 
dose regimen.  
Grade 3 ( >3.0 – 10 
ULN)  
 Interrupt treatment.  
Repeat LFTs within 48-72 hours, then monitor LFTs 
weekly until resolution to ≤ Grade 1 or to baseline.  
Grade 4 (> 10 x ULN)   See footnote* - otherwise discontinue treatment  
Foot note:   an isolated bilirubin elevation is not typical for DILI. Bilirubin can be elevated either as part of a “Hy’s 
law” constellation with a preceding elevation of ALT/AST, or as part of a cholestatic reaction with simultaneous 
elevation of other cholestatic parameters (ALP, GGT). Isolated bilirubin can be seen in conjunction wit h drugs that 
inhibit bilirubin conjugation or excretion, but both scenarios do not typically represent liver injury. Alternative 
causes of bilirubin elevation should therefore, be ruled out before basing dose modification decisions on bilirubin 
values alon e. 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  57 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 4-10.  Mandatory dose modification requirements and recommended clinical  
                    management guidelines for potential immune -related skin events                                      
at least possibly related to spartalizumab  treatment  
Skin Events  
Grade  Recommended adverse event 
management guidelines Mandatory dose modification requirements (unless specified 
otherwise)  
Grade 1 (e.g. rash, pruritus)  • Initiate prophylactic and symptomatic treatment  
• Consider mild/moderate potency topical steroids or urea containing creams in combination with oral antipruritics  
• Reassess after 2 weeks  May continue treatment 
(recommendation)  
 
Grade 2 (e.g. rash, pruritus)  • Consider initiating systemic 
steroids (e.g. oral prednisolone 
0.5-1mg/kg daily).  
• In addition, treat with topical emollients, oral antihistamines, and medium/high-potency topical steroids  
• If symptoms persist or recur consider skin biopsy  • Consider dose interruption (recommendation)  
• In case of bullous dermatitis, acute 
generalized exanthematous pustulosis or DRESS, interrupt spartalizumab until recovery to grade ≤1 
or baseline (mandatory)  
Grade 3 (e.g. rash, pruritus and other severe cutaneous adverse reactions, bullous dermatitis)  • Consult with dermatologist and consider skin biopsy.  
• Initiate systemic steroids (1 mg/kg/d prednisone or IV equivalent); consider increasing if no improvement  
• High-potency topical steroids  
• Topical emollients, oral antihistamines as indicated  
• Consider GABA agonists or  
aprepitant in case of severe 
pruritus  • Interrupt treatment until recovery to grade ≤1 or baseline 
• For patient s with severe 
cutaneous adverse reaction or bullous dermatitis, risk/benefit before resuming treatment 
should be carefully 
considered.  
Grade 4: life- threatening  • Urgent dermatologic consultation and additional measures as per 
local guidelines  Permanently discontinue treatment  
Stevens -Johnson syndrome, 
toxic epidermal necrolysis  • Hospitalization and urgent dermatology consultation  
• Institute supportive care 
immediately as per institutional 
guidelines  Permanently discontinue treatment  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  58 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 4-11.  Mandatory dose modification requirements and recommended clinical  
                    management guidelines for potential immune -related nephritis  at least possibly  
                    related to spartalizumab treatment  
 
Nephritis  
Creatinine increased  Recommended adverse event 
management guidelines Mandatory dose modification requirements (unless 
specified otherwise)  
Creatinine >ULN  to ≤1.5x 
ULN; >1 to ≤1.5x baseline  • Monitor creatinine weekly  
• Rule-out other causes (e.g. fluids, medications, IV contrast)  
• Promote hydration and consider 
cessation of nephrotoxic drugs  May continue treatment (recommendation)  
 
Creatinine >1.5 to ≤3 x 
ULN; >1.5 to ≤3 x baseline • Monitor creatinine every 2 to 3 days and consult with nephrologist  
• Rule-out other causes (e.g. fluids, medications, IV contrast)  
• Initiate 0.5 to 1 mg/kg/d prednisone or equivalents if other causes are ruled-out  
• If worsening or no improvement: 1 to 2 mg/kg/d prednisone or equivalents  
• Promote hydration and cessation of nephrotoxic drugs  
• Consider renal biopsy  Interrupt treatment until 
serum creatinine recovers to ≤ grade 1 or baseline.  
 
Creatinine >3.0 ULN  • Monitor creatinine every 1 to 2 days and 
consider hospitalization  
• Consult with nephrologist and consider renal biopsy  
• Start 1 to 2 mg/kg/d prednisone or equivalents  
• Once event improves to grade ≤1, slowly taper steroids over at least 4-6 
weeks  Permanently 
discontinue treatment  
 
  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  59 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 4-12.  Mandatory dose modification requirements and recommended clinical  
                    management guidelines for potential immune -related pneumonitis                                 
                    at least possibly related to spartalizumab  treatment  
 
Pneumonitis   
Grade  Recommended adverse event 
management guidelines Mandatory dose modification requirements (unless 
specified otherwise)  
Grade 1: asymptomatic; clinical or diagnostic observations only; intervention not indicated  
 • Confirm diagnosis by appropriate investigations (CT scan) and rule out other causes e.g. infection.  
• Chest imaging/CT scan; repeat imaging in 3-4 weeks or as clinically indicated  
• Monitor symptoms every 2-3 days; clinical evaluation and laboratory work -up 
for infection: pulse oximetry  
• Consultation with pulmonologist 
recommended  Consider treatment interruption (recommendation)  
 
Grade 2: symptomatic; medical intervention indicated; limits instrumental ADLs  • Chest imaging/CT scan; repeat imaging 
in 3-4 weeks or as clinically indicated  
• Monitor symptoms daily, consider 
hospitalization  
• Clinical evaluation and laboratory work 
up for infection, pulse oximetry  
• Consult pulmonologist  
• Pulmonary function tests  
• Bronchoscopy with biopsy and/or BAL to 
rule out infection and/or disease progression/lung infiltration  
• Initiate steroids (1 to 2 mg/kg/d 
prednisone or equivalent)  
• Consider empirical antibiotics  
• If no improvement within 2-3 days, or 
worsening, treat as grade 3  • Interrupt treatment 
until recovery to grade ≤1 or baseline 
• Permanently 
discontinue 
treatment in case of recurring grade 2 pneumonitis  
Grade 3: severe symptoms; limits self -care 
ADLs; oxygen indicated 
 Grade 4: life- threatening 
respiratory compromise; 
urgent intervention required (e.g. tracheotomy or int ubation)  • Same as grade 2; in addition:  
• Hospitalization and pulmonary and 
infectious disease consultation  
• Methylprednisolone (1-2 mg/kg/d or 
equivalent) until symptoms improve to Grade ≤1, then slow taper over ≥4-6 weeks  
• If no improvement within 48 hours, 
consider infliximab and/or other immune-suppressive therapy, or IVIG as per local guidelines  
• Consider empiric antibiotic therapy  Permanently discontinue treatment  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  60 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 4-13.  Mandatory dose modification requirements and recommended clinical  
                        management guidelines for potential immune -related endocrine events                     
                        at least possibly related to spartalizumab treatment  
 
Endocrine events  
Grade  Recommended adverse 
event management 
guidelines  Mandatory dose modification requirements (unless 
specified otherwise)  
Grade 1: e.g. asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated   • Consider endocrinologist consult  
• If hypophysitis  is suspected, 
consider pituitary gland imaging (MRIs with gadolinium and sellar cuts); evaluate hormone levels as clinically indicated  
• Repeat labs in 1 to 3 
weeks/MRI in 1 month if 
laboratory abnormalities persist but normal lab/pituitary scan 
• If TSH <0.5 x LLN, or 
TSH >2x ULN, or consistently out of range in 2 subsequent measurements, include free T4 at subsequent cycles as 
clinically indicated  May continue treatment (recommendation)  
 
Grade 2: moderately symptomatic endocrinopathy (e.g., hypophysitis, adrenal 
insufficiency, hypothyroidism, hyperthyroidism), or minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL  
 
 • Endocrinology consultation  
• Rule out infection/sepsis and 
other alternative causes with appropriat e cultures/imaging 
• Evaluate hormone levels (e.g. ACTH, cortisol, FSH/FH, TSH, free T4, testosterone/estrogen), metabolic panel (e.g. Na, K, 
CO2, glucose), and imaging 
(e.g. brain MRI) as clinically indicated 
• Initiate hormone replacement therapy as appropri ate  
• Consider steroids (methylprednisolone 1 to 2 mg/kg/d or equivalent) in case of severe hypophysitis or thyrotoxicosis  
• Consider beta-blocker in case of severe hyperthyroidism  
• Consider hospitalization 
(e.g. in case of severe • Interrupt treatment until recovery to mild or no symptoms, and controlled with hormone replacement therapy. Hypothyroidism may be managed with 
replacement therapy 
without treatment interruption (unless life-threatening) (recommendation)  
• Permanently discontinue spartalizumab for life-threatening endocrinopathies (i.e. hyperthyroidism, adrenal insufficiency, hypophysitis) or recurring severe/life-threatening events not 
controlled by hormone 
replacement therapy.  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  61 PanCAN-SR1 Orig Version: 22JUL2020 
 Endocrine events  
Grade  Recommended adverse 
event management 
guidelines  Mandatory dose modification 
requirements (unless 
specified otherwise)  
adrenal insufficiency/crisis) , 
fluid replacement, and 
other supportive measures 
as clinically indicated  
Autoimmune diabetes  
(grade 3 hyperglycemia, or symptomatic hyperglycemia)  
 
 
Autoimmune diabetes  
(grade 4 hyperglycemia, or life-
threatening complications)  • Initiate anti -glycemic therapy 
(i.e. insulin) as medically indicated and monitor glucose levels regularly until metabolic control is achieved  
• Evaluate for ketoacidosis as medically indicated  
• Consultation with endocrinologist  
• Consider hospitalization (e.g.  
in case of ketoacidosis)  • Interrupt treatment until recovery to grade 1 or baseline 
• Permanently discontinue treatment in case of recurring severe/life-
threatening events not 
controlled by anti -glycemic 
therapy.  
 
 Table 4-14. Mandatory dose modification requirements and recommended clinical  
                    management guidelines for “other” potential immune -related AEs                                
at least possibly related to spartalizumab treatment  
 
Other (e.g. autoimmune  neuropathy, demyelinating polyneuropathy, Guillain -Barre syndrome, 
myasthenia gravis-like syndrome, encephalitis, non -infectious myocarditis, pericarditis, 
pancreatitis, grade 3 fatigue with rapid onset in absence of disease progression, etc.)  
Grade  Recommended Adverse Event 
management guidelines Mandatory dose modification requirements 
(unless specified otherwise)  
Grade 1: mild  • Provide symptomatic treatment 
evaluate/monitor adequately  May continue treatment 
(recommendation)  
Grade 2: moderate  • Ensure adequate evaluation to confirm 
etiology or exclude other causes  
• Provide symptomatic treatment  
• Systemic corticosteroids may be indicated 
• Consider biopsy or additional tests for confirmation of diagnosis  
• A specialist should be consulted  Consider interruption of 
treatment until recovery to ≤ grade 1 or baseline (recommendation)  
 
 
Grade 3: severe  • Initiate systemic corticosteroids (prednisone 
at a dose of 1-2 mg/kg/d or equivalent) and other therapies as appropriate 
• Monitor closely and consult with a specialist  
 • Interrupt treatment until recovery to ≤ grade 1 or baseline.  
• May restart treatment at the same dose and schedule taking into account the risks and 
benefits  
Grade 4: life-
threatening  • Hospitalization and consult with specialist  Permanently discontinue 
treatment  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  62 PanCAN-SR1 Orig Version: 22JUL2020 
 Other (e.g. autoimmune  neuropathy, demyelinating polyneuropathy, Guillain -Barre syndrome, 
myasthenia gravis-like syndrome, encephalitis, non -infectious myocarditis, pericarditis, 
pancreatitis, grade 3 fatigue with rapid onset in absence of disease progression, etc.)  
Grade  Recommended Adverse Event 
management guidelines Mandatory dose 
modification requirements 
(unless specified otherwise)  
• Initiate systemic corticosteroids (prednisone 
a dose of 1-2 mg/kg/d or equivalent) and 
other therapies as appropriate  
Encephalitis or aseptic meningitis  • Rule out infectious or other causes of moderate to severe neurologic deterioration, and consult with specialist.  
• If other etiologies are ruled out, administer corticosteroids at a dose of 1 to 2 
mg/kg/day prednisone equivalents.  Permanently discontinue treatment  
Guillain -Barre, 
neuropathy (motor, sensory or autonomic) OR , or transverse myelitis  
(grade 3: s evere 
symptoms; limiting self-care and 
ADL)  • Hospitalization and consult with specialist  Permanently discontinue 
treatment  
Myasthenia gravis  
 • Consult with specialist  
• Consider pyridostigmine and systemic corticosteroids (prednisone or equivalent) at a dose of 1-2 mg/kg/d; other therapies as appropriate (e.g. IVIG)  
• Hospitalization in case of severe cases  Grade 2: Interrupt treatment until recovery to ≤ grade 1 or baseline  
Grade ≥3: Permanently discontinue treatment  
Myocarditis grade 
≥2 or cardiac 
event grade ≥3 • Initiate systemic corticosteroids (prednisone or equivalent) at a dose of 1-2 mg/kg/d  
• Consult with specialist; hospitalization as 
indicated  Permanently discontinue 
treatment  
Pancreatitis/serum amylase/lipase increase 
 
Grade ≥2  
 
 • Evaluate for pancreatitis (clinical 
assessment, abdominal imaging and/or MRCP as appropriate)  
• Initiate steroids in case of ≥ grade 2 acute pancreatitis  
• Treatment may be continued in case of asymptomatic, isolated enzyme elevations without evidence for pancreatitis  Grade 2: interrupt treatment until recovery to ≤ grade 1 or baseline  
 
Grade≥3: permanently discontinue treatment  
Autoimmune hemolytic anemia, hemolytic uremic syndrome, or 
acquired 
hemophilia, grade 
≥3 • Consult with specialist  
• Consider systemic  corticosteroids and 
other therapies as appropriate (e.g. transfusion) per local institutional guidelines  • Permanently discontinue treatment  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  63 PanCAN-SR1 Orig Version: 22JUL2020 
 Other (e.g. autoimmune  neuropathy, demyelinating polyneuropathy, Guillain -Barre syndrome, 
myasthenia gravis-like syndrome, encephalitis, non -infectious myocarditis, pericarditis, 
pancreatitis, grade 3 fatigue with rapid onset in absence of disease progression, etc.)  
Grade  Recommended Adverse Event 
management guidelines Mandatory dose 
modification requirements 
(unless specified otherwise)  
Ocular events  • Consult with ophthalmologist  • Grade 2: interrupt treatment 
until recovery to ≤ grade 1 or baseline 
• Grade 3 and 4: permanently 
discontinue treatment  
 
Table 4-15. Mandatory dose modification requirements and recommended clinical  
                    management guidelines for  potential  infusion -related reactions or injection site  
                    reaction at least possibly related to spartalizumab treatment  
 
Infusion reaction  
Grade  Recommended adverse event 
management guidelines Mandatory dose modification 
requirements (unless 
specified otherwise)  
Grade 1: mild reaction; 
infusion interruption not 
indicated; intervention not indicated • Increase monitoring of vital signs/pulse oximetry as medically indicated until patient is deemed medically stable  
• Consider slowing infusion rate until recovery of symptoms  May continue treatment (recommendation)  
Grade 2: requires infusion 
interruption but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrs.  • Additional medical therapy as per local institutional guidelines that may include :  
o IV fluids  
o Antihistamines  
o NSAIDS, acetaminophen 
o Narcotics  
o Oxygen and corticosteroids as indicated  
• Increase monitoring of vital signs/pulse oximetry as medically indicated until patient is deemed medically stable  
• If symptoms resolve, the infusion may be restarted at 50% of the original infusion rate 
 
• Pre- medicate patient s 
approximately 1.5 hours prior to next infusion with:  
o Diphenhydramine (50 mg PO 
or equivalent)  • Stop infusion and keep line open  
• Permanently discontinue treatment in case of recurring infusion reaction despite adequate 
premedication and 
prolonged infusion/slow infusion rate  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  64 PanCAN-SR1 Orig Version: 22JUL2020 
 Infusion reaction  
Grade  Recommended adverse event 
management guidelines Mandatory dose modification 
requirements (unless 
specified otherwise)  
o Acetaminophen (500 -1000 
mg PO or equivalent)  
o Or as per local institutional 
guidelines  
Grade 3:  prolonged (i.e., 
not rapidly responsive to 
symptomatic medication and/or brief interruption of  infusion); recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae (e.g., renal impairment, pulmonary infiltrates)  
 
Grade 4: life- threatening; 
pressor or ventilatory 
support indicated  • Stop Infusion  
• Additional medical therapy as per local institutional guidelines that may include:  
o IV fluids  
o Antihistamines  
o NSAIDS, acetaminophen 
o Narcotics  
o Oxygen 
o Corticosteroids  
o Epinephrine  
• Close monitoring of vital signs, pulse oximetry and ECG as medically indicated until the patient is deemed medically stable 
• Hospitalization as indicated  Permanently discontinue 
treatment  
 
4.2.5.1  Guidance for Corticosteroids Tapering for Management of  Immune -Related 
AEs  
Consultation with disease -specific experts is recommended. Steroids should be tapered slowly and 
based on response/recovery of clinical symptoms. Consider complete tapering over a period of at 
least 4 weeks (sometime 6 -8 weeks or longe r) to present recurrent irAEs. Slower tapering or re -
escalation of corticosteroids therapy may be needed if the adverse event is not showing 
improvement. Once corticosteroid tapering is achieved at a level of 10 mg of prednisone/day (or 
equivalent) or less , spartalizumab can be restarted as indicated in the dose modification tables.  
4.2.6 Permanent discontinuation of spartalizumab  
In general, spartalizumab  must be permanently discontinued in case of:  
• Any grade 4 (life -threatening) adverse reactions (excluding en docrinopathies controlled 
with hormone replacement therapy)  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  65 PanCAN-SR1 Orig Version: 22JUL2020 
 • Persistent grade 2 or 3 adverse reactions (excluding endocrinopathies controlled with 
hormone replacement therapy) that do not recover to ≤ grade 1 within 12 weeks  
• Inability to reduce the dose of  steroids (for the management of irAE) to 10 mg/day or less 
of prednisone or equivalent within 12 weeks*  
• Any severe or grade 3 recurring adverse event that is at least possibly related to spartalizumab  
*The 12 week timeframe will begin from the time the irAE reaches a grade that leads to 
spartalizumab interruption.  
4.3 Follow- up for toxicities  
4.3.1  Follow- up of Immune -Related AEs  
 
The emergence of Immune- Related AE (irAE ) may be anticipated based on the mechanism of 
action of immunomodulatory therapies. Serologic, histologic (tumor sample) and immunological 
assessments should be performed as deemed appropriate by the Investigator to verify the immune-related nature of the AE and to exclude alternative explanations. Recommendations have been 
developed to assist investigators in assessing and managing the most frequently occurring irAEs.  
Patient s whose treatment is interrupted or permanently discontinued due to an irAE, AE or 
clinically significant laboratory value, must be followed -up at least once a week (or more 
frequently if required by institutional practices, or if clinically indicated) for 30 days, and subsequently at approximately 30- day intervals (or more frequently  if required by institutional 
practices, or if clinically indicated), until resolution or stabilization of the event, whichever comes 
first. Appropriate clinical experts should be consulted as deemed necessary.  
If an AE is suspected to be immune- related th e relevant immunological assessments (e.g. 
rheumatoid factor, anti -DNA Ab, etc.) should be performed . All patient s must be followed -up for 
irAEs for 150 days following the last dose of spartalizumab . If SAEs suspected to be related to 
study medication occur beyond Day 150, information should also be collected.  
4.3.2 Follow- up of Potential Drug -Induced Liver Injury (DILI) Cases  
Patient s with transaminase increase combined with total bilirubin ( TBIL ) increase may be 
indicative of potentially severe DILI (including  immune -related DILI), and should be considered 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  66 PanCAN-SR1 Orig Version: 22JUL2020 
 as clinically important events and should be assessed appropriately to establish diagnosis. The 
required clinical information, as detailed below, should be sought to obtain the medical diagnosis 
of the most l ikely cause of the observed laboratory abnormalities.  
The threshold for potential DILI may depend on the patient ’s baseline AST/ALT and TBIL value 
(please see Table 5-1); patient s meeting any of the following criteria will require further follow -
up and ass essments as outlined below:  
• For patient s with normal ALT and AST and TBIL value at baseline: AST or ALT > 3.0 x ULN 
combined with TBIL > 2.0 x ULN  
• For patient s with elevated AST or ALT or TBIL value at baseline: [AST or ALT > 3.0  x 
baseline ] or 8.0x ULN,  whichever is lower, combined with [TBIL > 2.0 x baseline AND > 2.0 
x ULN]  
NOTE: As DILI is essentially a diagnosis of exclusion, other causes of abnormal liver tests 
should be considered and their role clarified before the diagnosis of DILI is confirmed.  
A detailed history, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any pre -existing liver 
conditions or risk factors, should be collected.  
Laboratory tests should include ALT, AST, total bilirubin, direct and indirect bilirubin, GGT, 
GLDH, prothrombin time (PT)/INR, alkaline phosphatase, albumin, and creatine kinase.  
Evaluate status of liver metastasis (new or exacerbation) or vascular occlu sion with  CT, MRI, 
duplex sonography.   
Perform relevant examinations (Ultrasound or MRI, ERCP) as appropriate, to rule out if LFTs are 
caused by cholestasis (defined as ALP elevation > 2.0 x ULN with R value < 2 in patient s without 
bone metastasis, or elevation of ALP liver fraction in patient s with bone metastasis).  
Note: (The R value is calculated by dividing the ALT by the ALP, using multiples of the ULN for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
choles tatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury).  
Table 4-16 provides guidance on specific clinical and diagnostic assessments to be (OR which can 
be) performed to rule out possible alternative causes of the observed LFT abnorma lities.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  67 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 4-16.       Guidance for specific clinical and diagnostic assessments  
Disease  Assessment  
Hepatitis A, B, C, E  • IgM anti -HAV; HBsAg, IgM & IgG anti -HBc, HBV DNA; anti -HCV, 
HCV RNA, IgM & IgG anti -HEV, HEV RNA  
CMV, HSV, EBV infection  • IgM & IgG  anti-CMV, IgM & IgG anti -HSV; IgM & IgG anti -EBV 
Autoimmune hepatitis  • ANA & ASMA titers, total IgM, IgG, IgE, IgA  
Alcoholic hepatitis  • Ethanol history, γGT, MCV, CD -transferrin  
Nonalcoholic steatohepatitis  • Ultrasound or MRI  
Hypoxic/ischemic hepatitis  • Medical history: acute or chronic CHF, hypotension, hypoxia, 
hepatic venous occlusion. Ultrasound or MRI.  
Biliary tract disease  • Ultrasound or MRI, ERCP as appropriate.  
Wilson disease (if <40 yrs old)  • Ceruloplasmin  
Hemochromatosis  • Ferritin, transferrin  
Alpha -1-antitrypsin deficiency  • Alpha -1-antitrypsin  
 
 
Other causes should also be considered based upon patients  medical history (hyperthyroidism / 
thyrotoxic hepatitis – T3, T4, TSH; CVD / ischemic hepatitis – ECG, prior hypotensive episodes; 
T1D / glycogenic hepatitis).  
Obtain PK sample to determine exposure to study drug and metabolites.  
Following appropriate cau sality assessments, as outlined above, the causality of the drug is 
estimated as “probable” i.e. >50% likely, if it appears greater than all other causes combined. The 
term “drug- induced” indicates probably caused by the drug, not by something else, and only such 
a case can be considered DILI case and should be reported as an SAE.  
4.3.3 Follow- up for Infections  
Patients  should be followed closely for any signs or symptoms of infection and receive prompt 
appropriate treatment for any suspected infection.  
4.4 Concomitant M edications  
 A detailed list of a patient ’s current medications will be gathered at consent and assessed against 
the list of concerning or prohibited concomitant medications  listed below , as appropriate. Any 
required medication adjustments or w ash outs will be documented on an individual basis. Once on 
study, newly prescribed concomitant medications will be added and similarly reviewed to ensure patient safety and compliance.  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  68 PanCAN-SR1 Orig Version: 22JUL2020 
 4.4.1 Permitted Concomitant T herapy  
In general, concomitant medications and  therapies deemed necessary for the supportive care (e.g. 
such as anti -emetics, anti -diarrhea) and safety of the patient are allowed except those prohibited in 
Section 4.4.3  and Appendix A (Package Inserts for gemcitabine and nab -paclitaxel) . 
• Medications to prevent or treat nausea or vomiting  
• Anti-diarrheal medications (e.g. loperamide) for patient s who develop diarrhea  
• Pain medication to allow the patient to be as comfortable as possible  
• Treatment with bisphosphonates or denosumab for pre -existing, painful bone/liver metastases, 
and limited -field palliative radiotherapy or surgery is permitted. Patient s requiring initiation of 
such treatment during the course of the study must be evaluated  for disease progression; 
radiotherapy like any concomitant medication must be listed on the CRF. Spartalizumab should 
be held for ≥1 week prior to radiotherapy or surgery, and be resumed ≥2 weeks after radiation 
or surgery, provided the patient has recove red from radiation or surgery related toxicity. 
Caution is advised for radiation that include lung tissue or heart.  
• Immunosuppressive agents to treat suspected irAEs  
• Hematopoietic colony -stimulating growth factors (e.g. G -CSF, GM -CSF, M -CSF), 
thrombopoieti n mimetics or erythroid stimulating agents as per local or published guidelines 
are permitted  at least > 2 weeks before the start  of study treatment; in case of anemia, 
thrombocytopenia or neutropenia, potential immune -mediated etiology should be ruled out  
before administration of these agents  
• Nutritional support or appetite stimulants (e.g. megestrol)  
• Oxygen therapy and blood products or transfusions  
• Inactivated vaccines  
• The patient must be told to notify the investigational site about any new medications  he/she 
takes after the start of the study drug. All medications (other than study drug) and significant 
non-drug therapies (including physical therapy, herbal/natural medications and blood 
transfusions) administered during the study must be listed on the Concomitant Medications.  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  69 PanCAN-SR1 Orig Version: 22JUL2020 
 4.4.2 Permitted concomitant therapy requiring caution and/or action  
If a patient is using erythropoiesis stimulating agents (ESAs) prior to enrollment (at least > 2 weeks 
before start of study treatment), he/she may continue the treatment.  
Anticoagulation and anti -aggregation agents are permitted if the patients are already at stable doses 
for > 2 weeks at time of first dose and International Normalized Ratio (INR) should be monitored 
as clinically indicated per investigator’s dis cretion. However, ongoing anticoagulant therapy 
should be temporarily discontinued to allow tumor sample according to the institutional guidelines.  
In cases of isolated brain progression or other local progression, patients may receive palliative 
radiother apy or surgery. In addition, localized, palliative radiotherapy for pre -existing bone/liver 
metastases is permitted. Spartalizumab should be held for ≥1 week prior to radiotherapy or surgery. 
Spartalizumab may be resumed ≥2 weeks after radiation or surgery , provided the patient has 
recovered from radiation or surgery related toxicity. If palliative radiotherapy or surgery is initiated after start of study treatment, the reason for its use must be clearly documented and progression as 
per RECIST 1.1 must be assessed and documented  (Patients must  not continue study treatment 
beyond disease progression  per RECIST 1.1  [see Section 5.4.1 ]). 
Since the metabolism of nab -paclitaxel is catalyzed by CYP2C8 and CYP3A4, caution should be 
exercised when administering pac litaxel/nab -paclitaxel concomitantly with medicines known to 
inhibit or induce either CYP2C8 or CYP3A4.  
Cytochrome P450 (CYP450) enzymes are suppressed by increased levels of cytokines (e.g.,IL -1) 
during chronic inflammation. CYP450 expression may be normalized when potent cytokine 
inhibitory therapy, such as canakinumab, is introduced. This is clinically relevant for CYP450 
substrates with a narrow therapeutic index. Caution should be exercised when administering these 
agents  concomitantly with canakinumab. Given the potential DDI via cytokine modulation by 
canakinumab, subjects who are on warfarin or warfarin -like treatment with narrow therapeutic 
index, should have their international normalized ratio (INR) measured locally and warfarin or 
warfarin -like treatment dose adjusted accordingly within one month from starting study treatment.  
 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  70 PanCAN-SR1 Orig Version: 22JUL2020 
 4.4.3 Prohibited concomitant therapy  
 
There are no prohibited or required concomitant medications for combination of gemcitabine and 
nab-paclitaxel. Other antineoplastic agents or investigational drugs, other than what is specified in 
this protocol , are prohibited.  
Over the course of this study, additional medications may be required to manage aspects of the disease state of the patient s, including  side effects from study treatments or disease recurrence. 
Supportive care, including but not limited to antiemetic medications, may be administered at the 
discretion of the Investigator, consistent with institutional guidelines.  
For information regarding other drugs that may interact with either nab-paclitaxel or gemcitabine  
and affect their metabolism, pharmacokinetics, or excretion, see the nab-paclitaxel and 
gemcitabine package inserts (refer to Prescribing Information) , Appendix A. 
Treatment with the following agents is not permitted within ≤ 2 weeks prior start of study 
treatment:  
• hematopoietic colony -stimulating growth factors (e.g. G -CSF, GM -CSF, M -CSF), or  
• thrombopoietin mimetics, or  
• erythroid stimulating agents.  
If erythroid stimulating agents were initiated more than 2 weeks prior to the first dose of study treatment and the patient is on a stable dose, they can be maintained. In addition, hematopoietic colony -stimulating growth factors and thrombopoietin mimetic s may be used to treat treatment 
emergent cytopenias during the course of the study.  
During the course of the study, patients must not receive other additional investigational drugs, devices, chemotherapy, or any other therapies that may be active against cancer or modulate the immune responses. However, limited -volume palliative radiotherapy may be allowed as 
concomitant therapy. Such local therapies administered during the study treatment must be documented. Additionally, no other therapeutic systemic antineoplastic agents and no immunosuppressive medication may be administered while on this study unless given for the management of immune toxicity or circumstances where there is further discussion with the 
Medical Monitor . 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  71 PanCAN-SR1 Orig Version: 22JUL2020 
 4.4.3.1  Prohibited concomitant therapy f or spartalizumab  
The use of systemic steroid therapy and other immunosuppressive drugs is not allowed except for 
use as pre -medication for chemotherapy (when needed), the treatment of infusion reaction, irAEs, 
treatment for brain metastasis, and for prophy laxis against imaging contrast dye allergy or 
replacement -dose steroids in the setting of adrenal insufficiency (providing this is < 10 mg/day 
prednisone or equivalent), or transient exacerbations of other underlying diseases such as COPD requiring treatme nt for ≤ 3 weeks. If systemic corticosteroids are required for the control of 
infusion reactions or irAEs, it must be tapered and be at non -immunosuppressive doses (<10 
mg/day of prednisone or equivalent) before the next administration of study treatment. If the dose 
of prednisone or equivalent cannot be reduced to less than 10 mg/day within 12 weeks from irAE 
cause delay dosing then spartalizumab must be discontinued.  
The use of live vaccines is not allowed through the whole duration of the study. Inactivated vaccines are allowed.  
There are no spartalizumab -specific prohibited therapies during the post -treatment follow -up 
period. 
4.4.3.2   Prohibited concomitant therapy for canakinumab 
Due to the potential risk of serious infections and increased risk of neutropenia, caution should be excised when administering canakinumab in combination with immuno -suppressive medications.  
The use of below is not allowed after the start of study treatment and for at least 130 days after 
discontinuation of canakinumab unless medically indicated for the management of immune related AEs or other serious conditions. In these cases patients should be closely monitored for infection 
and the dose modification guidelines should be followed.  
• Any systemic antiretroviral agents and / or any bio logic drugs targeting the immune system 
(e.g. TNF -alpha blockers, anakinra, rituximab, abatacept, tocilizumab)  
• Live vaccines.  All immunizations should be completed at least 3 months prior to initiating 
canakinumab. Patient s should discontinue canakinumab i f administered any live vaccine 
during the course of the study. Inactivated vaccines are allowed.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  72 PanCAN-SR1 Orig Version: 22JUL2020 
 4.5 Overdose  
 
Overdose, as defined for this protocol, refers to the medications included in the therapeutic 
regimens to which patient s are randomized (the agents  being given to treat pancreatic cancer).  On 
a per dose basis, an overdose is defined as 10% over the protocol -specified dose given to a patient , 
regardless of any associated AEs or sequelae. On a schedule or frequency basis, an overdose is 
defined as anything more frequent than the protocol -required schedule or frequency. Complete 
data about drug administration, including any overdose, regardless of whether the overdose was accidental or intentional, should be reported in the eCRF.  
4.6 Investigational Product Accountability and Disposal  
 
Investigational product (IP) should be disposed of in accordance with institutional/regional 
requirements. Disposition should be recorded on the investigational drug accountability forms. 
The Investigator, or designee, shall record the dispensing of IP to patient s in the IP accountability 
record. The IP record will be made available to authorized sponsor -designated monitoring 
personnel, for the purpose of accounting for the IP supply.  
 Inspections of the IP supply for inventory purposes and assurance of proper storage will be 
conducted as necessary. Any significant discrepancy will be recorded and reported to the sponsor designee and a plan for resolution will be documented.  
 Investigational product will not be loaned or dispense d by the Investigator to another  
Investigator or site.  
4.7 Investigational Product Compliance  
 
Accurate recording of all IP administration will be made in the appropriate section of the patient ’s 
eCRF and source documents. The Investigator or designee is resp onsible for the accountability for 
all study -specific IP either administered or in their custody during the course of the study.  
 
 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  73 PanCAN-SR1 Orig Version: 22JUL2020 
 5.0 STUDY ASSESSMENTS 
All patient s will undergo uniform assessments and procedures defined below  in Section 5.1. For 
ease of  review, the procedures are described below : 1) Screening / Baseline , 2) Study Treatment  
Assessments, 3) End of Treatment, 4) As Needed Assessments, 5) Safety Follow -Up, 6) Post 
Treatment Efficacy Follow Up , and 7) Survival Follow -Up.  
 
  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  77 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 5-1:  Schedule of Events (Continued)  
Footnotes:              
 ***A cycle is at defined as 4 weeks***    
1       Treatment ICF must be signed by patient prior to the initiation of treatment  
2       Tuberculosis screening is performed per local and  institutional guidelines  
3       Only study treatment -related AEs will be reported after the start of new anti -cancer therapy and until the end of the Safety Follow -Up period;  
4       Only study treatment -related SAEs will be reported after the end of safety f/u or after the start of new anti -cancer therapy, whichever is the earliest, until the end of survival   f/u;   
         After the Safety Follow -up Period, and i n the post -treatment efficacy f ollow -up period, report only treatment -related SAEs until the start of a new anti -neoplastic therapy ; 
5       The specific Pharmacokinetic  and blood collection for canakinumab, spartalizumab, gemcitabine and nab -paclitaxel is outli ned in Section 5. 6 below. Blood   
draws for canakinumab and spartalizumab will be performed on Days 1,8, and 15 of Cycle 1, and Day 1 of Cycles 2- 5 (pre -dose);  Blood draws for gemcitabine and nab -paclitaxel   
will be performed on Day 1 of Cycles 1 and 2  (pre-dose);  
6      Concomitant medications should be recorded from 28 days prior to starting study treatment (during screening period) until end of safety follow up  or start of new antineoplastic 
medications, whichever is sooner. After starting a new antineoplastic medication, only report medications related to study treatment -related  AEs/SAEs  
7       Conc omitant  med ications  must be collected at any visit when AEs are collected ; No need to report conmeds  after the end of safety f/u or at the start of new anti -cancer therap y; 
8       Thyroid panel should be performed on Day 1 of the first two cycles, and Day 1 of every second cycle (cycles 4,6, etc.)  
9       CA 19 -9 should be evaluated every 4 weeks from C 1D1 of treatment (every Cycle)  
10    HIV testing during screening period to be conducted only if there is a known history of HIV documented in clinical notes or i f patient is currently receiving treatment for HIV. HIV  
testing  is not required in the absence of clinical suspicion  (i.e. this test is NOT mandatory) . 
11     HBV/HCV during screening period to be conducted only if there is an active infection of HBV and/or HCV. Patients who have tes ted positive for antibody (due to e xposure) with no 
history of active infection do not need a HBV/HCV test during screening period  
12    Procedures completed within 14 days of last study treatment can be used for End of Treatment values when appropriate ; Reason for stopping treatment will be recorded  in EDC;  
13   
  
14    CT or MRI of chest, abd omen , pelvis , and Tumor evaluation per RECIST 1.1 is performed Every 8 weeks (every 2 cycles) starting from C1D1 of study treatment .  
15    If brain lesions are documented at baseline, follow same schedule as CT/MRI of chest, a bdomen, and pelvis . 
16    Only for lesions on whole body scan that are not visible on the chest, a bdomen and pelvis scans. If bone lesions were documented at screening, follow same schedule as  
         CT/MRI of the chest, abdomen, and pelvis .  
17     Post Treatment Efficacy Follow -up visit is for those patients who  discontinue treatment due to reasons other than disease progression, and therefore could have these assessments  
         performed  to show possible disease progression during the follow -up period. The frequency of assessment for patients in post -treatment efficacy follow -up is the same  
         as during the  treatment p eriod . 
18    This test will only occur prior to the two biopsies on  the Screening/ Day 1 visit and the Cycle 3 Day 1 treatment (after 8 weeks of treatment).   
19    Gemcitabine and nab- paclitaxel will be administered on days 1, 8, and 15 of each 28 -day cycle.  
  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  78 PanCAN-SR1 Orig Version: 22JUL2020 
  
5.2 Baseline  Procedures  
Patient s will have the following procedures conducted within 28 days of Day 1 of Study treatment .  
Questions regarding eligibility should be directed to the Medical Monitor or his/her authorized  
designee.  
 The following procedures will be performed within 28 days prior to Cycle 1 Day 1 treatment 
(Baseline) : 
• Informed consent  
• Medical History, Family History, Demographics, and Cancer History (including 
specifically previous PDAC treatments)  
• Tuberculosis Status Assessment  
• Hepatitis Status Assessment  
• Vital signs (includ ing blood pressure, temperature, and heart rate)  
• Physical examination  (including height and weight)  
• Clinical assessment of neuropathy performed according to local practice  
• 12-lead electrocardiogram (ECG)  
• Adverse Event and Serious Adverse Event assessment  
• List of prior and concomitant medications going back over the last 6 month s 
• ECOG Performance Status (see Table 5 -2 below)  
• Laboratory blood test s (collected and assessed locally)  
• Complete blood count (CBC) with differential (absolute), including but not lim ited to:  
o Red blood cell (RBC) count  
o Hemoglobin 
o Hematocrit  
o Differential White blood cell (WBC) count  
o Absolute neutrophil count (ANC)  
o Platelet count  
• Chemistry panel including, but not limited to: o Sodium  
o Potassium  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  79 PanCAN-SR1 Orig Version: 22JUL2020 
 o Calcium  
o Chloride  
o Uric Acid  
o Blood urea nitrogen (BUN)  
o Creatinine  
o Glucose  
o Aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
(AST/SGOT)  
o Alanine aminotransferase/serum glutamic -pyruvic transaminase  (ALT/SGPT)  
o LDH  
o Serum Lipase  
o Alkaline phosphatase  
o Bilirubin (total and direct)  
 
• Coagulation tests including  (only performed prior to the two biopsies per patient —
please see Section 5.7 below  (As Needed Assessments) ): 
o Prothrombin time (PT) and international normalized ratio (INR)  
o Partial thromboplastin time (PTT)  
• Thyroid Panel  (free T3, free T4, and TSH)  
• Pregnancy test (serum) is required for WOCBP  and will be performed within 14 days 
of Day 1 of study treatment.  
• Urinalysis  
• CA 19 -9 (as defined by local practice)  
• HIV test (if there is a known history of HIV in clinical not es or if pa tient is currently 
receiving treatment for HIV ; HIV testing is not required in the absence of clinical 
suspicion  (this is NOT mandatory) );  
• Laboratory Assessments for active viral infections: Hepatitis B surface antigen (HBV 
sAG) and Hepatitis C antibody (HCV Ab) or Hepatitis C RNA (HCV RNA)  
•  
•  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  81 PanCAN-SR1 Orig Version: 22JUL2020 
  
The following procedures will be performed at Day 1 of every cycle , prior to any study 
treatment administration, unless otherwise specified below:  
• Vital signs (including blood pressure, temperature, and heart rate)  (also performed on Day 
8 of Cycle 1 only);  
• Physical examination ; 
• Clinical assessment of neuropathy performed according to local practice ; 
• Adverse Event and Serious Adverse Event assessment (performed on Days 1,8, and 15 of 
every treatment cycle)  
• Pharmacokinetics (PK) and  blood draw s performed on Days 1, 8, and 15 
of Cycle 1, and Day 1 of Cycles 2 -5 (pre -dose); (See Section 5. 6 below for details on 
specific days and times for PK and draws)  
• New  concomitant medications since last visit ; 
• ECOG Performance Status (see Table 5 -2 above ) 
• Weight  
• Laboratory blood test (collected and assessed locally)  
o Complete blood count (CBC) with differential (absolute)  to be performed on Days 1 
and 15 of Cycles 1 and 2, and Day 1 only of Cycle 3 and thereafter, including but not 
limited to:  
 Red blood cell (RBC) count  
 Hemoglobin 
 Hematocrit  
 Differential White blood cell (WBC) count  
  Absolute neutrophil count (ANC)  
  Plate let count  
o Chemistry panel to be performed on Days 1 and 15 of Cycles 1 and 2, and Day 1 only of Cycle 3 and thereafter including, but not limited to:  
 Sodium  
 Potassium  
 Calcium  
 Chloride  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  82 PanCAN-SR1 Orig Version: 22JUL2020 
  Uric Acid  
 Blood urea nitrogen (BUN)  
 Creatinine  
 Glucose  
 Aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
(AST/SGOT)  
 Alanine aminotransferase (ALT/SGPT)  
 Alkaline phosphatase  
 LDH  
 Serum Lipase  
 Bilirubin (total and direct)  
• Thyroid Panel ( free T3, free T4, and TSH)  
• Pregnancy test ( urine ) is required for WOCBP   
• Urinalysis  
• CA 19 -9 (as defined by local practice)  (to be performed on Day 1 Cycle 1 and every 
cycle thereafter (every 4 weeks))  
•  
 
 
5.4 Study Treatments   
Please also refer to Section 4.0  for complete study drug administration information, and for dose 
modification and toxicity information.   
 
Canakinumab 
Canakinumab is provided as ready -to use pre -filled syringes to be a dministered by study center 
personnel.  Two strengths of solution for injection will be supplied:  
• Canakinumab 50 mg/ 0.5 mL  
• Canakinumab 200 mg/ 1.33 mL  
 

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  83 PanCAN-SR1 Orig Version: 22JUL2020 
 The starting dose of canakinumab will be 250 mg, administer subcutaneously (SC) in the abdomen, 
upper outer thigh or upper outer arm once every 4 weeks  (on Day 1 of each treatment cycle) . To 
administer a target dose of canakinumab of 250 mg, two separate subcutaneous injections  must 
be administered to the patient at a visit and should not be injected in the same site (e.g. if first 
injection was done in the thigh, the second injection should be done in the opposite thigh). Alternate injection sites should be used throughout the study.  
If this initial dose level (DL1) of 250 mg Q4W is not tolerated, the next reduced dose level  -1 (DL 
-1) will be explored. DL -1 aims to reduce canakinumab exposure by increasing the dosing interval 
of 250 mg dose from Q4W to Q8W  without change in actual dose st rength. 
 
 For additional guidance refer to canakinumab (ACZ885) Instructions for Use/Pharmacy Manual 
and to the canakinumab Investigat or’s Brochure.  
 
Spartalizumab  
Spartalizumab will be supplied in a liquid solution. The starting dose of spartalizumab  is 400 mg 
(prepared by reconstituting four vials with sterile water for injection (SWFI) and diluted in a 5% 
dextrose infusion bag before use) administered via intravenous infusion over 30 minutes (up to 2 hours, if clinically indicated) once every 4 week s (on Day 1 of every cycle) . For additional 
guidance refer to spartalizumab Instructions for Use/Pharmacy Manual and to the spartalizumab 
Investigat or’s Brochure.  
On days of combination therapy canakinumab will be injected first followed by 30 min observa tion 
period and then by spartalizumab infusion.  After spartalizumab infusion, patient s should be 
closely observed for potential infusion -related reactions including rigors, chills, wheezing, 
pruritus, flushing, rash, hypotension, hypoxemia, and fever, and  vital signs monitored more 
frequently if clinically indicated, during and for at least 2 hours after the first two spartalizumab 
infusions (before administration of chemotherapy). The same may apply for the subsequent spartalizumab infusions if medically indicated.   
 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  84 PanCAN-SR1 Orig Version: 22JUL2020 
 Gemcitabine/Nab -paclitaxel  
• Nab-paclitaxel is infused at an initial dose of 125 mg/m2 over 30 -40 min on days 1, 8, 15 
of each 28 -day cycle.  
• Gemcitabine is infused at an initial dose of 1000 mg/m2 over 30 min, immediately after 
completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28- day cycle 
If one of the chemotherapy medications is held, the other study medications may be given.  
Doses should be re -adjusted if the patient ’s BSA changes by +/ - >10%. If the patient ’s BSA 
changes by < 10%, no adjustment is necessary  unless the site has a standard procedure to adjust 
doses based upon current BSA according to institutional guidelines.  
On days of combination therapy, chemotherapy will be administered at least 30 minutes after the 
end of s partalizumab infusion. Any pre -medication for the chemotherapies, if required, should be 
administered at least 30 minutes after the end of the infusion of spartalizumab.  
Specifics on dosing and toxicity modifications for gemcitabine and nab -paclitaxel can be found in 
their Package Inserts (Appendix A).  
 
5.4.1 Study Treatment B eyond D isease Progression  
Patients will not continue study treatment b eyond PD per RECIST 1.1 , since progression prior to 
response has not been reported in pancreatic cancer treated with immunotherapy and was associated with grade 3/4 AEs  when treatment continued beyond progression (Parseghian et al 
2018). Therefore, the overall risk -benefit for cont inuing the study treatment beyond disease 
progression is considered as not favorable.  
5.4.2 Study Treatment Duration  
Patient s will continue to receive study treatment until one of the following events occur:  
• disease progression per RECIST 1.1 is radiologically documented by investigator 
assessment;  
• unacceptable toxicity that precludes further treatment;  
• treatment is discontinued at the discretion of the investigator;  
• patient  withdrawal of consent;  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  85 PanCAN-SR1 Orig Version: 22JUL2020 
 • pregnancy;  
• patient  is lost to follow -up;  
• death  
If study chemotherapy drugs are permanently discontinued because of chemotherapy -related 
intolerable toxicities, the investigator can continue spartalizumab with canakinumab until RECIST 
1.1 disease progression as per investigator  assessment , as long  as:  
• The patient  is continuing to benefit from investigational drug treatment as assessed by the 
investigator, and 
• The patient  is tolerating the treatment and clearly understands the risks associated with 
continuing treatment with canakinumab.  
If spartali zumab and/or canakinumab have been discontinued because of treatment -related 
toxicity, treatment with chemother apy may continue as long as the patient  is continuing to benefit 
from chemotherapy continuation as assessed by the investigator.  
 
 
5.5 End of Tre atment Procedures  
 
All the procedures outlined below need to be completed within 14 days of last dose of study 
treatment, or otherwise repeated.   
• Vital signs (including blood pressure, temperature, and heart rate);  
• Physical examination;  
• Clinical assessment of neuropathy performed according to local practice;  
• Adverse Event and Serious Adverse Event assessment ; 
• New concomitant medications since last visit;  
• ECOG Performance Status (see Table 5 -2 below) ; 
• Pharmacokinetics (PK) and  blood draws performed during the End of 
Treatment Visit ; (See Section 5. 6 below for details on specific days and times for PK and 
 draws)  
• Weight ;  
• Laboratory blood test (collected and assessed locally) ; 
o Complete blood count (CBC) with differe ntial (absolute), including but not limited to:  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  86 PanCAN-SR1 Orig Version: 22JUL2020 
  Red blood cell (RBC) count  
 Hemoglobin 
 Hematocrit  
 Differential White blood cell (WBC) count  
  Absolute neutrophil count (ANC)  
  Platelet count  
o Chemistry panel including, but not limited to: 
 Sodium  
 Potassium  
 Calcium  
 Chloride  
 Uric Acid  
 Blood urea nitrogen (BUN)  
 Creatinine  
 Glucose  
 Aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
(AST/SGOT)  
 Alanine aminotransferase (ALT/SGPT)  
 Alkaline phosphatase  
 LDH  
 Serum Lipase  
 Bilirubin (total and direct)  
• Thyroid Panel ( free T3, free T4, and TSH)  
• Pregnancy test ( Serum ) is required for WOCBP   
• Urinalysis  
• CA 19 -9 (as defined by local practice) ; 
•  
 
 

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  88 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 5-4: Pharmacokinetic  Blood C ollection Log for 
Spartalizumab ( PDR001 ) 
Cycle  Day Scheduled Time Point (hr)  PK 
 
1 1 Pre-dose Cycle 1  Spartalizumab  PK 
1 1  End of infusion (within 5  
min) Spartalizumab  PK 
1 8 168 hr post -dose (±8 hr)  Spartalizumab  PK 
 
1 15 336 hr post -dose (±24 hr)  Spartalizumab  PK 
 
2 1 Pre-dose Cycle 2  Spartalizumab  PK 
 
3 1 Pre-dose Cycle 3  Spartalizumab  PK 
 
4 1 Pre-dose Cycle 4  Spartalizumab  PK 
 
5 1 Pre-dose Cycle 5  Spartalizumab  PK 
 
5 1 End of infusion within 5 
min ) Spartalizumab  PK 
 
6 1 Pre-dose Cycle 6  Spartalizumab  PK 
EOT  Anytime  Spartalizumab  PK 
 
Unscheduled   Anytime  Spartalizumab  PK 
 
Table 5-5: Pharmacokinetic draws for Gemcitabine  
Cycle  Day Scheduled Time Point (hr)  
1 1 Pre-infusion  
1 1  EOI (within 5 minutes)  
1 1 0.5 hr (±10 minutes) post -EOI 
1 1 1 hr (±10 minutes) post -EOI 
1 1 2 hr (±10 minutes) post -EOI 
1 1 4 hr (±10 minutes) post -EOI 
2 1 Pre-infusion  
2 1 EOI (within 5 minutes)  
2 1 0.5 hr (±10 minutes) post -EOI 
2 1 1 hr (±10 minutes) post -EOI 
2 1 2 hr (±10 minutes) post -EOI 
2 1 4 hr (±10 minutes) post -EOI 
Unscheduled   Anytime  
EOI- end of infusion  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  89 PanCAN-SR1 Orig Version: 22JUL2020 
 Table 5-6: Pharmacokinetic draws  of nab -paclitaxel 
Cycle  Day Scheduled Time Point (hr)  
1 1 Pre-infusion  
1 1  EOI (within 5 min)  
1 1 4 hr (±10 minutes) post -EOI 
1 1 6 hr  (± 1 hour) post -EOI 
1 2 24  hr (±1 hour minutes) post -EOI 
2 1 Pre-infusion  
2 1 EOI (within 5 min)  
2 1 4 hr (±10 minutes) post -EOI 
2 1 6 hr  (± 1 hour) post -EOI 
2 2 24  hr (±1 hour minutes) post -EOI 
Unscheduled   Anytime  
EOI- end of infusion  
 
 
5.7 As Needed Assessments  
•  
 
• After every 8 weeks of study treatment, a Computerized tomography (CT) scans (with PO 
and IV contrast) of the chest, abdomen, and pelvis will be performed.  In the case of CT 
contrast agent allergy, Magnetic Resonance Imaging (MRI) of the abdomen and pelvis (with IV contrast) along with CT scan of  the chest is acceptable. Scans will be reviewed 
and interpreted at each site per standard a protocol detailed in the Study Manual/ Imaging 
Guidelines. 
Note: the imaging modality chosen at baseline should remain the same throughout the duration 
of this stu dy. 
• Coagulation tests including  (to be performed prior to each biopsy at the Screening Visit 
and prior to the biopsy after 8 weeks of treatment (prior to Cycle 3 Day 1) ): 
o Prothrombin time (PT) and international normalized ratio (INR)  
o Partial thromboplastin  time (PTT)  
• Re-assessment of Tuberculosis Status at any time during Study treatment, if clinically 
indicated;  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  90 PanCAN-SR1 Orig Version: 22JUL2020 
 • Re-assessment of Hepatitis  Status at any time during Study treatment, if clinically 
indicated;  
• 12-lead ECG at any time during Study treatment, i f clinically indicated;  
• Re-assessment of HIV Status at any time during Study treatment, if clinically indicated;  
• Brain CT or MRI at any time during Study treatment, if clinically indicated;  
• Whole Body bone scan at any time during Study treatment, if clinically indicated;  
• Localized bone CT, MRI or X -Ray at any time during Study treatment, if clinically 
indicated;  
 
5.8       Safety Follow Up  (30- day, 60- day, 90 -day, 120 -day and 150- day Assessments)  
The following assessments below will occur at 30 days after the last study treatment, (and 
at 60 -days, 90- days, 120- days and 150-days after treatment, when indicated). All patient s 
will be followed for safety assessment 150 days following the last dose of spartalizumab 
and canakinumab or 30 days after the last dose of the combination chemotherapy, 
whichever is later.  
• Vital signs (including blood pressure, temperature, and heart rate);  
• Physical examination;  
• Adverse Event and Serious Adverse Event assessment  (at 30 -day,60- day, 90-day , 120-day 
and 150- day after last study treatment (suspected AEs and SAEs) , until resolution to Gra de 
1/baseline levels ;  unsuspected AEs or SAEs are followed up to the 150- day follow -up 
visit, or until the initiation of a new anti -cancer therapy  (whichever is sooner )); 
• New concomitant medications since last visit  (at 30 -day,60- day, 90-day , 120- day and 150- 
day after last study treatment, or until the start of new anti -neoplastic medications ;  
• ECOG Performance Status (see Table 5 -2 above ); 
• Weight ;  
• Laboratory blood test (collected and assessed locally);  
o Complete blood count (CBC) with differential (absolute), including but not limited to:  
 Red blood cell (RBC) count  
 Hemoglobin 
 Hematocrit  
 Differential White blood cell (WBC) count  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  91 PanCAN-SR1 Orig Version: 22JUL2020 
   Absolute neutrophil count (ANC)  
  Platelet count  
o Chemistry panel including, but not limited to: 
 Sodium  
 Potassium  
 Calcium  
 Chloride  
 Uric Acid  
 Blood urea nitrogen (BUN)  
 Creatinine  
 Glucose  
 Aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
(AST/SGOT)  
 Alanine aminotransferase (ALT/SGPT)  
 Alkaline phosphatase  
 LDH  
 Serum Lipase  
 Bilirubin (total and direct)  
• Thyroid Panel ( free T3, free T4, and TSH)  
• Pregnancy test (Serum) is required for WOCBP at 30 -day follow up only;   
• Pregnancy test (Urine) is required for WOCBP at 60-day, 90-day , 120- day and 150-
day follow -up visits;  
• Urinalysis is required at 30 -day and 150- day follow up visits;  
• Recording of anti -neoplastic therapies since the discontinuation of the study treatment 
is required at 30 -day, 60- day, 90- day, 120-day and 150- day follow -up visits;  
 
5.9 Post Treatment Efficacy Follow Up  
Post treatment efficacy follow -up is for those patients who discontinue treatment due to reasons 
other than disease progression, e.g. adverse event . Patients will be followed until disease 
progression, withdrawal of consent, or lost to follow -up, whichever comes first. The frequency of 
Phase 1b Safety Run -In Study Pancreatic Cancer Action Network  
Confidential and Proprietary  92 PanCAN-SR1 Orig Version: 22JUL2020 tumor response
 assessments and Ca -19-9 measurements for patients in post -treatment efficacy 
follow -up is the sa me as during the treatment period.  
5.10 Survival Fol
low Up  
After the end of the Safety Follow -Up and Post Treatment Efficacy Follow Up periods above  
(where applicable) , all patient s will be followed for overall survival every three months (+/ - 14 
days) until d eath, withdrawal of consent, or lost to follow -up, whichever comes first.  Survival 
follow -up will continue until the end of study, death, or withdrawal of consent by the patient.  
If a patient  star
ts a new anti -cancer therapy prior to disease progression  during the follow -up 
period , those patient s will continue to be followed for post treatment efficacy and overall survival. 
This data should be captured in the EDC.  
The followi
ng procedures will be performed during the efficacy and survival follow -up per iod: 
•Overall survival assessment  (phone call every 3 months after the 150 -day safety follow -up
period);
•Documentation of n ew anti -cancer therapy  if applicable;
•CT/MRI for response assessment, if applicable . For patient s that discontinue study
treatment in the absence of disease progression (unacceptable toxicity or
patient /investigator discretion) , CT/MRI scans should be performed accordingly to
standard practice to assess efficacy status .
5.11 Patient Disc
ontinuations  
The reason for study discontinuation should be recorded in the eCRF and in the source documents. 
The decision to discontinue a patient  remains the responsibility of the treating physician. However, 
prior to discontinuing a patient , the Investigator may contact  the Medical Monitor with the decision 
to discontinue/withdraw a patient  due to an AE (any unacceptable toxicity) and forward  
appropriate supporting documents for review and discussion. Every attempt should be made to 
collect all survival information, unle ss the patient  has specifically withdrawn consent from further 
follow -up. The Investigator should make every effort to obtain minimal information regarding the 
patient ’s survival status before determining the patient  is lost to follow -up.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  93 PanCAN-SR1 Orig Version: 22JUL2020 
 6.0  
 
   
  
 
 
 
 
  
 
  
 
 
 
 
6.1 Tumor B i
omarker Collection  
Unlike other solid tumors, where traditional imaging modalities provide an accurate and reliable 
means to assess tumor size and response, pancreatic cancer poses difficulties in lesion measurements. Due to the desmoplastic component of its lesions, unequivocal measurements are 
challenging  (Brand et  al. 1998). For this reason, there is increasing interest in identifying 
correlative endpoints by which to evaluate the effectiveness of therapy.  Carbohydrate antigen 19-9 (CA 19- 9), a tumor marker widely used in clinical practice in the assessment of patients with 
pancreatic cancer, has prognostic significance in overall survival and response to treatment in patients with metastatic PDAC  (Maisey et al. 2005, Ko et al. 2005, Boeck et al. 2006).  Although 
CA 19 -9 is not detectable in 15% of metastatic pancreatic cancer  patients, the opportunity for 
serial CA 19 -9 measurements across a variety of novel therapeutic evaluations, including 

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  94 PanCAN-SR1 Orig Version: 22JUL2020 
 immunotherapy, stromal disruption and DNA damage pathways, makes this an interesting target 
for further surrogate development  (Poruk et al. 2013, Chiorean et al. 2016). 
 
6.2 Specimen Collection Overview  
   
 
 
  
.  
 
6.2.1   
 
  
 
 
 
 
   
 
   
 
  
  
 
  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  96 PanCAN-SR1 Orig Version: 22JUL2020 
  
 
 
 
   
 
 
 
7.0 SAFETY ASSESSMENTS  
All patient s will be uniformly monitored for safety and tolerability. Patient  safety assessments will 
be performed based as outlined in the Schedule of Events in  Section 5.1.  
Toxicity will be evaluated  according to the NCI Common Terminology Criteria for Adverse 
Events (CTCAE) v 5.0 criteria  and assessed by a qualified clinician.  
 
7.1 Definition of Adverse Event  
An Adverse Event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a patient  during their study participation.  
An AE can therefore be any of the following:  
• Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicina l product, whether or 
not, considered related to the medicinal product.  
• Any new disease or exacerbation of an existing disease (a worsening in the character, 
frequency, or severity of a known condition), except as if related to tumor progression.  
• Recurrenc e of an intermittent medical condition (e.g., headache) not present at baseline.  
• Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant treat ment 
or discontinuation from study drug.  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  97 PanCAN-SR1 Orig Version: 22JUL2020 
 • AEs that are related to a protocol -mandated intervention, including those that occur prior 
to assignment of study treatment (e.g., screening invasive procedures such as biopsies).  
 
7.2 Definition of a Serious Adverse Event  
A serious adverse event (SAE) is any adverse event that meets any of the following criteria:  
• Death  
• A life -threatening adverse event  
• Inpatient hospitalization or prolongation of existing hospitalization  
• A persistent or significant incapacity or substantial disruption of the ability to perform 
normal life functions  
• A congenital anomaly or birth defect  
• Important medical events that may not be immediately life -threatening or resulting in death 
or hospitalization should also be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient and may require intervention to prevent one of 
the other outcomes.  
  
Events not considered to be SAEs are hospitalizations for:  
• Routine treatment or monitoring of the studied in dication, not associated with any 
deterioration in condition  
• Elective or pre- planned treatment not related to the condition being studied  
• Emergency outpatient treatment for an event not fulfilling the serious criteria outlined 
above and not resulting in in patient admission  
• Respite/hospice care 
 
7.3 Monitoring 
Patient s will be monitored for S/AEs during the trial.   All S/AEs will be recorded from the time 
the patient  signs the Informed Consent Form (ICF) through study treatment. During the 150- day 
(5 month s) period after the last dose of study treatment  of canakinumab  or spartalizumab  (due to 
the half -life of th is drug) , only treatment- related  S/AEs will be recorded.   
Assessments may include monitoring of any or all the following parameters:  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  98 PanCAN-SR1 Orig Version: 22JUL2020 
 • Patient s’ clinical symptoms, laboratory, pathological, radiological or surgical findings  
• Physical examination finding  
• Findings from other tests and/or procedures  
 
7.4 Reporting  
All AEs and SAEs will be coded using MedDRA for reporting to the FDA, and Institutional 
Review Boards (IRBs), as required. All reportable adverse events should be recorded in the 
Electronic Data Capture ( EDC ) system .  
 
7.4.1  Adverse Events  
Pre-specified AEs that occur after signing the ICF through the completion of the Treatment Phase 
related or not to the study assessments, must be entered in the EDC.  Refer to the detailed Data Plan with these definitions and specific data entry instructions.  Adverse Event assessment will 
occur until there is a resolution to Grade 1/baseline levels, stabilization, or the initiation of new 
anti-cancer therapies.  
 
For each reportable AE, the treating clinician will evaluate and report the following:  
• Event onset date and event ended date  
• AE verbatim term  
• Severity grade  
• Attribution to study agent (relatedness) with rationale for causality assessment  
• Whether or not the event was reported as an SAE (if SAE, criterion/a for seriousness)  
• Action taken  with study drugs and any treatment given for the AE  
• Outcome of the event  
• Whether or not the patient  discontinued study treatment due to AE  
• If treatment was temporarily interrupted, date and dose of re- administration   
 
Progression of malignancy (including fatal outcomes), if documented by use of appropriate method 
(for example , as per RECIST 1.1 criteria) should not be reported as an AE or SAE except if the 
investigator considers that progression of malignancy is related to study treatment.               
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  99 PanCAN-SR1 Orig Version: 22JUL2020 
 AEs separate from the progression of malignancy (example,  i.e. deep vein t hrombosis at the time 
of progression or hemoptysis concurrent with finding of disease progression) will be reported as 
per usual guidelines used for such events with proper attribution regarding relatedness to the study 
drug/s . 
Conditions that were already  present at the time of informed consent should be recorded as the 
medical history. Condition /s which developed or worsened after signing informed consent 
(including during the screening period) should be recorded as AE.  
 If a laboratory abnormality is one  component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded as a S/AE.  If the abnormality was not a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.  
Abnormal laboratory value s or test results constitute adverse events only if they fulfill at least one 
of the following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically significant  
• they require therapy  
 
7.4.2  Severity of AEs  
It is important to distinguish between serious and severe AEs.  An AE of severe intensity may not 
necessarily be considered serious and vice versa. See definition of SAEs  in Section 7.2. 
 
Severity is a measure of intensity which will be graded by using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 criteria. These are based on the general guidelines 
described in Table 7-1 below and should be used to assess severity for  AE terms not listed in the 
CTCAE v 5.0.  
  
 
   
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  101 PanCAN-SR1 Orig Version: 22JUL2020 
 Adverse events of special interest are defined on the basis of  an ongoing review of the safety data.  
 
Based upon the available safety information from  spartalizumab and canakinumab oncology  
clinical  development programs and known mechanism of action of these drugs and potential 
overlapping toxicity of all combinat ion drugs, following adverse events are considered of special 
interest in this trial population:  
• Infections (severe infections and opportunistic infections) , including sepsis  
• Neutropenia CTCAE Grade >3 
• Febrile neutropenia  
• Peripheral/Sensory neuropathy  CTCAE  Gra de >3 
• Thrombocytopenia  CTCAE  Gra de >3  
• In addition, the potential immune -related AEs considered to be AESIs include, 
endocrinopathies, colitis, skin reactions, hepatitis, nephritis, pneumonitis and infusion 
reaction .  
 
Details regarding these adverse events are provided in the spartalizumab and canakinumab  
Investigator’s Brochure s. Potential emergent new AEs will be monitored during the course of the 
study.  
7.4.5 Serious Adverse Events  
Any AE that meets any criterion for a SAE requires the completion of a SAE Report Form in 
addition to being recorded in the EDC.  All SAEs must be reported to Sponsor or his/her authorized 
designee immediately , but no later than within 24 hours of the awareness of the event, via phone 
or e-mail, along with the SAE report form completed . The Investigator is required to ensure that 
the data on these forms is accurate and consistent.  SAEs must be followed until resolved.  
 
Complete information is important to assess the SAE, but at least t he following information needs 
to be provided within initial 24- hour notification, and additional information may be collected in 
follow -up contacts : 
• Date and time of SAE  
• Name of reporter  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  102 PanCAN-SR1 Orig Version: 22JUL2020 
 • Institution Name  
• Protocol number/title  
• Description of SAE, including reason of seriousness and causality to study treatment  
The Medical Monitor and safety/regulatory staff of the Pancreatic Cancer Action Network 
(PanCAN ) or his/her designee will determine which SAEs require expedited FDA submission as 
safety reports.  
All institutions will comply with applicable regulatory requirements related to reporting SAEs to 
the IRB. The Investigator must keep copies of all SAE information on file including 
correspondence with Sponsor or his/her authorized designee and the IRB.  
 7.4.6 Manufacturer Communications  
SAEs and AEs will be communicated to the relevant agent manufacturer per their individual safety reporting requirements regarding timing, frequency, and format.  
 7.4.7 End of Treatment safety Follow -up 
All S/AEs , including any laboratory abnormalities, that fit the reportable criteria described in 
Section 7.4.1,   will be recorded from the time the patient  signs the Informed Consent Form (ICF) 
until 150 days (5 months) after the last dose of study treatment of canakinumab or spartalizumab 
(due to the half -life of these  drugs) , or 30 days after the last dose of the combination chemotherapy, 
whichever is later . 
  
For SAEs, Investigator (or sub -investigator) and/or their research staff should submit follow -up 
reports when additional information is available or requested by Sponsor or his/her authorized designee.  
 
8.0 RESPONSE ASSESSMENT  
Response assessments (tumor evaluations) should be performed radiographically (CT/MRI) at screening (within a 28- day window prior to Day 1 of treatment), every 8 weeks (± 7 days) until 
disease progression, at suspected progression if off cycle for evaluation, or withdrawal of consent . 
CT is the imaging modality of choice for all patient evaluations, although MRI is permitted if CT 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  103 PanCAN-SR1 Orig Version: 22JUL2020 
 contrast allergies occur. Tumor/Response evaluations will be conducted according to RECIST 1.1 
guidelines. RECIST evaluations at baseline must be performed at the treating institution.  
The primary evaluation of response should be performed using RECIST 1.1 guidelines, by 
clinician assessment. The same modality (CT/ or MRI) chosen at screening should be used 
throughout the study. Please refer to Appendix C and Section 9.6 below for full details on the 
RECIST 1.1 Guidelines to follow for this study.  
 
8.1 Methods for Evaluation of Measurable Disease  
 
8.1.1  Imaging Requirements  
Response assessments will be evaluated by imaging (either CT or MRI if CT contrast allergies 
occur).  PET scans are not permissible.  The regions to be imaged are the chest and abdomen/pelvis, as well as any other sites that in the opinion of the clinician  and medical monitor required tumor 
imaging. The same mode of imaging for lesion evaluation at pretreatment must be used 
consistently throughout the study. Adherence to the planned imaging schedule is critical regardless 
of dose delays, unscheduled or miss ed assessments.  
The CT imaging should include contrast unless medically contraindicated.  
 
8.1.2  Tumor Marker Requirements  
Tumor marker response assessments will be evaluated by measuring serum 19 -9 (CA19 -9) levels 
at the beginning of each cycle, including at the time of every CT/MRI scan assessment (+/ - every 
4 weeks).  Measurements will be analyzed according to local practice. If feasible, the same assay 
should be used serially for each patient . Tumor marker levels will b e recorded with response, 
although not included as official response criteria.  
Please refer to Appendix C  and Section 9.6  below for full details on the RECIST 1.1 Guidelines 
to follow for this study.  
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  104 PanCAN-SR1 Orig Version: 22JUL2020 
 9.0 STATISTICAL CONSIDERATIONS  
9.1 Analysis Sets 
9.1.1 Full Analysis Set  
The Full Analysis Set (FAS) and Safety set are defined in the same way and comprise all  patients 
who received at least one dose of study treatment.  
9.1.2 Safety Set  
See definition of Full Analysis Set ( FAS) in Section 9.1.1  above . 
 
9.1.3 Dose -Determining  Analysis Set (DDS)  
The Dose -Determining Set (DDS) includes all patient s from the safety set who meet the minimum 
exposure criterion and have sufficient safety evaluations, or experienced a dose limiting toxicity 
(DLT) during the first two cycles (8 weeks)  of dosing.  
A patient  meets the minimum exposure criterion if the patient  received:   
• 2 doses of canakinumab (for Q4W dosing regimen cohort) or 1 dose of canakinumab (for Q8W 
dosing regimen cohort in case the canakinumab dose is de- escalated)  and 2 infusions of 
spartalizumab (full dose)  within the first 56 days (8 weeks) of study treatment  
• Takes at least 75% of planned doses of gemcitabine plus nab -paclitaxel chemotherapy  within 
the first 56 days (8 weeks) of study treatment  
If the patient  did not  receive the planned number of doses due to DLT, the patient  will be 
considered as meeting the minimum exposure criterion.  Patient s who do not experience a DLT 
during the first 56 days (8 weeks) are considered to have sufficient safety evaluations if they have been observed for ≥ 56 days (8 weeks) following the fir st dose, and are considered by the dose 
level  review team (DLRT) to have sufficient safety data to conclude that a DLT did not occur.  
9.1.4 Pharmacokinetic Analysis Set  
 
The Pharmacokinetic Analysis Set (PAS) consists of all subjects who received at least one do se 
of study drug and have at least one evaluable pharmacokinetic (PK) sample. The definition of  
an evaluable PK blood sample will be further specified in the statistical analysis plan (SAP).  
PAS will be defined for canakinumab, spartalizumab, nab -paclitaxel, and gemcitabine separately.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  105 PanCAN-SR1 Orig Version: 22JUL2020 
 9.2 Subject Demographics and Other Baseline Characteristics   
 
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively.  
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented.  
Relevant medical histories and current medical conditions at baseline will be summarized 
separately by system organ class and preferred term.  
9.3            Study Treatment and Dose Exposure   
The duration of exposure in months as well as the dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of  dose intensity and planned dose intensity) will be summarized by means 
of descriptive statistics using the safety set.  
The number of patients with dose adjustments (reductions, interruption, or permanent discontinuation) and the reasons will be summarized  by treatment group; and all dosing data will 
be listed. The reason for discontinuation from treatment will be summarized and listed, along with 
dates of first and last dose of study drug.  
Concomitant medications and significant non- drug therapies prior to  and after the start of the study 
treatment will be listed and summarized according to the Anatomical Therapeutic Chemical (ATC) 
classification system by dose level.   
9.4             Study Primary Objective  
The primary objective is to confirmation of the recommended dose for Phase II/III study.     The 
primary endpoint is the incidence of dose limiting toxicities (DLT) in the first 56 days (8 weeks) 
of the study treatment.  
9.4.1 Statistical Model, Hypothesis, and Method of Analysis   
For the dose confirmation of c anakinumab and spartalizumab in combination with nab- paclitaxel 
and gemcitabine, a Bayesian hierarchical logistic regression model (BLRM) will be applied to estimate the relationship between dose and the probability of a patient experiencing a dose limitin g 
toxicity (DLT).    Some dose -limiting toxicity data are available from previous studies on single 
agent and combination of canakinumab and spartalizumab (PDR001X2101,  ACZ885I2202, 
PRD001X2103) and a phase I/II study of  nab -paclitaxel + gemcitabine (Von  Hoff D, et.al., 2011).  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  106 PanCAN-SR1 Orig Version: 22JUL2020 
 These data will be incorporated into BLRM model using a meta -analytic -predictive (MAC) 
approach  (Neuenschwander et al 2016). The detai ls of the historical study and the data  are provided 
in Appendix B.   
 
The decision on dose toler ability for will be based on the totality of all relevant data from the 
ongoing study and a review of safety data from during the DLT evaluati on period ( the first 8 
weeks ). A Bayesian logistic regression model (BLRM) for combinations using the escalation with 
overdose control (EWOC) criterion to evaluate the risk of DLT will guide the decision.    
 Additional information on the BLRM statistical model is located in Appendix B.  
9.4.2 Assessment of Patient Risk  
Dose recommendations will be based on summaries of the posterior di stribution of DLT rates for 
each dose level of the respective combination therapy. After each cohort of patient s, the posterior 
distribution for the risk of DLT for new patient s at combination doses of interest will be evaluated. 
The posterior  distributions will be summarized to provide the posterior probability that the risk of 
DLT for each dose regimen lies within the following intervals :  
• Under -dosing: [0 , 0.16)  
• Targeted toxicity: [0.16 , 0.33)  
• Excessive toxicity: [0.33 , 1]  
 
Dosing regimen  decisions are guided by the escalation with overdose control (EWOC) principle 
(Rogatko et al 2007
).   The possibility of excessive toxicity is of interest in this study as the 
objective is to confirm the safety of the proposed dose regimen.  A dosing regimen may only be 
used for newly enrolled patient s if the risk of excessive toxicity  (within the interval [0.33, 1])  at 
that dosing regimen is less than 25%.  
 
 
 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  107 PanCAN-SR1 Orig Version: 22JUL2020 
 Hypothetical on -study scenarios  
To illustrate the performance of the BLRM model used to guide dose escalation, hypothetical dose 
escalations scenarios are presented in Table  9-1 .  In each scenario, the table displa ys the next dose 
level with the mean expected probability of dose limited toxicity P(DLT) and the probability of having excessive toxicity  P(excessive toxicity) at that dose level.  Note that next dose level could be the same dose level.   If P(excessive t oxicity) is ≥ 25%, then the next dose level does not meet 
EWOC and no more patients should be enrolled at this dose level and a new cohort should be 
opened at a lower dose level. The hypothetical scenarios considered various cases with 10 
evaluable patients or 6 evaluable patients.   Scenario 1, 5,  and 6 are cases such that the starting dose is considered safe to proceed (meet EWOC),  while scenario 2, and 7 are cases such that starting dose is not considered safe ( do not meet EWOC).  In those cases, cohort 2 will be opened 
at a lower dose level (scenario 3, 4, 8, and 9).  If cohort 2 is considered unsafe to proceed, no more cohort  will be opened.     
Table 9-1 Hypothetical D ose Escalation S cenarios  
Scenario  Cohort  Canakinumab  
dose Schedule*  Number of   Next dose level  
Evaluable 
patients  DLTs   Canakinumab 
dose schedule*  Median 
P(DLT)  P(excessive 
toxicity)  
1 Cohort 1  Q4W  10 2  Q4W  0.152  0.081  
2 Cohort 1  Q4W  10 3  Q4W  0.239  0.257  
3 Cohort 1  Q4W  10 3     
 Cohort 2 Q8W  10 1  Q8W  0.126 0.019 
4 Cohort 1  Q4W  10 3     
 Cohort 2  Q8W  10 2  Q8W  0.172  0.071  
5 Cohort 1  Q4W  6 0  Q4W  0.038  0.008  
6 Cohort 1  Q4W  6 1  Q4W  0.119  0.075  
7 Cohort 1  Q4W  6 2  Q4W  0.240  0.301  
8 Cohort 1  Q4W  6 2     
 Cohort 2  Q8W  6 1  Q8W  0.150  0.074  
9 Cohort 1 Q4W  6 2     
 Cohort 2  Q8W  6 2  Q8W  0.226  0.234  
* Canakinumab 250 mg Q4W or Q8W in combination with fixed dose of  spartalizumab 400mg Q4W  + nab-
paclitaxel 125 mg/m2  + gemcitabine 1000 mg/m2 (Day 1, 8 ,15 of each cycle)  
 
 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  108 PanCAN-SR1 Orig Version: 22JUL2020 
 Listing/ summary of DLTs  
DLTs will be listed and their incidence summarized by primary system organ class, worst grade 
based on the CTCAE version 5.0, type of adverse event, and by treatment group in the dose 
escalation. The dose- determining set will be used for th ese summaries.  
 
9.5 Secondary Safety Objective 
 
Safety summaries will use the Safety Analysis Set.  
The overall observation period will be divided into three mutually exclusive segments:  
• Pre-treatment period:  from day of subject’s informed consent to the day before first dose of 
study treatment 
• On-treatment period:  from day of first dose of study medication to 30 days after last dose of 
study treatment 
• Post-treatment period:  starting at day 30+1 after last dos e of study treatment 
 
9.5.1 Adverse Events  
Safety summaries (tables, figures) include only data from the on -treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from baseline summaries). In addition, a  separate summary for death including on treatment and post 
treatment deaths will be provided.   Summary tables for adverse events (AEs) will include AEs 
with onset date during the on- treatment period, the treatment -emergent AEs. The incidence of 
treatment- emergent adverse events will be summarized by system organ class and or preferred 
term, severity (based on CTCAE 5.0  grades), type of adverse event, and relation to study treatment.   All AEs, deaths and serious adverse events (including those from the pre and post -
treatment periods) will be listed and those starting during the pre -treatment and post -treatment 
period will be flagged.  
Serious adverse events, non -serious adverse events and adverse events of special interest (AESI) 
during the on -treatment per iod will be tabulated. AESIs will be defined based on the current case 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  109 PanCAN-SR1 Orig Version: 22JUL2020 
 retrieval strategy (CRS). All reported deaths (on -treatment and post- treatment) will be 
summarized.  
9.5.2 Clinical laboratory evaluations  
For laboratory tests covered by the Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0  the study’s biostatistical and reporting team will grade laboratory data accordingly. For laboratory tests covered by CTCAE, a Grade 0 will be assigned for all non -missing values not 
graded as 1 or higher . Grade 5 will not be used.  
For laboratory tests where grades are not defined by CTCAE, results will be graded by the 
low/normal/high classifications based on laboratory normal ranges.  
The following by -treatment/patient group summaries will be generated separately for hematology, 
biochemistry and urinary laboratory tests:  
Shift tables using CTCAE grades to compare baseline to the worst on -treatment value.  
Listing of all clinically relevant laboratory data with values flagged to show the corresponding CTCA E grades and the classifications relative to the laboratory normal ranges.  
In addition to the above mentioned tables and listings, other exploratory analyses, for example 
figures plotting time course of raw or change in laboratory tests over time or box pl ots might be 
specified in the SAP.  
9.5.3 Other safety data  
Other safety data, include vital signs and ECGs will be listed by dose level and subject, and 
visit/time and if ranges are available, abnormalities (and relevant orthostatic changes) will be flagged. Sum mary statistics will be provided by treatment and visit/time.  
 
9.6 Secondary Efficacy and PK Objective(s)  
 
9.6.1  Secondary Efficacy Objective(s)  
 
• Analysis of efficacy endpoints will be performed on the Full Analysis Set.  
• Tumor response will be determined per local  investigators’ assessment.  
• Response related efficacy assessments will be defined and analyzed based on RECIST 1.1 
(primary).  ORR and DCR will be estimated, and the exact binomial 95% CI will be 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  110 PanCAN-SR1 Orig Version: 22JUL2020 
 reported.  Time to event efficacy endpoints using Kaplan -Meier method and the median 
along with 95% confidence intervals.  
 
Overall response rate (ORR)  
ORR is defined as the proportion of subjects with best overall response (BOR) of complete 
response (CR) or partial response (PR), according to RECIST 1.1. ORR will  be calculated based 
on the FAS. ORR and its 95% exact confidence interval will be presented  
Duration of response (DOR)  
DOR only applies to subjects in FAS whose BOR is CR or PR according to RECIST 1.1. The start date is the date of first documented response of CR or PR (i.e., the start date of response, not the date when response was confirmed), and the end date is defined  as the date of the first documented 
progression or death due to underlying cancer. Subjects continuing without progression or death 
due to underlying cancer will be censored at the date of their last adequate tumor assessment.   
Kaplan -Meier method will b e used to estimate median PFS and 95% confidence intervals will be 
presented by dose level  in FAS (by investigator assessment).  
Disease Control Rate (DCR)  
DCR is defined as the proportion of subjects with a BOR of CR, PR, or SD, according to RECIST 
1.1.  DCR will be calculated based on the FAS. DCR and its exact 95% confidence interval will 
be presented.  
Progression Free Survival (PFS)  
PFS is defined as the time from the date of first dose  to the date of the first documented disease 
progression based on local investigator assessment as per RECIST 1.1 (assessed by investigator) 
or death due to any cause.   Kaplan -Meier method will be used to estimat e median PFS and 95% 
confidence intervals will be presented by dose level  in FAS (by investigator assessment) . 
 
Time to response (TTR)  
Time to response (TTR) is defined as the time from the date of first dose to the date of first  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  111 PanCAN-SR1 Orig Version: 22JUL2020 
 documented response (CR or PR, which must be confirmed subsequently). Summary statistics will 
be presented.   
Overall survival (OS)  
OS is defined as the time from date of first dose of study treatment to date of death due to any 
cause. If a subject is not known to have died, then OS will be censored at the latest date the subject 
was known to be alive (on or before the cut -off date).  
OS w ill be analyzed in the FAS population. The OS distribution will beestimated using the Kaplan -
Meier method, and the Kaplan -Meier medians and 95% confidence intervals of the medians will 
be presented.  
9.6.2 Secondary PK Objective(s)  
 
PAS will be used in the pharm acokinetic data analysis.. Descriptive statistics (n, m (number of 
non-zero concentrations), mean, coefficient of variation CV%, SD, median, geometric mean, 
geometric CV%, minimum and maximum) for each analyte (canakinumab, spartalizumab, nab -
paclitaxel an d gemitabine) will be presented separately at each scheduled timepoint.  
All concentration data for canakinumab, spartalizumab, nab -paclitaxel and gemitabine vs. time 
profiles will be displayed graphically.  
The descriptive statistics (n, mean, CV%, standard  deviation (SD), median, geometric mean,  
geometric CV%, minimum and maximum) will be presented for PK parameters as well, except  
Tmax, where only n, median, minimum and maximum will be presented, when applicable. PK 
parameters (e.g. AUC, Cmin, Cmax, Tmax, T1/2) will be estimated and reported at appropriate 
timepoints, when derivation of selective PK parameters is feasible.  
 
9.7 Exploratory Objectives  
 
9.7.1 Biomarkers 
This clinical trial is not designed to address specific biomarkers -related exploratory objectives, 
the analysis of the data should be viewed as hypotheses generating.  
There may be circumstances when a decision is made to stop a collection, or not to perform or discontinue the analysis of samples due to either practical or strategic reasons. Under such 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  112 PanCAN-SR1 Orig Version: 22JUL2020 
 circumstances, the sample size number may be too small or the quality of the data not sufficient to 
perform any data analysis and the available data will be only listed.  
Additional analyses that may be performed after the completion of the end -of-study CSR w ill be 
documented in separate reports. These analyses may include but are not limited to the meta-
analysis of data from this study combined with data from other studies or the analysis of 
biomarkers generated from samples collected during the study but ana lyzed after the database lock 
and completion of the CSR. The data analysis will be described in an addendum of the Statistical Analysis Plan or in a stand -alone analysis plan document, as appropriate.  
Data transformations, such as base 2 logarithms, may be used to summarize and adequately 
analyze the data and will be described in detail in the statistical analysis plans.  
 
9.7.2 Data H andling Principles  
 
Analysis sets  
 
Unless otherwise mentioned, the Full Analysis Set is used to describe biomarkers; Safety Set is 
used to assess the relationship between biomarkers and selected safety endpoints, while the PK Set is used to assess the relationship between PK parameters and biomarkers. Since no imputation is usually planned, the number of subjects included in a given analysis will reflect the 
number of subjects in the chosen analysis set which have valid biomarker assessments.  
 
Basic tables, figures and listings  
 
Unless other wise specified, analysis will be performed by dose groups (if more than one dose)  
 
will be summarized using means, medians, standard deviations, minimums, and maximums, by visit. Both level and change from baseline levels (absolute, percent and fold changes) will be summarized for biomarker that also have assessments at post -baseline visits.  
 
 will be summarized using frequency counts and percentages.  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  113 PanCAN-SR1 Orig Version: 22JUL2020 
 If sample size is limited then the biomarker data will be listed. For large panels, selected sets of 
relevant markers will be selected for the listing.  
 
9.7.3  
 
 
 
 
 
 
9.8 Handling of Missing Values/ Censoring/ Discontinuations  
 
Patient s who are ineligible for the DDS will be excluded from the primary analysis (assessment of 
recommended dose using incidence of DLT during first 56 days of treatment with canakinumab in 
combination with spartalizumab, nab -paclitaxel and gemcitabine), althou gh their data will be used 
for all remaining analyses.  
Continuing events (e.g. AEs, concomitant medication, etc.) will be summarized using the data cut -
off date as the date of completion, with an indication within listings that the event is  
continuing. For patients who discontinue the study with ongoing events, the discontinuation  
date will be used as the completion date of the event with the appropriate censoring as described  
in the above paragraph.  
 
The reason for discontinuation from study will be sum marized and listed, along with dates of  
first and last study drug treatment, duration of exposure to study drug treatment and date of  
discontinuation for each patient. Other missing data will simply be noted as missing on appropriate tables/listings.   
A subject whose disease has not progressed or died by the date of the analysis cut -off will have  
their PFS censored at the time of the last adequate tumor evaluation performed on or before the 
cut-off date. Clinical deterioration will not be considered as docu mented disease progression.  
Censoring rules for PFS follow the RECIST 1.1 guidelines and will be further detailed in the  
SAP.  

Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  114 PanCAN-SR1 Orig Version: 22JUL2020 
 A subject who has not died by the date of the analysis cut -off date will have their OS censored  
at the last known date the subject  is alive.  
 
9.9            Sample size  
 
Approximately 10 patients will be enrolled to the starting dose level to  have at least 6 evaluable 
patients.  If the starting dose level is considered unsafe,  the dose will be de- escalated to dose level 
-1 and  approxi matley 10 patients will be enrolled to achieve at least 6 evalulable patients.  For 
further elaboration of safety and pharmacokinetic parameters, additio nal patients may be enrolled 
if considered neccessary by Novarits and PIs. Appendix B provided hypothet ical scenarios  to 
illustrate the dose recommedation by BLRM.   
 
 
10.0 STUDY OVERSIGHT  
 
10.1  Investigator Responsibilities  
The Investigator will conduct all aspects of this study in accordance with applicable national, state, 
and local laws of the pertinent regulatory authorities.  
 
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and i n the 
local regulations. PanCAN Chief Medical Officer or an authorized representative will evaluate and 
approve all Investigators who in turn will select their staff.  
 
The Investigator should ensure that all persons assisting with the study at his or her site are 
adequately informed about the protocol, amendments, study treatments, as well as study -related 
duties and functions, including obligations of confidentiality.  
 The Investigator should maintain a list of sub -Investigators and other appropriately qualified 
persons to whom he/she has delegated  authority to perform  significant study -related duties.  
The Investigator is responsible for keeping a record of all patient s who sign an ICF document and 
are screened for entry into the study. Patient s who fail screening must have the reason(s) recorded 
in the patient ’s source documents.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  115 PanCAN-SR1 Orig Version: 22JUL2020 
  
The Investigator must ensure that a patient ’s records and documents pertaining to the conduct of 
the study and the distribution of the investigational agent are complete, accurate, filed and retained.  
The Investigator, or a designated member of the Investigator’s staff, must be available during monitoring visits to review data, resolve queries and allow direct access to patient  records. The 
Investigator must ensure timely and a ccurate completion of electronic Case Report Forms (eCRF) 
and queries.  
 
10.2 Good Clinical Practice  
The procedures set out in this study protocol pertaining to the conduct, evaluation, and  
documentation of this study are designed to ensure that the sponso r, its authorized representative,  
and Investigator abide by Good Clinical Practice (GCP), as described in International  Conference 
on Harmonization (ICH) Guideline E6 and in accordance with the general ethical  principles 
outlined in the Declaration of Helsinki. The study will receive approval from an  IRB/EC prior to 
commencement. The Investigator will conduct all aspects of this study in  accordance with 
applicable national, state, and local laws of the pertinent regulatory authorities . 
 10.3 Data Manage ment  
The Investigator must ensure that the records and documents pertaining to the conduct of the study and the distribution of the IP are complete, accurate, filed and retained. Examples of source 
documents include: hospital records; clinic and office charts; laboratory notes; memoranda; 
patient ’s diaries or evaluation checklists; dispensing records; recorded data from automated 
instruments; copies or transcriptions certified after verification as being accurate copies; x -ray film 
and reports; and records kept at the pharmacy, and the laboratories, as well as copies of CRFs or 
CD-ROM.  
 Data will be entered into the RAVE -X electronic data capture (EDC) platform by study staff . This 
data will be electronically verified through the use of programmed edit checks specified by 
Covance . Discrepancies in the data will be brought to the attention of the clinical team, and 
investigational site personnel, if necessary. Resolutions to these issues will be reflected in the database. An audit trail within the system will track  all changes made to the data.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  116 PanCAN-SR1 Orig Version: 22JUL2020 
  
10.4 Data Monitoring 
This study focuses data collection on critical and essential variables to ensure important efficacy and safety information are captured.  The Data Plan specifies the variables collected and those that 
are not. The Data Plan also details the process (and systems) for data collection, cleaning, and 
verification in Precision Promise
SM. The objective is to decrease data quality issues, improve site 
compliance and data completeness, control operational bias and ultimately improve patient  
management and safety.  
 
10.5 Study Monitoring  
PanCAN or its authorized designee will ensure that appropriate monitoring procedures are 
performed before, during and after the study. All aspects of the study, including review the 
protocol, eCRFs, ICF documents and procedures for obtaining and withdrawing informed consent, 
record keeping, and reporting of AEs/SAEs, are reviewed with the Principal Investigator, sub -
investigators and the study research staff at a study initiation visit and/or at an Investigator meeting.  
Monitoring will include remote and on -site visits with the Investigator, sub -investigators, and 
study rese arch staff as well as any appropriate communications by mail, email, fax, or telephone. 
During monitoring visits, the facilities, investigational agent storage area, eCRFs, patient s’ source 
documents, and all other study documentation will be inspected/rev iewed by PanCAN or its 
authorized designee(s) in accordance with the Study Monitoring Plan.  
 10.6 Audits and Inspections  
PanCAN or its authorized designee(s), local IRB or the FDA may conduct audits of clinical 
research activities to evaluate compliance with Good Clinical Practice guidelines and regulations.  
 The Investigator is required to permit direct access to the facilities where the study takes place, source documents, eCRFs and applicable supporting records of study participation for audits and 
inspections by IRBs, FDA and PanCAN or his/her authorized designees. The Investigator should 
make every effort to be available for the audits and/or inspections. If the Investigator is contacted 
by any regulatory authority regarding an inspection, he/she should contact PanCAN  or his/her 
authorized desi gnee immediately.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  117 PanCAN-SR1 Orig Version: 22JUL2020 
  
10.7 Pharmaceutical Agreements  
Investigational agents are provided under a contract  between Agent Manufacturer and PanCAN.  
They may not be used outside of the study protocol.  
 
11.0  ETHICAL AND REGULATORY CONSIDERATIONS  
11.1  Good Clinical Practice  
This protocol describes procedures pertaining to conduct, evaluation, and documentation to ensure 
that PanCAN, its authorized designee(s), and the study Investigators, sub -investigators and site 
staff abide by Good Clinical Practice (GCP), as described in International Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsinki.  
 
11.2  Record Keeping  
Study sites selected for participation in this study  will be responsible for submitting essential 
regulatory documents to PanCAN or its authorized designee.  
  
The collection of regulatory documents will take place in accordance with applicable ICH GCP 
guidelines, state and federal regulations. Regulatory do cuments must be maintained per all 
applicable institutional and federal regulations.  All questions related to regulatory document 
submission should be directed to the attention of PanCAN or his/her authorized designee. The 
following documents comprise the  essential regulatory document packet required . 
 
11.2.1  Form FDA 1572  
The Investigator will provide an  original signed  Form FDA 1572 stating that the study will be 
conducted in compliance with regulations for clinical investigations and listing all the su b-
investigators at that institution that will participate in the protocol prior to study initiation.  
 
11.2.2 Other Required Documents  
• CV/Biosketch for the Investigator and all sub- investigators listed on Form FDA 1572  
• Current professional licenses (where  applicable) for the Investigator and all sub -
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  118 PanCAN-SR1 Orig Version: 22JUL2020 
 investigators listed on Form FDA 1572  
• Financial Disclosure Form for the Investigator and all sub- investigators listed on Form 
FDA 1572  
• Certification of Human Subjects Protection Training (NIH or institution -based training 
program certificate) for the Investigator and all sub -investigators listed on Form FDA 1572  
• Delegation of Responsibilities Log signed by the Investigator.  This document lists the 
names and responsibilities of all study staff, including all sub -investigators listed on Form 
FDA 1572  
• Lab certifications (CLIA and CAP) and lab normal ranges for all labs listed on each site’s 
Form FDA 1572.  
• Documentation of Federal  wide Assurance (FWA). A print -out of the institutional FWA 
number may be accessed via the OHRP website as follows: 
http://ohrp.cit.nih.gov/search/fwasearch.aspx?styp=bsc . (Click the button for FWAs [FWA 
numb er]) 
• Investigator’s Brochure (IB) Acknowledgment Form signed by the Investigator for 
each  IB received  
• IRB approval for all PanCAN -approved Protocol versions, ICFs, IB versions (if 
applicable) and patient educational and recruitment materials  
 
11.2.3  Submis sion of Required Documents  
All required documents may be transmitted via email with the exception of the following 
documents for which signed originals must be sent via traceable courier:  1) Form FDA 1572 2) 
Financial Disclosure Form . 
 
11.3 Patient  Information and Informed Consent  
The investigator  or his/her  authorized  designee must obtain informed consent of a patient  and/or a 
patient ’s legal representative prior to any study -related procedures.  
 
Documentation that informed consent occurred prior to the patient ’s entry into the study and of 
the informed consent process should be recorded in the study patient ’s source documents including 
the date. The original ICF documents signed and dated by the patient  and by the person consenting 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  119 PanCAN-SR1 Orig Version: 22JUL2020 
 the patient  prior to the patient ’s entry into the study, must be maintained in the Investigator’s study 
files and a copy given to the study patient .  
In addition, when the protocol is amended and the information changes patient  risk, the ICF 
document will be revised. Study patient s who are active in the study when the updated relevant 
informed consent is implemented must be re -consented with the revised version of the appropriate 
ICF. Those patient s that are on active treatment must be re- consented only to the treatment p hase 
ICF and investigational arm ICF, if appropriate. If the Screening ICF is updated once a patient  
proceeds to the Treatment Phase, re- consenting to the Screening ICF is not required.  The revised 
ICF document signed and dated by the study patient  and by the person re -consenting the study 
patient  must be maintained in the Investigator’s study files and a copy given to the study patient .  
 
11.3.1  Informed Consent Form(s) Review and Approval Process  
Prior to study initiation, the ICF documents must be reviewed and approved by PanCAN or his/her 
authorized designee, and the IRB at each institution at which the protocol will be implemented. 
Any subsequent changes to the ICF document(s) must be approved by PanCAN or his/her 
authorized designee, and then s ubmitted to each institution’s IRB for approval prior to initiation.  
 
11.4 Institutional Review Board (IRB) Approval  
Prior to initiating the study and receiving the investigational agent(s), written approval to conduct the study from the appropriate IRB must be obtained. As changes to the study become necessary, 
protocol amendments will be submitted to PanCAN according t o Amendment Guidelines. 
PanCAN -approved amended protocol must be approved by the IRB prior to implementation.  
As investigational arms move in and out of the trial, protocol amendments will be issued.  
  
11.4.1  IRB Approval Timeline Guidelines  
Participating  institutions will be notified of the allowable timeframe permitted to get each 
amendment approved by their institutional IRB.  
• Major Modification : Participating institutions have 60 calendar days to submit and obtain 
IRB approval. If an institution’s IRB approval letter is not received by PanCAN or his/her 
authorized designee ≤  60 calendar days, accrual at that institution may be placed on hold 
until IRB approval is obtained and approval letters have been received and processed by 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  120 PanCAN-SR1 Orig Version: 22JUL2020 
 PanCAN or his/her authori zed designee.  
• Minor Modification ( not including administrative amendments) : Participating 
institutions have 30 calendar days to submit and obtain IRB approval. If an institution’s 
IRB approval letters are not received by PanCAN or his/her authorized designee ≤30 
calendar days, accrual at that institution may be placed on hold until institutional IRB approval is obtained,  and approval letters have been received and processed by PanCAN 
or his/her authorized designee.  
• Administrative Amendments : Amendments that are administrative in nature do not 
require IRB approval will be submitted to the IRB for information purposes.  
 
11.5  Joint Safety Committee and Dose Confirmation Meeting  
Decisions for confirmation of dose or to assess a different dose  level will be made jointly by 
Investigators and study personnel that will include at least Medical Monitor and a biostatistician. 
Decisions will be based on a synthesis of all relevant data available from all dose levels evaluated 
in the ongoing study inc luding safety information, DLTs, all CTCAE Grade ≥ 2 toxicity data 
during the first two cycles, and PK data from evaluable patients. The recommended dose for the 
next cohort of patients will be guided by the BLRM.  
 
11.6 Study Termination 
The Sponsor ( PanCAN) or FDA can terminate the trial at any time. Appropriate measures would 
be made to try to ensure support and continuance of patient  care.  
 
12.0 RECORD KEEPING/QUALITY CONTROL  
12.1   Inspection  
PanCAN or its authorized  designee must be allowed to conduct site visits for monitoring any 
aspects of the study.   Source data/documents must be available for inspection for PanCAN, its 
authorized designee or any Regulatory Authority.  Monitoring can include inspection of drug 
storage area, study drug stocks, drug accountability records, patient  medical records and study 
source documents, and other records related to study conduct.  
  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  121 PanCAN-SR1 Orig Version: 22JUL2020 
 12.2 Record Retention  
In accordance with applicable regulatory requirements, following closure of  the trial, the 
Investigator will maintain a copy of all essential documents in a safe and secure location. Essential  
documents must be retained by the Investigator according to the period of time outlined in the 
Clinical Trial Agreement.  
 Documents inclu ded in this retention policy include but is not limited to:  
• Signed ICF’s for all patient s 
• Pre-screening and screening logs  and enrollment logs  
• Record of all communication with Investigator and IRB  
• Composition of IRB or confirmation statement that the IRB is composition is in accordance 
with GCP, if composition may not  be disclosed.  
• Communication between Investigator and Sponsor and authorized designees  
• Delegation of Responsibility Log  
• Access to eCRFs  
• Study treatment accountability records  
• Record of and bod y fluid or samples retained  
• All other source documents listed in Section 8 of ICH consolidated guideline on GCP (Essential Documents for the Conduct of a Clinical Trial)  
 
PanCAN or his/her authorized designee must be notified, in writing, if the Investigat or wishes to 
assign the study records to another party or move them to another location or destroy any documents.  Institutions/Investigator s should take measured to prevent accidental or premature 
destruction of these documents.  
    
 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  122 PanCAN-SR1 Orig Version: 22JUL2020 
 13.0 CONFIDENTIALITY  
The information contained in th is Study Protocol (except for the information provided by PanCAN 
in public scientific presentations and publications, public websites or through press releases ) is 
considered PanCAN confidential information. O nly information that is previously disclosed by 
PanCAN in public scientific presentations and publications, public websites or through press 
releases may be freely disclosed by the Investigator, his/her sub -investigators, study staff or 
institution, or as outlined in the Clinical Trial Agreement. This Study Protocol is not to be made 
publicly available (for example on the Investigator’s or his/her institution’s website) without 
written approval from PanCAN.   
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  123 PanCAN-SR1 Orig Version: 22JUL2020 
 14.0 REFERENCES  
American Cancer Society.  Cancer Facts & Figures 2017.  
Apte RN,  Dotan S, Elkabets M, et al. The involvement of IL -1 in tumorigenesis, tumor 
invasiveness, metastasis and tumor -host interactions. Cancer Metastasis Rev. 2006 ; p. 387-
408. 
Arranz L,  Arriero MDM, Villatoro  A.  Interleukin -1β as emerging therapeutic target in 
hematological malignancies and potentially in their complications. Blood Rev. 2017 ; p. 306-
317. 
Babb J,  Rogatko A, Zacks S .  Cancer phase I clinical trials: efficient dose escalation  
with overdose cont rol. Stat Med. 1998; 17(10):1103-20. 
Becker Y . Molecular immunological approaches to biotherapy of human cancers -a review, 
hypothesis and implications. Anticancer Res. 2006; p. 1113-34. 
Biankin AV,  Waddell N, Kassahn  KS, et al. Pancreatic cancer genomes reveal aberrations in 
axon guidance pathway genes. Nature 2012; 491:399-405. 
Biotechnology Innovation Organization,  BIomedtracker, Amplion. Clinical development 
success rates, 2006 -2015. Published. 2016 
Boeck S,  Haas M, Laubender RP, Kullmann F, Klose C, Bruns CJ, Wilkowski R, Stieber P, 
Holdenrieder S, Buchner H, Mansmann U, Heinemann V. Application of a Time -Varying 
Covariate Model to the Analysis of CA 19 -9 as Serum Biomarker in Patients with Advanced 
Pancreat ic Cancer. Clin Cancer Res.  2006; 16(3):986–94. 
Brahmer  JR, Tykodi SS,  Chow LQ, et al. Safety and activity of anti -PD-L1 antibody in 
patients with advanced  cancer. N Engl J Med.  2012; 366: 2455-65 
Brahmer, J . R., Lacchetti, C., Schneider, B. J., et al . Management of Immune -Related Adverse 
Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of 
Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1 714-1768.  
Brand RE  and Tempero MA. Pancreatic cancer. Curr Opin Oncol . 1998; 10:362–366. 
Bray F , Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates 
of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 
68: 394–424) 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  124 PanCAN-SR1 Orig Version: 22JUL2020 
 Conroy T, Desseigne F, Ychou  M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul J -
L, Gourgou -Bourgade S, de la Fouchardiere C, Bennouna J, Bachet J -B, Khemissa -Akouz F, 
Pere- Verge D, Delbaldo C, Assenat E. Chauffert B, Michel P, Montoto -Grillot C, Ducreaux 
M. FOLFIRINOX versus gemc itabine for metastatic pancreatic cancer N Engl J Med. 2011; 
364(1 9):1817-1825. 
Daley D , Mani VR, Mohan N, Akkad N, Pandian G, Savadkar S, et al. NLRP3 signaling drives 
macrophage- induced adaptive immune suppression in pancreatic carcinoma. J Exp Med 2017;  
214:1711–24. 
Das S,  Shapiro B, Vicic E et al. Tumor Cell– Derived IL1b Promotes Desmoplasia and Immune 
Suppression in Pancreatic Cancer January 8, 2020; DOI: 10.1158/0008-5472.CAN-19-2080 Dinarello CA.  Biologic basis for interleukin -1 in disease. Blood 1996; p. 2095-147 
Ebrahimi  B, Tucker SL, Li D,  et al. Cytokines in pancreatic carcinoma: correlation with 
phenotypic characteristics and prognosis.  2004; 101:2727-36. 
      EMA, Guideline on Clinical Trials in Small Populations,  February 1  2007 
      FDA, Challenges and Opportunities Report . Innovation or Stagnation: Challenge and  
      Opportunity on the Critical Path to New Medical Products . March 2004.  
Fox BA , Schendel DJ,  Butterfield LH  et al . Defining the critical hurdles 
in cancer  immunotherapy. J Transl Med. 2011; 9:214. doi: 10.1186/1479-5876-9-214 
Freeman  GJ. Structures of  PD-1 with its ligands: sideways and dancing cheek to cheek. Proc 
Natl Acad Sci USA 2008; 105:10275-6. 
Garlanda C,  Dinarello CA, Mantovani  A. The interleukin- 1 family: back to the future. 
Immunity 2013; p. 1003- 18.  
Gowen M,  Wood DD, Ihrie EJ, et al. An interleukin 1 like factor stimulates bone resorption 
in vitro. Nature 1983; p. 378 -80. 
Guo Q , Jin Z, Yuan Y, et al . New Mechanisms of Tumor -Associated Macrophages on 
Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy. J Immunol Res 2016; p. 9720912. 
Haanen JBAG,  Carbonnel F, Robert C  et al. Management of toxicities from i mmunotherapy: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol.  2017; 
1;28(suppl_4):iv119-iv142.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  125 PanCAN-SR1 Orig Version: 22JUL2020 
 Howlader N,  Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, 
Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer 
Statistics Review, 1975- 2014, National Cancer Institute. Bethesda, 
MD, https://seer.cancer.gov/csr/1975_2014/ , based on November 2016 SEER data 
submission, posted to the SEER web site, April 2017.  
Hu ZI,  Shia J,  Stadler ZK  et al. Evaluating Mismatch Repair Deficiency in Pancreatic 
Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res 2018 ; 24:1326-1336. 
Incio J , Liu H, Suboj  P, Chin SM, Chen IX, Pinter M, et al. Obesity- induced inflammation 
and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. 
Cancer Discov 2016;  6:852–69. 
Johnson BE,  Kim TA, Hilterman JN et al. Safety Run- in Results From Phase  3 Study of 
Canakinumab (CAN) or Placebo in Combination with Pembrolizumab (PEM) Plus Platinum -
based Doublet Chemotherapy (Ctx) as 1st  Line Therapy in Patients (pts) with Advanced or 
Metastatic NSCLC (CANOPY -1). Poster Presented at AACR -NCI-EORTC Internati onal 
Conference on Molecular Targets and Cancer Therapeutics, October 26 -30, 2019  
Jones S , Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, 
Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio -Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, 
Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core Signaling Pathways  in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science.  
2008; 321(5897): 1801–1806. 
Kaplanov I,  Carmi Y, Kornetsky et al. Blocking IL -1β reverses the immunosuppression in 
mouse breast cancer and synergizes with anti –PD-1 for tumor abroga tion. PNAS  
2019; 116:1361-1369 
Keir  ME, Butte MJ,  Freeman GJ,  Sharpe AH.  PD-1 and its ligands in tolerance and immunity.  
Annu Rev Immunol.  2008;   26:677-704. 
Ko AH , Hwang J, Venook AP, Abbruzzese JL, Bergsland  EK, Tempero MA. Serum CA19 -9 
response as a surrogate for clinical outcome in patients receiving fixed -dose rate gemcitabine 
for advanced pancreatic cancer. Br J Cancer  2005; 93(2):195–199. 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  126 PanCAN-SR1 Orig Version: 22JUL2020 
 Koch AE , Kunkel SL, Chensue SW, et al. Expression of interleukin -1 and interleukin -1 
receptor antagonist by human rheumatoid synovial tissue macrophages. Clin. Immunol. 
Immunopathol. 1992; p. 23-9  
Krelin Y , Voronov E, Dotan S, et al . Interleukin -1beta -driven inflammation promotes the 
development and invasiveness of chem ical carcinogen -induced tumors. Cancer Res. 2007; p. 
1062-71. 
Le DT,  Wang -Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and 
Listeria Monocytogenes -expressing mesothelin (CRS -207) boost vaccines for metastatic 
pancreatic cancer. J Clin Oncol 2015; 33:1325-33. 
Le DT, Durham JN, Smith KN, et al . Mismatch repair deficiency predicts response of solid 
tumors to PD -1 blockade. Science  2017; 357:409-413 
Lesina M,  Kurkowski MU, Ludes K, et al . Stat3/Socs3 activation by IL -6 transsignaling  
promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic 
cancer.  Cancer Cell  2011; 19:456-69. 
Lewis AM,  Varghese S, Xu H, et al. Interleukin -1 and cancer progression: the emerging role 
of interleukin -1 receptor antagonist  as a novel therapeutic agent in cancer treatment. J Transl 
Med 2006; p. 48.  
Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19 -9 as a prognostic 
factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer.  2005; 
93(7):740-743. 
Mahadevan D,  Von Hoff DD. Tumor -stroma interactions in pancreatic ductal 
adenocarcinoma. Mol Cancer Ther.  2007; 6(4):1186-97 
Maker AV,  Katabi N, Qin LX, Klimstra DS, Schattner M, BrennanMF, et al. Cyst fluid 
interleukin -1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary 
mucinous neoplasms of the pancreas. Clin Cancer Res 2011;  17: 1502–8. 
Malvezzi M,  Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality 
predictions for the year 2013. Ann Oncol.  2013; 24(3):792-800. 
Mangsbo SM, Sandin LC, Anger K,  et al. Enhanced tumor eradication by combining CTLA -
4 or PD -1 blockade with CpG therapy. J Immunother . 2010; 33:225-35. 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  127 PanCAN-SR1 Orig Version: 22JUL2020 
 Mantovani A,  Barajon I, Garlanda C. IL -1 and IL -1 regulatory pathways in cancer pro gression 
and therapy. Immunol. Rev. 2018 ; p. 57-61. 
McMillan  DC. The systemic inflammation -based  Glasgow  Prognostic  Score: a decade of 
experience in patients with cancer. Cancer Treat Rev . 2013; 39:534-40 
Minchinton AI,  Tannock  IF. Drug penetration in solid tumours. Nat Rev Cancer.  2006; 
6(8):583- 92. 
Mkrtichyan M, Najjar YG, Raulfs EC,  et al. Anti-PD-1 synergizes with cyclophosphamide to 
induce potent anti -tumor vaccine effects through novel mechanisms. Eur J Immunol  2011; 
41:2977-86. 
Moore MJ, Goldstein D, Hamm J et al. Erlotinib p lus gemcitabine compared with gemcitabine 
alone in patients with advanced pancreatic cancer: a phase  III trial of the National Cancer 
Institute of Canada Clinical Trials Group J Clin Oncol. 2007; 25: 1960-1966. 
Mora J,  Weigert A. IL -1 family cytokines in cancer immunity - a matter of life and death. 
Biol. Chem. 2016; p. 1125-1134. 
Natanegara F,  Neuenschwander B, Seaman JW Jr, et al. The current state of Bayesian  
methods in medical product develop ment: survey results and recommendations from the DIA  
Bayesian Scientific Working Group. Pharm Stat. 2014 Jan-Feb;13(1):3-12. 
Neuenschwander, B,  Branson M ,. and Gsponer T. Critical aspects of the Bayesian  approach 
to phase I cancer trials.  Statistics in medicine,  2008. 27(13), pp.2420 -2439  
Neuenschwander B,  Capkun- Niggli G. , Branson M. , and Spiegelhalter D.J. Summarizing 
historical information on controls in clinical trials.  Clinical Trials,  2010; 7(1), pp.5 -18. 
Neuenschwander B,  Roychoudhury S, Schmidli H. On the Use of Co -Data in Clinical Trials. 
Statistics in Biopharmaceutical Research. 2016 ; 8:345-354.  
      Neuenschwander, B.  et al. Robust exchangeability designs for early phase clinical  
      trials with multiple strata.  Pharmaceutical statistics, 2016; 15(2), pp.123–134 . 
Nomi T,  Sho M, Akahori T, et al.: Clinical significance and therapeutic potential of the 
programmed death -1 ligand/programmed death -1 pathway in human pancreatic cancer. Clin 
Cancer Res 2007; 13: 2151–2157. 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  128 PanCAN-SR1 Orig Version: 22JUL2020 
 Parseghian CM,  Patnana  M, Bhosale et al Evaluating for Pseudoprogression in Colorectal 
and Pancreatic Tumors Treated with Immunotherapy. J Immunotherapy  2018; 41:284-291.  
Poruk KE,  Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill 
SJ. The clinical utilit y of CA 19 -9 in pancreatic adenocarcinoma: diagnostic and prognostic 
updates. Curr Mol Med.  2013; 13(3): 340–351. 
Pu N , Wnhui L and Jun Y . PD-1 immunotherapy  in pancreatic cancer current status. J 
Pancreatol . 2019; 2:6-10 
Ridker PM.  From C -Reactive Protein to Interleukin -6 to Interleukin- 1: Moving Upstream To 
Identify Novel Targets for Atheroprotection. Circ. Res. 2016; p. 145- 56. 
Ridker PM,  Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for 
Atherosclerotic Di sease. N. Engl. J. Med. 2017 ; a. p. 1119-1131. 
Riley JL.  PD-1 signaling in primary T cells.  Immunol Rev. 2009;  229:114-25.  
Rogatko A, Schoeneck D, Jonas W, et al . Translation of innovative designs into phase I trials.  
J Clin Oncol  2007; 25:4982-6. 
Rosenblatt J,  Glotzbecker B, Mills H,  et al. PD-1 blockade by CT -011, anti -PD-1 antibody, 
enhances ex vivo  T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J 
Immunother . 2011; 34:409-18. 
Royal RE, Levy C, Turner K, et al . Phase 2 trial of single agent ipilimumab (anti -CTLA -4) 
for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother . 2010; 33:828-
33. 
Salmiheimo  A, Mustonen H, Stenman UH et al.  Systemic inflammatory response and elevated 
tumour markers pred ict worse survival in resectable pancreatic ductal adenocarcinoma. PLoS 
One 2016; 11:e0163064 
Siegel R, Miller K , Jemal A: Cancer statistics, 20 20. CA Cancer J Clin.  2020; 70(1): 7-30 
Sommer C,  Kress M. Recent findings on how proinflammatory cytokines cause pain: 
peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci. Lett. 2004; 
p. 184- 7. 
Spiegelhalter, D J. Incorporating Bayesian Ideas into Health- Care  Evaluation.  Statisti cal 
Science,  2004. 19(1), 156 -174. 
 
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  129 PanCAN-SR1 Orig Version: 22JUL2020 
 Tan CR,  Yaffee PM, Jamil LH, et al . Pancreatic cancer  cachexia: a review of mechanisms and 
therapeutics. Front Physiol  2014; 5:88. doi: 10.3389/fphys.2014.00088 
Thompson JA,  Schneider BJ, Brahmer J . et al . Management of Immunotherapy -
Related  Toxicities, Version 1.2019.  J Natl Compr Canc Netw . 2019; 17:255-289 
Wang  W, Lau R,  Yu D, et al.  PD1 blockade reverses the suppression of melanoma antigen -
specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009; 21:1065-77. 
Whatcott CJ,  Han H, Von Hoff DD. Orchestrating the tumor microenvironment to improve 
survival for patients with pancreatic cancer: normalization, not destruction. Cancer J.  2015; 
21(4): 299–306. 
Weiss GJ,  Blaydorn L, Beck J, et al. Phase Ib/II  study of gemcitabine, nab -paclitaxel, and 
pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs  2018; 36: 96–
102. Werner J,  Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced -stage 
pancreatic cancer: therapy options. Nat Rev Clin Oncol.  2013; 10(6):323-33. 
Wu T,  Hong Y, Jia L, et al. Modulation of IL -1β reprogrammes the tumor microenvironment 
to interrupt oral carcinogenesis. Sci Rep 2016 ; p. 20208.  
Von Hoff DD , Ramanathan R, Borad M, Laheru D, Smith L,  Wood TE, Korn R, De sai N, 
Trieu  V, Igl esias J, Zhang H, Soon- Shiong  P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. 
Gemcitabine plus Nab -Paclitaxel is an Active regimen in patients with advanced pancreatic 
cancer : A Phase I/II trial. J Clin Onc ol. 2011; 29(34): 4548-4554. 
Von  Hoff DD , Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab - 
paclitaxel plus gemcitabine. N Engl J Med. 2013;  369(18):1691-1703. 
Zhang J,  Xiang D, Zhu S, et al. Interleukin 1 receptor antagonist inhibits normal 
hematopoiesis and reduces lethality and bone marrow toxicity of 5 -fluouracil in mouse. 
Biomed. Pharmacother. 2009 ; p. 501- 8. 
Zhang D,  Li L, JiangH, LiQ,Wang -Gillam A, Yu J, et al. Tu mor-Stroma IL1beta- IRAK4 
feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res 2018;  78:1700–12 
Zitvogel L,  Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and 
targeted anticancer therapies: reinstating immunosurveillance . Immunity  2013 39: 74–88;  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  130 PanCAN-SR1 Orig Version: 22JUL2020 
 Zitvogel L , Kepp O, Kroemer G Immune parameters affecting the efficacy of 
chemotherapeutic regimens . Nat Rev Clin Oncol  2011; 8: 151–160.  
 
 
   
 
   
 
   
 
  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  131 PanCAN-SR1 Orig Version: 22JUL2020 
 15.0 APPENDICES  
 
APPENDIX A 
Gemcitabine and Nab -paclitaxel Package Inserts  
 
Gemzar USPI 2019 http://uspl.lilly.com/gemzar/gemzar.html  
 
Abraxane USPI 2019 https://media2.celgene.com/content/uploads/abraxane- pi.pdf  
 
  
 
  
 
  
  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  132 PanCAN-SR1 Orig Version: 22JUL2020 
 APPENDIX B 
BLRM Statistical Model  
This appendix provides details of the statistical model used for each treatment  arm, the derivation 
of prior distributions, and the results of the Bayesian analyses and respective dosing decisions for 
some hypothetical data scenarios.  
1 Statistical model for triple combination  
For each treatment arm, the statistical model comprises sin gle-agent toxicity parts, which allow 
the incorporation of single -agent toxicity information, and interaction parts to describe two -way 
drug safety interactions. The proposed statistical model uses a meta- analytic framework 
(Neuenschwander 2016 ) to combine all historical and concurrent data.  
 
1.1 Single agent parts  
Let 𝜋𝜋𝑖𝑖(𝑑𝑑𝑖𝑖) be the risk of DLT for compound i given as a single agent at dose 𝑑𝑑𝑖𝑖 (i=1, 2, 3).  The 
single agent dose -DLT models are logistic:  
logit�𝜋𝜋i(𝑑𝑑𝑖𝑖)� =  log (𝛼𝛼𝑖𝑖) +  𝛽𝛽i log(𝑑𝑑i𝑑𝑑i∗⁄) i=1, 2, 3  (1)  
where 𝑑𝑑𝑖𝑖∗ , the reference dose, is used to scale the doses of each compound. The reference doses 
are defined in the appropriate model specification sections.  
Hence, 𝛼𝛼𝑖𝑖 (>0) is the single -agent odds  of a DLT at 𝑑𝑑𝑖𝑖∗ and  𝛽𝛽𝑖𝑖 (>0) is the increase in the log -odds 
of a DLT by a unit increase in log -dose.  
 
1.2 Interaction  
Under no interaction, the risk of a DLT for combination dose (𝑑𝑑1,𝑑𝑑2,𝑑𝑑3) is: 
𝜋𝜋1230(𝑑𝑑1,𝑑𝑑2,𝑑𝑑3)= 1− �1−𝜋𝜋1(𝑑𝑑1)��1−𝜋𝜋2(𝑑𝑑2)��1−𝜋𝜋3(𝑑𝑑3)� 
To allow for interaction between each pair of compounds, odds multipliers , 𝜂𝜂12,𝜂𝜂13,𝜂𝜂23 
are introduced.  
The risk of DLT for combination dose (𝑑𝑑1,𝑑𝑑2,𝑑𝑑3) is then given by:  
odds�𝜋𝜋123(𝑑𝑑1,𝑑𝑑2,𝑑𝑑3)�=exp�𝜂𝜂12𝑑𝑑1𝑑𝑑2
𝑑𝑑1∗𝑑𝑑2∗+𝜂𝜂13𝑑𝑑1𝑑𝑑3
𝑑𝑑1∗𝑑𝑑3∗+𝜂𝜂23𝑑𝑑2𝑑𝑑3
𝑑𝑑2∗𝑑𝑑3∗�×odds�𝜋𝜋1230(𝑑𝑑1,𝑑𝑑2,𝑑𝑑3)� 
Where,  
 odds (𝜋𝜋) =𝜋𝜋(1−𝜋𝜋)⁄ ; 
 𝜂𝜂𝑖𝑖𝑖𝑖 is the log of the odds ratio  between the interaction and no interaction model at dose 𝑑𝑑i∗ and 𝑑𝑑j∗ 
for treatments i and j and a zero dose of the third treatment;  
𝜂𝜂.=𝜂𝜂12+𝜂𝜂23+𝜂𝜂32 is the log of the odds r atio between the interaction and no interaction model 
at dose 𝑑𝑑1∗, 𝑑𝑑2∗ and 𝑑𝑑3∗ for all three treatments. Here 𝜂𝜂.= 0 corresponds to no overall interaction, 
with 𝜂𝜂.> 0 and 𝜂𝜂.< 0 representing overall synergistic and antagonistic toxicity respectively.  
Phase 1b Safety Run -In Study     Pancreatic Cancer Action Network  
 
Confidential and Proprietary  139 PanCAN-SR1 Orig Version: 22JUL2020 
 APPENDIX C 
RECIST Guidelines 1.1  
 
 
 
 
THIS DOCUMENT WILL BE PROVIDED SEPARATELY  
   
 
  
                                                                
  
  
 
 
 
  
 
 CONFIDENTIAL  Page 1 of 53 
  ST-AD-008 version 05  
  
Statistical Analysis Pla n 
 
Pancreatic Cancer Action Network  
PanCAN -SR1 
 
 
Labcorp Drug Development Study ID: 000000203412  
Document Version: 1.0 
Document Date: 16Sep 2022 
 
 
 
 
 
 
 
Labcorp Drug Development  
 
 
Table of Contents  
1. Source Documents  ................................ ................................ .................  8 
2. Protocol Details  ................................ ................................ .....................  8 
2.1 Study Objectives ................................ ................................ .................  8 
2.1.1  Study Primary Objective ................................ ................................ ................................ ........  8 
2.1.2  Study Secondary Objectives  ................................ ................................ ................................ .. 8 
2.1.3  Study Exploratory Objectives  ................................ ................................ ................................  8 
2.2 Overall Study Design  ................................ ................................ ...........  8 
2.3 Sample Size and Power  ................................ ................................ ..... 11 
3. Efficacy and Safety Variables ................................ ................................ . 11 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 2 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 3.1 Primary Safety Endpoint  ................................ ................................ .... 11 
3.2 Secondary Efficacy Endpoints  ................................ .............................  11 
3.2.1  Derivation of RECIST Visit Responses  ................................ ................................ ..................  12 
3.2.2  Overall response rate (ORR)  ................................ ................................ ...............................  17 
3.2.3  Duration of response (DOR)  ................................ ................................ ................................  18 
3.2.4  Disease control rate (DCR)  ................................ ................................ ................................ .. 18 
3.2.5  Progression free survival (PFS)  ................................ ................................ ............................  18 
3.2.6  Time to response (TTR)  ................................ ................................ ................................ .......  19 
3.2.7  Overall survival (OS)  ................................ ................................ ................................ ............  19 
3.3 Safety Variables ................................ ................................ ................  20 
3.3.1  Secondary Safety Endpoints ................................ ................................ ................................  20 
3.3.2  Other safety variables  ................................ ................................ ................................ .........  26 
3.4 Exploratory Endpoints  ................................ ................................ ....... 29 
4. Secondary Pharmacokinetic  (PK) endpoint  ................................ .............  30 
5. Analysis populations  ................................ ................................ .............  31 
5.1 All Screened  ................................ ................................ .....................  31 
5.2 Safety Analysis Set (SAF)  ................................ ................................ .. 31 
5.3 Full Analysis Set (FAS)  ................................ ................................ ...... 31 
5.4 Dose-Determining Analysis Set (DDS)  ................................ .................  31 
5.5 Pharmacokinetic Analysis Set (PAS)  ................................ ....................  31 
5.6 Important Protocol Deviations  ................................ ............................  32 
6. DATA Handling  ................................ ................................ ....................  33 
6.1 Time points and Visit Windows  ................................ ...........................  33 
6.2 Handling of Dropouts, Missing Data, and Outliers  ................................ .. 34 
7. Statistical Methods  ................................ ................................ ...............  34 
7.1 General Principles  ................................ ................................ .............  34 
7.2 Patient Disposition and Data Sets Analyzed  ................................ ..........  36 
7.3 Protocol Deviations  ................................ ................................ ...........  37 
7.4 Demographics and Other Baseline Characteristics  ................................ . 37 
7.4.1  Medical History  ................................ ................................ ................................ ...................  39 
7.4.2  Previous and Concomitant Medications  ................................ ................................ .............  39 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 3 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 7.5 Efficacy  ................................ ................................ ............................  39 
7.5.1  Primary Efficacy Analysis  ................................ ................................ ................................ ..... 39 
7.5.2  Secondary Efficacy Analysis  ................................ ................................ ................................  41 
7.5.3  Secondary Pharmacokinetic Analysis  ................................ ................................ ..................  42 
7.6 Exploratory  Analysis  ................................ ................................ .........  44 
7.7 Safety  ................................ ................................ .............................  45 
7.7.1  Secondary Safety Analysis  ................................ ................................ ................................ ... 45 
7.7.2  Other Safety Variables  ................................ ................................ ................................ ........  50 
7.8 Interim Analysis ................................ ................................ ................  51 
8. Changes in Planned Analysis  ................................ ................................ . 52 
9. .Data Issues ................................ ................................ ........................  52 
10. References  ................................ ................................ ..........................  52 
11. Appendices  ................................ ................................ .........................  53 
Appendix 1:  Document History  ................................ ............................  53 
 
  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 6 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 OS Overall Survival  
PAS Pharm acokinetic analysis set  
PD Progressive disease  
PDAC  Pancreatic adenocarcinoma  
PK Pharmacokinetic  
PFS Progression -free survival  
PK Pharmacokinetic  
PR Partial response  
PT Preferred Term  
RBC Red blood cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE Serious Adverse Event  
SAF Safety   
SAP Statistical Analysis Plan  
SD Stable Disease  
SOC System Organ Class  
SoC Standard of Care  
tlast Time of the last quantifiable concentration  
tmax Time to reach maximum plasma concentration  
TTR Time to response  
TFLs Tables, figures, and listings  
TEAE Treatment -emergent adverse event  
TESAE  Treatment -emergent serious adverse event  
ULN Upper Limit of Normal  
WBC White Blood Cell  
  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 7 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 STATISTICAL ANALYSIS PLAN AMENDMENT 1  
 
This section is not required at this time, but may be populated in a future approved 
version of this document.  
  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 9 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 This is an open -label multi -center phase Ib study to confirm the recommended 
phase II/III dose of canakinumab  and spartalizumab in combination with 
nab-paclitaxel and gemcitabine as first -line therapy for patients with metastatic 
pancreatic cancer.  
Patients will be treated until disease progression  per RECIST 1.1 , unacceptable 
toxicity, or until the patient or treating physician decides to stop treatment. 
Pharmacokinetic (PK)  samples will be collected at specific 
time points throughout treatment. Each treatment cycle is 4 weeks.  
The study population is treatment naïve  patients with  metastatic PDAC.   
All patients must be followed for safety up to 150 days after the last dose of 
spartalizumab or canakinumab, or 30 days after the last dose of the combination 
chemotherapy,  whichever the later.  
After the end of safety follow -up, patients will be followed for disease progression if 
disconti nuation of treatment is due to any reason other than progression, and for 
survival  until the end of study. The study completion is defined as when the last 
patient has completed the study treatment, safety follow -up,  and completed 
survival follow up perio d up to 1 year from first treatment, whichever is later or in 
the event of an early study termination decision, the date of that decision.  
For this study, the investigational drugs (INDs) are spartalizumab (PDR001) and 
canakinumab (ACZ885)  while the  non-investigational drugs are gemcitabine and 
nab-paclitaxel.  The study treatment is defined as canakinumab in combination with 
spartalizumab , gemcitabine and nab -paclitaxel.  
Table 1 defines the starting dose level.  In case of unacceptable toxicity of the 
starting dose level, the enrollment to the current dose level will be stopped and a 
lower dose ( -1 dose level) will be used.   
Table 1 Initial Dose and Treatment Schedule  
Study 
treatments  Pharmaceutical 
form and route of 
administration  Strength  Starting 
Frequency 
and/or Regimen  Dose 
Administered  
Spartalizumab 
(PDR001)  Concentrate for 
solution for IV 
infusion   4 x 100 mg 
vials Day 1 of each 28 -
day cycle  
 400 mg  
 
Canakinumab 
(ACZ885)  Solution for SC. 
injection  
in prefilled syringe  200 mg/1.33 
mL AND 1 x       
50 mg/0.5 mL  Day 1 of each 28 -
day cycle   250 mg  

Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 10 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 Study 
treatments  Pharmaceutical 
form and route of 
administration  Strength  Starting 
Frequency 
and/or Regimen  Dose 
Administered  
Gemcitabine  IV  Days 1, 8, 15 of  
each 28 -day cycle                     1000 mg/m2 
Nab-paclitaxel  IV  Days 1, 8, 15 of  
each 28 -day cycle                     125 mg/m2 
IV = intravenous; SC = subcutaneous  
 
Table 2 below describes the starting dose and the -1 dose level in case the starting 
dose has unacceptable toxicity.  
Table 2 Provisional dose levels for the canakinumab  with fixed dosage of 
spartalizumab, Gemcitabine and nab -paclitaxel  
Dose level  Proposed dose  of canakinumab  
  
1 (starting dose)  250 mg SC Q4W Canakinumab  
-1* 250 mg SC Q8W  Canakinumab  
SC = subcutaneous Q4W= every 4 weeks Q8W= every 8 weeks  
Spartalizumab : 400 mg SC. Q4W; Gemcitabine: 1000 mg/m2+ nab -paclitaxel 125 mg/m2 
(on day 1, 8, and 15 of every cycle).  
  
*Dose level -1 represents the treatment dose for patients requiring a dose reduction from 
the starting dose level.  
 
Approximately 10 patients will be enrolled initially to have at least 6 evaluable 
patients per dose level (additional patients may  be enrolled as needed in order to 
have 6 evaluable patients). Patients must complete a minimum of 56 days (8  
weeks) of dosing of study treatme nt with the minimum safety evaluation and drug  
exposure or have had a DLT within the first 56 days of study treatment to be  
considered evaluable for recommended dose decisions . Additional ly, approximately 
ten patients (to have at least 6 additional evaluab le patients) may be enrolled at 
lower dose level in case a dose de -escalation is necessary.  This could occur if a 
minimum of 6 evaluable patients has been treated and deemed evaluable at this 
dose and unacceptable toxicity is observed at that dose . 
The de cision on dose tolerability will be based on all relevant data from the ongoing 
study and a review of safety data from the first 8 weeks  (see section 4.1.5 of CSP ). 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 11 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 2.3 Sample Size and Power  
 
Approximately 10 patients will be enrolled to the starting dose leve l to have at least 
6 evaluable patients.  If the starting dose level is considered unsafe, the dose will be 
de-escalated to dose level -1 and approximately  10 patients will be enrolled to 
achieve at least 6 evaluable  patients. For further elaboration of sa fety and PK 
parameters, additional patients may be enrolled if considered necessary  by Novartis  
and Principal Investigators . Appendix B of the clinical study protocol ( CSP) provided 
hypothetical scenarios to illustrate the dose recommendation  by Bayesian h ierarchical 
logistic regression model ( BLRM ). 
3. Efficacy and Safety Variables  
3.1 Primary Safety  Endpoint  
 
The primary endpoint is the incidence of dose limiting toxicities (DLT) in the first 56 
days (8 weeks) of the study treatment.  
See Section 4.1.5.1 of the CSP for the definition of DLTs.  
A dose -limiting toxicity (DLT) is defined as an adverse event (AE) or abnormal 
laboratory value assessed as unrelated to disease, disease progression, inter -
current illness, or concomitant medicat ions that occurs within the first 8 weeks of 
study treatment  and at least possibly related to the study drug . The investigator 
must notify the sponsor immediately (within 24 hours of the treating physician’s 
knowledge) of any unexpected CTCAE grade ≥ 3 AEs  or laboratory abnormalities.  
National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE ) v5.0 
will be used for all grading as per Table 4 -3 of CSP.  
Events which will NOT be considered as DLT are:  
 Clinically insignificant laboratory values ≤ grade 2.  
 For electrolyte abnormalities ≥ grade 3, the maximum allowable time limit 
for correction to ≤ grade 1 is 72 hours . 
 
3.2 Secondary Efficacy Endpoints  
 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 12 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 3.2.1  Derivation of RECIST Visit Responses  
 
For all patients,  the Response Evaluation Criteria in Solid Tumors ( RECIST ) tumor 
response data will be used to determine each patient’s visit response according to 
RECIST Version 1.1  It will also be used to determine if and when a patient has 
progressed in accordance with  RECIST and their best overall  response (BOR) to 
study treatment.   
Baseline tumor evaluations are to be performed radiographically ( computed 
tomography [ CT] or magnetic resonance imaging [ MRI]) no more than 28 days 
before the administration  of first dose  of study medication and ideally as close as 
possible to the start of study treatment (prior to Day 1 of treatment). Tumor 
assessments are then performed every 8 weeks (± 7 days ) from the date of study 
treatment until either disease progression, at suspecte d progression if off cycle for 
evaluation, or withdrawal of consent.  
From the investigator’s review of the imaging scans, the RECIST tumor response 
data will be used to determine each patient’s visit response according to RECIST 
Version 1.1. At each visit , patients will be assigned a RECIST 1.1 visit response of 
complete response ( CR), partial response ( PR), stable disease ( SD) or progressive 
disease ( PD), using the information from target lesions (TLs), non -target lesions 
(NTLs) and new lesions , and depen dent upon the status of their disease compared 
with baseline and previous assessments. If a patient has had a tumor assessment 
that cannot be evaluated then the patient will be assigned a visit response of not 
evaluable (NE), (unless there is evidence of p rogression in which case the response 
will be assigned as PD).  
Please refer to section 3.2.1.2  for the full definitions of CR, PR, SD and PD.  
RECIST  outcomes ( progression free survival ( PFS), overall response rate ( ORR), 
disease control rate ( DCR), and duration of response ( DOR), time to response 
(TTR) ) and overall survival (OS)  will be calculated programmatically for the site 
investigator data (see section s 3.2.2 and onwards ) from the overall visit responses.  
 
3.2.1.1  Target lesions (TLs) – site investigator data  
Measurable disease is defined as having at least one measurable lesion, not 
previously irradiated , which is ≥10 mm in the longest diameter (LD), (except lymph 
nodes which must have short axis ≥15 mm) with CT or MRI  and which is suitable 
for accurate repeated measurements . A patient can have a maximum of 5 
measurable lesions recorded at baseline with a  maximum of 2 lesions per organ 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 13 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 (representative of all lesions involved and suitable for accurate repeated 
measurement) and these are referred to as target lesions (TLs).  If more than 1 
baseline scan is recorded, then measurements from the one that is clo sest and prior 
to first dose/administration of study treatment will be used to define the baseline 
sum of TLs. It may be the case that, on occasion, the largest lesion does not lend 
itself to reproducible measurement. In which circumstance the next largest  lesion, 
which can be measured reproducibly, should be selected.  
All other lesions (or sites of disease) pathological lymph nodes not recorded as TL 
should be identified as non -target lesions (NTLs) at baseline.  Measurements are 
not required for these les ions, but their status (present or absent or unequivocal 
progression) should be followed at subsequent visits.  
  
Table 3 TL Visit Responses (RECIST 1.1)  
Visit Responses  Description  
Complete response (CR)  Disappearance of all TLs.  Any pathological lymph nodes  
(whether target or non -target)  selected as TLs must have a 
reduction in short axis to <10mm.  
Partial response (PR)  At least a 30% decrease in the sum of diameters of TLs, 
taking as reference the baseline sum of diameters as l ong as 
criteria for PD are not met.  
Progressive disease (PD)  A ≥20% increase in the sum of diameters of TLs and an 
absolute increase of ≥5mm, taking as reference the smallest 
sum of diameters since treatment started including the 
baseline sum of diameters.  Note: the appearance of one or 
more new lesions is also considered progression  
Stable disease (SD)  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD.  
Not evaluable (NE)  Only relevant in certain situations  (i.e. if any of the TLs were 
not assessed or not evaluable or had a lesion intervention at 
this visit; and scaling up could not be performed for lesions 
with interventions – see ‘Scaling’ later in this section). Note: If 
the sum of diameters meets the pro gressive disease criteria, 
progressive disease overrides not evaluable as a TL response.  
 
Missing TL data  
If all TL measurements are missing, then the TL visit response is NE.  Overall visit 
response will also be NE, unless there is a progression of non-TLs or new lesions, in 
which case the response will be PD.  
 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 14 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 Lymph nodes  
 
For lymph nodes, if the size reduces to <10mm then these are considered non -
pathological. However, a size will still be given and this size should still be used to 
determine the TL visit response as normal.  In the special case where all lymph 
nodes are <10mm and all other TLs are 0mm then althou gh the sum may be 
>0mm the calculation of TL response should be over -written as a CR.  
 
TL visit responses subsequent to CR  
Only CR, PD or NE can follow a CR.  If a CR has occurred, then the following rules 
at the subsequent visits must be applied:  
 Step 1:   If all lesions meet the CR criteria (ie 0mm  or <10mm for lymph 
nodes) then response will be set to CR irrespective of whether the criteria 
for PD of TL is also met i.e. if a lymph node LD increases by 20% but 
remains <10mm.  
 Step 2:  If some lesion meas urements are missing but all other lesions 
meet the CR criteria (i.e. 0mm or <10mm for lymph nodes) then response 
will be set to NE irrespective of whether, when referencing the sum of TL 
diameters, the criteria for PD are also met.  
 Step 3:  If not all le sions meet the CR criteria  (i.e. a pathological lymph 
node selected as TL has short axis >10mm or the reappearance of 
previously disappeared lesion) or a new lesion appears, then response will 
be set to PD  
 Step 4:  If after steps 1 – 3 a response can stil l not be determined the 
response will be set to remain as CR  
 
3.2.1.2  Non-target lesions (NTLs) and new lesions – site 
investigator data  
3.2.1.2.1  Non-target lesions (NTLs)  
 
At each visit, the investigator should record an overall assessment of the NTL 
response. This section provides the definitions of the criteria used to determine and 
record overall response for NTL at the investigational site at each visit.  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 15 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 NTL response will be derived based on the investigator’s overall assessment of NTLs 
as follows:   
Table 4 NTL Visit Responses  
Visit Responses  Description  
Complete response (CR)  Disappearance of all NTLs present at baseline with 
all lymph nodes non -pathological in size (<10 mm 
short axis  and normalization of tumour marker 
level). 
Progressive disease (PD)  Unequivocal progression of existing NTLs. 
Unequivocal progression may be due to an 
important progression in one lesion only or in 
several lesions. In all cases, the progression MUST 
be clinically significant for the physician to 
consider changing (or stopping) therapy.  
Non-CR/Non -PD Persistence of one or more NTLs with no evidence 
of progression and/or maintenance of tumour 
marker level above the normal limits.  
Not evaluable (NE)  Only relevant when one or some of the NTLs were 
not assessed and, in the investigator's opinion, 
they are not able to provide an evaluable overall 
NTL assessment at this visit.  
Note: For patients without TLs at baseline, this is 
relevant if any of the NTLs were not assessed at 
this visit and the progressio n criteria have not 
been met.  
Not applicable (NA)  Only relevant if there are no NTLs at baseline.  
 
To achieve ‘unequivocal progression’ on the basis of NTLs, there must be an overall 
level of substantial worsening in non -target disease such that, even in  the presence 
of SD or PR in TLs, the overall tumor burden has increased sufficiently to merit a 
determination of disease progression.  A modest ‘increase’ in the size of one or 
more NTLs is usually not sufficient to qualify for unequivocal progression sta tus. 
3.2.1.2.2  New Lesions  
 
Details of any new lesions will also be recorded with the date of assessment.  The 
presence of one or more new lesions is assessed as progression.  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 16 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 The finding of a new lesion should be unequivocal: i.e. not attributable to 
differences in scanning technique, change in imaging modality or findings thought 
to represent something other than tumor.  
A lesion identified at a follow up assessment in an anatomical location that was not 
scanned at baseline is considered a new lesion and will indicat e disease 
progression.  
New lesions will be identified via a Yes/No tick box. The absence and presence of 
new lesions at each visit should be listed alongside the TL and NTL visit responses.  
A new lesion indicates progression so the overall visit response w ill be PD 
irrespective of the TL and NTL response.  
Symptomatic progression is not a descriptor for progression of NTLs: it is a reason 
for stopping study therapy and will not be included in any assessment of NTLs.  
Patients with ‘symptomatic progression’ re quiring discontinuation of treatment 
without objective evidence of disease progression at that time should continue to 
undergo tumor assessments where possible until objective disease progression is 
observed.  
 
3.2.1.3  Overall visit response – site investigator dat a 
 
Table 5 defines how the previously defined TL and NTL visit responses will be 
combined with new lesion information to give an overall visit response.   
Table 5 Overall visit responses  
TARGET  NON-TARGET  NEW LESIONS  OVERALL VISIT 
RESPONSE  
CR CR or NA  No (or NE)  CR 
CR Non-CR/Non -PD or 
NE No (or NE)  PR 
PR Non-PD or NE  No (or NE)  PR 
SD Non-PD or NE  No (or NE)  SD 
PD Any Any PD 
Any PD Any PD 
Any Any Yes PD 
NE Not PD No (or NE)  NE 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 17 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  
3.2.2  Overall response rate (ORR)  
 
ORR is defined as the proportion of patient s with best overall response (BOR) of 
complete response (CR) or partial response (PR), according to RECIST 1.1.  and will 
be based on a subset of all treated patients with measurable disease at  baseline per 
the site investigator.  
BOR is calculated based on the overall visit responses from each RECIST 
assessment, described in section  3.1. It is the best response a patient has had 
following the first day of study treatment , but prior to starting any subsequent 
cancer therapy and up to and including RECIST progress ion or the last evaluable 
assessment in the absence of RECIST progression. Categorization  of BOR will be 
based on RECIST using the following response categories: CR, PR, SD, PD and NE.  
Overall visit responses of CR or PR must be confirmed  for the purpose o f BOR 
assignment . A confirmed response of CR/PR means that a response of CR/PR 
recorded at 1 visit requires confirm ation by repeat imaging not less than 4 weeks 
after the visit when the response was first observed , with no evidence of 
progression between t he initial and CR/PR confirmation visit.  
For determination of a best response of SD, the earliest of the dates contributing 
towards a particular overall visit assessment will be used. SD should be recorded at 
least 8 weeks minus 1 week, i.e. at least 49 da ys (to allow for an early assessment 
within the assessment window), after first dose of study treatment.  For CR/PR, the 
initial overall visit assessment that showed a response will use the latest of the 
dates contributing towards a particular overall visi t assessment.  
BOR will be determined programmatically based on RECIST from the overall visit 
response using all site investigator  data up until the first progression event.   
For patient s whose progression event is death, BOR will be calculated based upon 
all evaluable RECIST assessments prior to death.  
For patient s who die with no evaluable RECIST assessments, if the death occurs 
≤17 weeks (i.e. 2x8 weeks + 1 week to allow for a late assessment within the 
assessment window) after first dose of study treatment, then BOR will be assigned 
to the progression (PD) categ ory.  For patient s who die with no evaluable RECIST 
assessments, if the death occurs >17 weeks after first dose of study treatment then 
BOR will be assigned to the NE category.  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 18 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 A patient  will be classified as a responder if the RECIST criteria for a CR or PR are 
satisfied at any time following first dose of study treatment, prior to RECIST 
progression and prior to starting any subsequent cancer therapy.  
 
3.2.3  Duration of response (DOR)  
 
DOR is defined  for patients whose BOR is either CR or PR and is calculated  as the 
time from the date of first documented response of CR or PR (which is subsequently 
confirmed, i.e., the start date of response, not the date when response was 
confirmed) until  the date of the first documented progression or death due to 
underlying ca ncer in the absence of disease progression (i.e. date of PFS event or 
censoring – date of first response + 1).   
Patient s continuing without progression or death due to underlying cancer, will be 
censored at the date of their last adequate tumor assessment . However, patient s 
who progress or die immediately after two or more consecutive missed visits will be 
censored at the time of the latest evaluable assessment prior to the two missed 
visits (note that an overall visit response of NE is not considered as a  missed visit).  
 
3.2.4  Disease control rate (DCR)  
 
DCR is defined as the proportion of patient s with a BOR of CR, PR, or SD  (without 
subsequent cancer therapy) for at least 7 weeks after start of treatment (to allow 
for an  early assessment within the assessment window) according to RECIST 1.1.  
 
3.2.5  Progression free survival (PFS)  
 
PFS is defined as the time from the date of first dose  to the date of the first 
documented disease progression based on local investigator assessmen t as per 
RECIST 1.1 (assessed by investigator) or death (due to any cause in the absence of 
progression) (i.e. date of PFS event or censoring – date of first dose of study 
treatment + 1). Patient s who have not progressed or died by the date of the analysis  
cut-off will be censored at the time of the latest date of assessment from their last 
evaluable RECIST assessment (on or before the cut -off date). Clinical deterioration 
will not be considered as documented disease progression.  However, if the patient  
progresses or dies immediately after two or more consecutive missed visits, the y will 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 19 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 be censored at the time of the latest evaluable RECIST 1.1 assessment prior to the 
two missed visits (Note: NE visit is not considered as missed visit).   
The PFS time will always be derived based on scan/assessment dates not visit 
dates.  
RECIST assessments/scans contributing towards a particular visit may be 
performed on different dates.  The following rules will be applied:  
 The date of progression will be determined based o n the earliest of the 
dates of the component that triggered the progression.  
 When censoring a patient for PFS the patient will be censored at the latest  
of the dates contributing to a particular overall visit assessment.  
Note: for TLs only the latest scan  date is recorded out of all scans performed at that 
assessment for the TLs and similarly for NTLs only the latest scan date is recorded 
out of all scans performed at that assessment for the NTLs.  
3.2.6  Time to response (TTR)  
 
TTR is defined as the time from the  date of first dose to the date of first 
documented response (CR or PR, which must be confirmed subsequently). The date 
of first documented response should coincide with that used for the D OR endpoint.  
Time to response will not be defined for those patient s who do not have a 
documen ted response which  is subsequently confirmed.   
3.2.7  Overall survival (OS)  
 
OS is defined as the time from the date of first dose of study treatment to the date 
of death due to any cause ( i.e., date of death or censoring – date of first dose of 
study treatment + 1). If a patient  is not known to have died, then OS will be 
censored at the latest date the patient  was known to be alive (on or before the cut -
off date). If a patient  is confirmed to b e alive or if the death date is post the data 
cut-off date, then this patient  will be censored at the date of data cut -off. 
 
If a patient is known to have died where only a partial death date is available then 
the date of death will be imputed as the lates t of the last date known to be alive +1 
from the database and the death date using the available information provided:  
a) For Missing day only – using the 1st of the month  
b) For Missing day and Month – using the 1st of January  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 20 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 If there is evidence of death but  the date is entirely missing, it will be treated as 
missing, i.e. censored at the last known alive date.  
 
3.3 Safety Variables  
3.3.1  Secondary Safety Endpoints  
3.3.1.1  Adverse events  
 
All AEs and SAEs , including any laboratory abnormalities, that fit the reportable 
criteria described in Section 7.4.1 of CSP, will be recorded from the time the patient  
signs the Informed Consent Form until 150 days (5 months) after the last dose of 
study treatment of can akinumab or spartalizumab (due to the half -life of these  
drugs), or 30 days after the last dose of the combination chemotherapy, whichever 
is later.  
Events  will be defined as treatment emergent if they onset or worsen (by investigator 
report of a change i n severity)  during the treatment period as defined in the CSP.  
More specifically,  
 
when the start times of adverse events are not available:  
 
treatment -emergent AEs (TEAEs) are events with a start date on or after the first 
dose date of canakinumab or spartalizumab up until the last dose date of 
canakinumab or spartalizumab plus 30 days. TEAEs are also events with a start 
date prior to the first dose date of any of the canakinumab or spartalizumab whose 
severity worsens on or after the earliest first do se date of any of the canakinumab 
or spartalizumab Events with an onset date during the on -treatment period will be 
considered as TEAEs. Ongoing events with a start date as described above will be 
considered as ongoing TEAEs.  
 
when the start times of adver se events are available:  
 
TEAEs are events with a start date -time on or after the first dose date -time of 
canakinumab or spartalizumab up until the last dose date of canakinumab or 
spartalizumab plus 30 days. TEAEs are also events with a start date -time pr ior to the 
first dose date -time of any of the canakinumab or spartalizumab whose severity 
worsens on or after the earliest first dose date -time of any of the canakinumab or 
spartalizumab Events with an onset date -time during the on -treatment period will be  
considered as TEAEs. Ongoing events with a start date -time as described above will 
be considered as ongoing TEAEs.  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 21 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 The Medical Dictionary for Regulatory Activities (MedDRA) (using the latest effective 
MedDRA  version) will be used to code the AEs.  AEs wil l be graded according to the 
NCI-CTCAE  for AEs (using the CTCAE version 5.0). 
 
AEs of special interest  
Adverse events of special interest (AESI) are defined as events (serious or non -
serious) which are of scientific and medical concern specific to the sponsor’s program, 
for which ongoing monitoring and rapid communication by the investigator to the 
sponsor may be appropriate. Such events may require further investigation in order 
to characterize and understand them.  
Adverse events of special interest ar e defined on the basis of an ongoing review of 
the safety data.  
An adverse event of special interest (AESI) is a grouping of AEs that are of scientific 
and medical concern specific to compound canakinumab.  
These groupings are defined using MedDRA terms, SM Qs (standardized MedDRA 
queries), high level group terms, high level terms, and PTs. Customized SMQs 
(Novartis MedDRA queries, NMQ) may also be used. An NMQ is a customized group 
of search terms which defines a medical concept for which there is no officia l SMQ 
available or the available SMQ does not completely fit the need. It may include a 
combination of single terms and/or an existing SMQ, narrow or broad. For each 
specified AESI, number and percentage of participants with at least one event of the 
AESI occurring during on -treatment period will be summarized. As more safety data 
and AE/SAE data are collected, we may identify different risks and change the list of 
AESI.  
A non -exhaustive list of AESI is provided below for investigational drug. This may 
change as further data becomes available.  
 Renal toxicity/serum creatinine ≥ Grade 2  
 Neutropenia ≥ Grade3  
 Febrile neutropenia  
 Immunogenicity/Hypersensitivity reactions ≥ Grade3  
 Infusion reactions ≥ Grade3  
 Diarrhea ≥ Grade3  
 Hypertension ≥ Grade3  
 Haemorrhage ≥ Grade3  
 Cardiac valvulopathy (symptomatic) ≥ Grade3  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 22 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  Skin reactions ≥ Grade3  
 Eyelid abnormality (≥ Grade 2)  
 
In addition, following health authority requests the following will also be assessed 
as AESIs:  
 Covid -19 / SARs -CoV2 positive cases, irrespective of c ausality  
 Covid -19 vaccination status in study subjects & subsequent infection 
incidence  
 
Summaries of these AESI will be provided by treatment arms (specifying grade, SAE, 
relationship, leading to treatment discontinuation, leading to dose interruption, 
hospitalization, death etc.). A listing of all grouping levels down to the MedDRA PTs 
used to define each AESI will be generated.  
 
The CRS  will be used to determine the MedDRA search  criteria to be used to identify 
events of special interest.  
 
Based upon the available safety information from spartalizumab  and canakinumab 
oncology clinical   development programs and known mechanism of action of these 
drugs and potential overlapping toxicity of all combination drugs, following adverse 
events are considered of special interest in this trial population:  
 Infections (severe infections and opportunisti c infections), including sepsis  
 Neutropenia CTCAE Grade >3 
 Febrile neutropenia  
 Peripheral/Sensory neuropathy CTCAE Grade  >3 
 Thrombocytopenia CTCAE Grade  >3  
 In addition, the potential immune -related AEs considered to be AESIs include, 
endocrinopathies, colitis, skin reactions, hepatitis, nephritis, pneumonitis and 
infusion reaction.   
Details regarding these adverse events are provided in the spartalizumab and 
canakinumab Investigator’s Brochures..  
3.3.1.2  12-lead electrocardiogram (ECG)  
 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 23 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 Twelve -lead electrocardi ograms ( ECGs) will be performed  and assessed at the 
scheduled time points according  to the Schedule of Events Table 5 -1 of the CSP.  
An overall Investigator assessment of ECG will be provided (categories <“normal”, 
“abnormal, not clinically significant” and “abnormal, clinically significant”>).  
The following quantitative 12-lead ECG measurements will be taken during the study:  
 heart rate (b eats/min ); 
 RR interval (ms);  
 PR interval (ms);  
 QRS interval (ms);  
 QT interval (ms);  
 Bazett corrected QT (QTcB) interv al (ms)  
 Fridericia corrected QT (QTcF) interval (ms)  
 
3.3.1.3  Clinical laboratory evaluations  
 
Laboratory blood tests will be collected  at the scheduled time points according  to 
the Schedule of Events Table 5 -1 of the CSP  and assessed locally. The protocol 
required laboratory parameters are: 
 Complete blood count (CBC) including but not limited to:  
o Red blood cell (RBC) count  
o Hemoglobin  
o Hematocrit  
o Platelet count  
o White blood cells (WBC) total Count  
o Neutrophils absolute count  
o Lymphocytes absolute count  
o Monocytes absolute count  
o Eosinophils absolute count  
o Basophils absolute count  
o Neutrophils %  
o Lymphocytes %  
o Monocytes %  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 24 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 o Eosinophils %  
o Basophils %  
 
 Chemistry panel including, but not limited to:  
o Total Bilirubin  
o Direct Bilirubin  
o Alkaline Phosphatase  
o ALT (SGPT)  
o AST (SGOT)  
o Albumin  
o Total Protein  
o Serum Creatin ine 
o Blood Urea Nitrogen  (BUN)  
o Sodium  
o Potassium  
o Calcium  
o Chloride  
o Glucose  
o C-reactive protein  
o Pre-Albumin  
 
 Thyroid Panel   
o TSH 
o T3FREE  
o T4FREE 
 
 Coagulation  
o INR 
o Prothrombin Time (PT)  
o Activated Partial Thromboplastin Time (APTT)  
 
 Urinalysis  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 25 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 o Gravity  
o pH 
o Color  
o Viscosity  
o Appearance (Clear, Cloudy, Not Done, Other)  
o Turbidity (Negative, Trace 1+, 2+, 3+_, 4+)  
o Ketones (Negative, Trace 1+, 2+, 3+_, 4+ , Not Done, Other ) 
o Bilirubin  ((Negative, Trace 1+, 2+, 3+_, 4+  Not Done, Other ) 
o Blood (Negative, Trace 1+, 2+, 3+_, 4+  Not Done, Other ) 
o Glucose (Negative, Trace 1+, 2+, 3+_, 4+  Not Done, Other)  
o Protein (Negative, Trace 1+, 2+, 3+_, 4+  Not Done, Other)  
o Nitrites (Negative, Trace 1+, 2 +, 3+_, 4+  Not Done, Other)  
o Urobilinogen (Negative, Trace 1+, 2+, 3+_, 4+  Not Done, Other)  
o Leukocyte Esterases (Negative, Trace 1+, 2+, 3+_, 4+  Not Done, 
Other)  
o Urine Microscopy  
o Red blood Cells  
o White blood cells  
o Epithelial cells  
o Bacteria  
o Crystals  
o Casts  
 
For laboratory tests covered by the CTCAE version 5.0 , the study’s biostatistical and 
reporting team will grade laboratory data accordingly. For laboratory tests covered 
by CTCAE, a Grade 0 will be assigned for all non -missing values not graded as 1 or 
higher. Grade 5 will not be used.  
For laboratory tests wh ere grades are not defined by CTCAE, results will be graded 
by the low/normal/high classifications based on  local laboratory normal ranges.  
Laboratory test with any clinically significant results will also be collected.  
 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 26 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 3.3.2  Other safety variables  
 
3.3.2.1  Duration of  exposure  
 
The duration of (total or intended exposure (in months ) will be calculated separately 
for each study drug . 
The duration of (total or intended) exposure (in months ), to any drug will also be 
calculated . 
Exposure will be defined as follows:  
For can akinumab:  
 (Total or intended) duration of exposure ( months ) = ((date of last dose  where 
dose >0 [units] – date of first dose where dose >0 [units] ) + length of dose 
frequency) / (365.25  / 12).  
Where length of dose frequency = 28 if last dose is given on Q4W  and 56 if 
last dose is given on Q8W  
For spartalizumab:  
 (Total or intended) duration of exposure ( months ) = ((date of last dose  where 
dose >0 [units] – date of first dose where dose >0 [units] ) + 28)/ (365.25  / 
12).  
For nab-paclitaxel  or gemcitabine : 
 (Total or intended) duration of exposure (days) = ((date of last dose where 
dose >0 [units] – date of first dose where dose >0 [units]) + i)) / (365.25 / 
12). 
 
Where i =7 if last dose is given on cycle day 1 or 8, i =14 if last dose is given 
on cycle day 15  
For Any Drug:  
 (Total or intended) duration of exposure (days) = ((date of last dose where 
dose >0 [units] – date of first dose where dose >0 [units]+ x) / (365.25 / 12).  
Where x is:  
 the length of dose frequency when the date of last dose is the last dose date 
of canakinumab  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 27 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  28 for date of last dose of spartalizumab  
 x = i =7 if last dose of nab -paclitaxel or gemcitabin is given on cycle day 1 or 
8 
 x= i =14 if last dose nab -paclitaxel or gemcitabin is given on cycle day 15  
 
3.3.2.2  Dose intensity  
 
The actual dose in tensity and the relative dose intensity (RDI) will be summarized 
for each study drug component nested within the groups as defined for the 
cumulative dose (i.e. total dose given during the study drug exposure ) by 
descriptive statistics. In addition, categorical summary of RDI for each study drug 
will be presented. The number of administrations (or treatment cycles) of each 
study drug component of the study treatment nested within the treatment groups 
as defined for the cumulative dose will be summariz ed by frequencies and 
descriptive statistics.  
The actual dose intensity (DI) is defined as:  
DI=actual cumulative dose / number of cycles on treatment , for subjects with non -
zero duration of exposure. For subjects who did not take the drug, the DI is by 
definition equal to zero.  
Number of cycles on treatment are defined as:  
 
For c anakinumab  
 
Number of cycles on treatment = ( last date of administration of study drug - first 
date of administration of study drug + length of dose frequency) /28 
 
For s partalizu mab 
 
Number of cycles on treatment = ( last date of administration of study drug - first 
date of administration of study drug + 28) /28 
 
For nab -paclitaxel or g emcitabine  
 
scheduled for Day 1, 8 and 15 of every 28 -day cycle, with the last non -zero 
administra tion of nab -paclitaxel  or gemcitabine at Cycle u Day v: 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 28 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 If v=1, number of cycles on treatment = (u -1)+1/3  
If v=8, number of cycles on treatment = (u -1)+2/3  
If v=15, number of cycles on treatment = u  
 
PDI (dosing unit/unit of time) = planned dose intensity  
PDI is the assigned dose by unit of time planned to be given to subjects as per 
protocol in the same dose unit and unit of time as that of the dose intensity.  
PDI and relative dose intensity (RDI) is defined as:  
 
For canakinumab : 
- PDI is the planned dose as per protocol in mg (i.e. 250 mg Q4W)  
- RDI (%) = DI (mg/cycle) / PDI (mg/cycle) * 100  
For spartilizumab:  
- PDI is the planned dose as per protocol in mg (i.e. 400 mg Q4W)  
- RDI (%) = DI (mg/cycle) / PDI (mg/cycle) * 100  
For chemotherapy : 
- nab-paclitaxel  
o PDI is  the planned dose as per protocol in mg/m2 (i.e. 375 mg/m2/cycle)  
o RDI (%) = DI (mg/m2/cycle) / PDI (mg/m2/cycle) * 100  
- gemcitabine  
o PDI is the planned dose as per protocol in mg/m2 (i.e. 1000 mg/m2/cycle)  
o RDI (%) = DI (mg/m2/cycle) / PDI (mg/m2/cycle) * 100  
 
3.3.2.3  Vital signs  
 
Vital signs will be performed and assessed at the scheduled time points according  
to the Schedule of Events Table 5 -1 of the CSP. Vital signs include temperature 
(°C), heart rate (beats per minute), systolic and diastolic blood pressure (mmHg).  
Results will be graded by the low/normal/high classifications based on  normal 
ranges  CTCAE w ill be used to define low/high classification.  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 29 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  
3.3.2.4  Physical examination  
 
A complete physical examination will be performed at the scheduled time points  
indicated in Schedule of Events Table 5 -1 of the CSP and will include an assessment 
of the following: gene ral appearance, cardiovascular, abdomen, skin, neck , lymph  
nodes,  HEENT,  thorax/lungs , musculoskeletal , neurological  and other.  
An overall Investigator assessment of physical examination  will be provided 
(categories <“normal”, “abnormal, not clinically sig nificant” and “abnormal, 
clinically significant”>)  
 
3.3.2.5  Previous  and Concomitant  medications  
 
Medications and significant non -drug therapies received prior to, concomitantly (after 
the start of the study treatment) or post -treatment will be coded by Covance us ing 
the WHODrug Dictionary Version B3 (or a later version if updated during the study)], 
Anatomical Therapeutic Chemical (ATC) Classification codes.  
Prior medications and concomitant medications are defined as follows:  
Prior medications are those taken pr ior to study treatment with a stop date prior to 
the first dose date of study treatment (i.e. the earliest first dose of any of the 
canakinumab  or spartalizumab).  
Concomitant medications are those with a start date  on or after the first dose date 
of study  treatment , or those with a start date before the first dose date of study 
treatment and a stop date on or after the first dose date  of study treatment or 
ongoing end of study.  
Post-treatment medication s are those with a start date after the last dose dat e of 
study treatment.  
If a medication cannot be classified as “prior” or “concomitant” after applying 
imputation rules for missing/incomplete dates, it will be classified as concomitant.  
Missing coding terms should be listed and summarized as "Not coded".  
 
 
 
 

Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 30 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
   
  
 
4. Secondary Pharmacokinetic   (PK)  endpoint  
The secondary PK endpoint comprises PK concentrations and parameters of 
canakinumab, spartalizumab , gemcitabine and nab -paclitaxel . 
The specific Pharmacokinetic blood collection for canakinumab, spartalizumab, 
gemcitabine and nab -paclitaxel is outlined in Section 5.6 of CSP .  
Blood draws for canakinumab and spartalizumab will be performed on Days 1,8, 
and 15 of Cycle 1, and Day 1 of Cycles 2 -6 (pre-dose) , (8 days post dose of Cycle 5 
for canakinumab   and spartalizumab ) and at End of Treatment.  PK draws for both 
gemcitabine and nab -paclitaxel will be performed on Day 1 of Cycles 1 and 2 .  
All PK samples collected will be sent to Novartis.  
The merging of PK concentration data  for canakinumab, spartalizumab, gemcitabine 
and nab -paclitaxel  with  eCRF data, i.e actual PK sampling times  and actual doses 
or infusion duration  will be performed by Covance Clinical and Periapproval Services 
Limited, UK, who will also be responsible for the summaries, figures, and data 
listings.  
The non -compartmental analysis  will be c arried out by the Covance Clinical 
Pharmacokinetic Alliance (CPKA). Pharmacokinetic parameters will be derived using 
non-compartmental methods with Phoenix® WinNonlin® Version 8.1, or higher.  
The PK parameters to be reported are: AUC last Cmin, Cmax, tmax, and t last. Half-life 
(t1/2) may be estimated for nab-paclitaxel and gemitabine  if data allow . 
 
The actual sampling times will be used in the final plasma PK parameter 
calculations. If actual times are missing, nominal times may be used.  
Plasam concentratio n below assay lower limited of quantitation (BLQ) will be 
treated as zero if it occurs prior to the first quantifiable concentration; thereafter, 
any BLQs will be treated as missing for PK parameters calculation.  
Cmax, Cmin, tmax, and t last are observed va lues based on concentration -time profile. 
AUC last will be calculated using linear up -log down trapezoidal method.  

Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 31 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 5. Analysis populations  
5.1 All Screened  
 
All patients who consent to participate in the study and who undergo screening will 
be included in the All Screened population.  
5.2 Safety Analysis Set ( SAF)  
All patient s treated with at least one dose  of any of the constituent  study 
treatment s will be included in the safety  population .  
5.3 Full Analysis Set  (FAS)  
The full analysis set FAS is defined in the same way as the SAF in section 5.2 and 
will comprise all patient s who received at least one dose of any of the constituent 
study treatments.  
5.4 Dose-Determining Analysis Set (DDS)  
The dose determining set  (DDS) includes all patient s from the SAF who meet the 
minimum exposure criterion and have sufficient safety evaluations, or experienced 
a dose limiting toxicity (DLT) during the first two cycles ( 8 weeks) of dosing.  
A patient  meets the minimum exposure criterion if the patient  received:   
 2 doses of canakinumab (for Q4W dosing regimen cohort) or 1 dose of 
canakinumab (for Q8W dosing regimen cohort in case the canakinumab dose is 
de-escalated)  and 2  infusions of spartalizumab (full dose)  within the first 56 days 
(8 weeks) of study treatment  
 Takes at least 75% of planned doses of gemcitabine plus nab -paclitaxel 
chemotherapy within the first 56 days (8 weeks) of study treatment.  
If the patient  did not receive  the planned number of doses due to DLT, the patient 
will be considered as meeting the minimum exposure criterion.  Patient s who do not 
experience a DLT during the first 56 days (8 weeks) are considered to have 
sufficient safety evaluations if they h ave been observed for ≥56 days (8 weeks) 
following the first dose, and are considered by the dose level  review team (DLRT) to 
have sufficient safety data to conclude that a DLT did not occur . 
5.5 Pharmacokinetic Analysis Set (PAS)  
 
The Pharmacokinetic Analysis  Set (PAS) is defined for canakinumab, spartalizumab, 
nab-paclitaxel, and gemcitabine separately.  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 33 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 study they will be documented in a SAP amendment  and included in all relevant 
protocol deviation reviews an d approvals.  
6. DATA Handling  
6.1 Time points and Visit Windows  
 
Day 1 is defined as the day of first dose of study treatment . Relative days after Day 
1 are calculated as (assessment date – Day 1 date) + 1. Relative days prior to Day 
1 are calculated as (assessment date – Day 1 date).  
The day prior to Day 1 is Day -1.  
The following visit windows will be used for the by -visit a nalyses of  laboratory , ECG 
and vital sign data.  All other analysis will use the nominal study visit as defined in 
the Study Schedule and eCRF.  
Table 1  Definition of visit windows  
Visit Acceptable visit window  
Screening  Cycle 1 Day -28 to -3 
Cycle 1 Day 1  Cycle 1 Day  -2 to 4 (Day 1±3 days)  
Cycle 1 Day 8  Cycle 1 Day 5  to 11 (Day 8±3 days)  
Cycle 1 Day 15  Cycle 1 Day 12  to 18 (Day 1 5±3 days)  
Cycle 2 Day 1  Cycle 2 Day  -1 to 3 (Day 1±2 days)  
Cycle 2 Day 8  Cycle 2 Day 6  to 10 (Day 8±2 days)  
Cycle 2 Day 15  Cycle 2 Day 13  to 16 (Day 1 5±2 days)  
For Cycles > 2   
Cycle X Day 1  Cycle X Day -1 to 3  (Cycle X Day 1± 2 days)  
EOT -7 days to +14  days of date of l ast dose or dec ision to 
discontinue study treatment (whichever date comes later)  
30 Day Safety Follow -up EoT + 23 to EoT + 37 (EoT +30 ±7 days)  
60 Day Safety Follow -up EoT + 53 to EoT + 67 (EoT +60 ±7 days)  
90 Day Safety Follow -up EoT + 83 to EoT + 97 (EoT +90 ±7 days)  
120 Day Safety Follow -up EoT + 113 to EoT + 127 (EoT +120 ±7 days)  
150 Day Safety Follow -up EoT + 143 to EoT + 157 (EoT +150 ±7 days)  
  
NA = not applicable; EoT = Date of last dose ;  
 
Multiple  visits within the same window will be dealt with as follows:  
 If both scheduled and unscheduled visits fall within the same visit window, the 
scheduled visit will be used for analysis.  
 If multiple scheduled visits occur within a single visit window,  then the visit 
closest to the target day of the visit window will be used in the analysis.  If there 
is a tie, the later visit will be used in the a nalysis.>  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 34 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  If multiple unscheduled visit s occur within a single visit window (with no 
scheduled visit within the window) then the unscheduled visit closest to the 
target day of the visit window will be used in the analysis.  If there is a tie, the 
later uns cheduled visit will be used in the analysis.  
6.2 Handling of Dropouts, Missing Data, and Outliers  
 
No rules for outlier detection are planned.  
Missing safety data will generally not be imputed. However, safety assessment values 
of the form of “<x” (i.e. below the lower limit of quantification) or “>x” (i.e. above 
the upper limit of quantification) will be imputed as “x” in the calculation of summary 
statistics but displayed as “<x” or “>x” in the listings. Additionally, adverse events 
that have missing causalit y (after data querying) will be assumed to be related to 
study drug.  
For missing start AE dates, the following will be applied:  
 Missing day – impute the 1st of the month unless month is same as month of 
first dose of study drug then impute first dose date.  
 Missing day and month – impute 1st January unless year is the same as first 
dose date then impute first dose date.  
 Completely missing – impute first dose date unless the end date suggests it 
could have started prior to this in which case impute the 1st January of the 
same year as the end date.  
Note: When imputing a start date ensure that the new imputed date is logical,  i.e. is 
prior to the end date of the AE or treatment.  
For missing end AE dates, the following will be applied:  
 Missing day – impute the la st day of the month unless month is the same as 
month of the last dose of study drug then impute last dose date.  
 Missing day and month – impute 31st December unless year is the same as last 
dose date then impute last dose date.  
7. Statistical Methods  
7.1 General Principles  
All data processing, summarization and analyses will be performed using Covance’s 
SAS Environment / Version 9. 4 (or later) of the SAS statistical software package.  
Descriptive statistics will be used for all variables, as appropriate.  Summary 
statistics will be presented for continuous variables, by way of  number  (n), mean, 
standard deviation ( SD), median, minimum and maximum and by way of group 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 37 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 The number of patients that were screen failures as well as the number of patients 
screened but not assigned to treatment  will be produced. No other information for 
screen failures will be presented.  
7.3 Protocol Deviations  
All protocol deviations will be listed and summarized by dose level for the FAS. 
All important protocol deviations see section 5.6 will be listed and summarized by 
dose level  for the FAS population.  
7.4 Demographics and Other Baseline Characteristics  
 
Demographic and baseline characteristics will be listed and summarized by dose level  
and overall for the FAS. Standard descriptive statistics will be presented for the 
continuous variables of:  
 age (years) ; 
 baseline weight (kg);  
 baseline height (cm);  
 baseline body mass index (kg/m2) (BMI)  [calculated as (weight/height2) 
where wei ght is in kg and height is in m];  
 baseline body surface area (m2) (BSA) (calculated as ( [body weight0.425  (kg) 
× height0.725  (cm) × 0.007184]  or as ([sqrt(height (cm) × body weight 
(kg)/3600 ]), depending on  the formula each site has used ) 
 
The total counts and percentages of  patient s will be presented for the categorical 
variables of: 
 
 age group (years) ( grouped as < 65 and 65); 
 sex (Male, Female ); 
 race (White, Black or African American, Asian, Native Hawaiian or Other 
Pacific Islander, American India n or Alaska Native,  Multiple, Other ); 
 ethnicity  (Hispanic or Latino, Not Hispanic or Latino, Unknown);  
 childbearing potential for females (Yes, No);  
 tumor treatment history (medications, surgery, radiation ); 
 baseline  Eastern Cooperative Oncology Group (ECOG) performance status  
(Grade 0,1, 2, 3, 4, 5) ; 
 baseline Ca 19 -9 tumor marker  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 38 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  number of target  lesions (1, 2, 3) and locations of lesions (liver, lung, 
pancreas, lymph nodes, other)  
 baseline t uberculosis / hepatitis  status  (Present, Absent) ; 
 disease history or diagnosis ; 
o Pancreatic tumor location (Head, Body, Tail, Neck);  
o Disease type (Locally advanced, Metastatic) ; 
o Cancer type from biopsy pathology report (Ductal adenocarcinoma, 
Adenosquamous carcinoma, Mucinous adenocarcinoma, Hepatoid 
carcinoma, Med ullary carcinoma, Signet ring cell carcinoma , 
Undefferentiated c arcinoma , Undefferentiated carcinoma with 
osteoclast -like cells, Primary h istology , Secondary h istology , 
Other ); 
o TNM Classification at Initial Diagnosis  (TX, T0, Tis. T1a, etc.);  
o Prior anti-cancer therapies (Yes, No);  
 
 prior systemic therapy ; 
o Prior systemic therapy (Yes, No);  
o Treatment setting (Adjuvant, Neoadjuvant, Not Applicable);  
o Best Response ( CR, PR, SD, PD, NE, NA, NR NA);  
o Treatment regimen ending reason (Progressive Disease, Tox icity, 
Completion of planned regimen, Other);  
 
 prior anti -pancreatic cancer surgeries  
o Prior pancreatic cancer related surgery (Yes, No);  
o Surgery (Pancreaticoduodenectomy, Distal pancreatectomy, Total 
pancreatectomy, Other);  
o Location;  
o Outcome (No residual tumor after resection, Tumor/metastases not 
resected completely with microscopic residual lesions, not resected 
completely with macroscopic residual lesions; Metastases, Other)  
 
 prior anti -cancer radiotherapy ; 
o Prior cancer related radiotherapy  (Yes, No);  
o Radiotherapy site;  
No formal tests of statistical significance will be performed on the demographic and 
baseline data . 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 39 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 Other baseline measurements, such as vital signs, ECG, will be summarized by dose 
level with the post -baseline measurements.  
ECOG will be  also summarized by dose level.  
7.4.1  Medical History  
 
Medical history will be coded using the MedDRA Version 23.1 (or a later version if 
updated during the study)].  Relevant  medical history  and current medical conditions 
at baseline  will be listed, and the num ber and percentage of patient s with any medical 
history will be summarized  separately  for the FAS by system organ class (SOC) and 
preferred term (PT) for each dose level  and overall.   
7.4.2  Previous and Concomitant Medications  
 
Prior medications and concomitant medications will be listed together for the SAF . 
The number and percentage of patient s using each medication will be displayed 
together with the number and percentage of patient s using at least one medication 
within each t herapeutic class (ATC -Level 2), chemical subgroup (ATC -Level 4), and 
generic term  by dose level  separately for prior and concomitant medications . 
 
7.5 Efficacy  
7.5.1  Primary Efficacy Analysis  
 
7.5.1.1  Statistical Model, Hypothesis and Method of Analysis  
 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 40 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 For the dose confirmation of canakinumab and spartalizumab in combination with 
nab-paclitaxel and gemcitabine, a BLRM will be applied to estimate the relationship 
between dose and the probability of a patient experiencing a DLT. Some DLT data 
are available from previou s studies on single agent and combination of canakinumab 
and spartalizumab (PDR001X2101, ACZ885I2202, PRD001X2103) and a phase I/II 
study of nab -paclitaxel + gemcitabine ( Von Hoff D, et.al., 2011 ). These data will be 
incorporated into BLRM using a meta -analytic-predictive (MAC) approach 
(Neuenschwander et al 2016 ). The details are provided in Appendix  B of the CSP . 
The decision on dose tolerability will be based on the totality of all relevant data from 
the ongoing study and a review of safety data from the  first 8 weeks. A BLRM for 
combinations using the escalation with overdose control (EWOC) criterion to evaluate 
the risk of DLT will guide the decision. Additional information on the BLRM statistical 
model is provided in Appendix B of the CSP.  
 
7.5.1.2  Assessment of Patient Risk  
 
Dose recommendations will be based on summaries of the posterior distribution of 
DLT rates for each dose level of the respective combination therapy. After each cohort 
of patients, the posterior distribution for the risk of DLT for new pat ients at 
combination doses of interest will be evaluated. The posterior distributions will be 
summarized to provide the posterior probability that the risk of DLT for each dose 
regimen lies within intervals (33%, 100%).  
Dosing regimen decisions are guided by the EWOC principle ( Rogatko  et al 2007). 
The possibility of excessive toxicity is of interest in this study as the objective is to 
confirm the safety of the proposed dose regimen. A dosing regimen may only be used 
for newly enrolled patients if the risk  of excessive toxicity at that dosing regimen is 
less than 25%.  
Listing/Summary of DLTs  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 41 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 All DLTs will be listed and their incidences summarized by primary SOC, worst grade 
based on the CTCAE Version 5.0, type of adverse event, and by treatment group in 
the dose escalation. The DDS will be used for these summaries.  
Patients who are ineligible for the DDS will be excluded from the primary analysis 
(assessment of recommended dose using incidence of DLT during first 56 days of 
treatment with canakinumab in comb ination with spartalizumab, nab -paclitaxel and 
gemcitabine), although their data will be used for all remaining analyses.  
Reports on DLT Analysis  
Following reports will be produced for DLTs based on the DDS:  
 The table of summary posterior interval probabilities will be presented in the 
body of the clinical study report (CSR)  
 For each DEM, summary of recommendations will be included in Appendix 
16.1.9 of the (CSR)  
 
7.5.2  Secondary Efficacy Analysis  
Analyses of secondary efficacy endpoints  as defined in sec tion 3.2 will be performed 
in the FAS.  
ORR and DCR will be summarized by dose level.  Summaries will present the number 
and percentage of patients achieving disease control  (BOR of CR, PR and SD).  
The point estimate of the ORR along with the exact  Clopper -Pearson (exact CI for a 
binomial proportion)  95% CI will be reported  by dose level  in the FAS   
Accompanying KM estimates of the  median PFS  and OS  alongside associated 95% 
CIs will be presented by dose level  in the FAS (by investigator assessment) . The CI s 
will be derived based on Brookmeyer -Crowley method . 
KM estimates of PFS and OS at 3-monthly intervals  will also be presented  along with 
associated  95% confidence bands (derived based on Hall -Wallner method) .  
The TTR  and DOR . based on the investigator assessment of RECIST 1.1.  will be 
listed  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 42 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 7.5.3  Secondary Pharmacokinetic Analysis  
 
A listing of PK blood sample collection times as well as derived sampling time 
deviations and all reportable concentrations will be presented for each analyte 
(canakinumab, spartalizumab, nab -paclitaxel and gemcitabine) separately for all 
patients for the PAS.  Plasma concentrations will be summarised for the PK analysis  
set for each time point  by dose level using protocol scheduled times and 
appropriate descriptive statistics ( i.e., n, n below LLOQ, geometric mean [gmean], 
gmean+geometric standard deviation [gSD], gmean -gSD, geometric coefficient of 
variance expressed as  a percentage [gCV%], arithmetic mean [mean], arithmetic 
SD [SD], coefficient of variance expressed as a percentage [CV%], median, 
minimum and maximum.  
The gmean is calculated as exponential (μ), where μ is the arithmetic mean 
calculated using log transformed  data. 
The gCV% is calculated as 100 x sqrt[exp(s2)-1], where s is the SD of the log -
transformed data.  
The gmean±gSD (gmean -gSD and gmean+gSD) are calculated as exp[μ±s].  
Individual concentrations below the LLOQ of the bioanalytical assay will b e reported 
as Not Quantifiable ( NQ) in the listings with the LLOQ defined in the footnotes of 
the relevant tables, figures and listings.  
Individual plasma concentrations that are Not Reportable will be reported as NR and 
those that are missing will be repo rted as NS (No Sample) in the listings.  
Plasma concentrations that are NQ, NR or NS will be handled as follows for the 
provision of descriptive statistics:  
Any values reported as NR or NS or flaggged for exclusion by pharmacokinet icist 
(eg. due to con comitant medication , dose modification, etc ) will be excluded from 
the summary tables and corresponding figures.  
All concentration values below the lower limit of quantitation (LLOQ) are set to zero 
by the  Bioanalyst, and will be displayed in the listings as z ero and flagged.  
LLOQ values will be  treated as zero in any calculations of summary statistics, and 
treated as missing for the calculation of the geometric means and their CV%. The 
number of non -zero concentrations will  also be reported in the summary sta tistics.  
Missing values for any PK data will not be imputed and will be treated as missing  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 43 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 If all values are NQ at a time  point, no descriptive statistics will be calculated for 
that time  point. The gmean, mean, minimum, median and maximum will be 
reported  as NQ and gmean±gSD, gCV%, SD and CV% as NC.  
The number of values below LLOQ (n <LLOQ) will be reported for each timepoint 
together with the total number of collected values (n).  
Three observations >LLOQ are required as a minimum for a plasma concentratio n 
to be summarised. Two values >LLOQ are presented as a minimum and maximum 
with the other summary statistics as NC.  
Plasma concentrations that are NQ will be handled as follows for display in figures:  
 For gmean concentration -time plots: NQ concentrations will be handled as 
described for the descriptive statistics. If this handling results in a geometric 
mean of “NQ”, then the value plotted at that time -point will be zero for linear 
plots and set to missing for semi -logarithmic plots. Any gmean±gSD error 
bar values that are negative will be truncated at zero on linear concentration -
time plots and omitted from semi -logarithmic plots.  
 For individual plots and combined individual plots: NQ values prior to the first 
quantifiable concentration in that profile wil l be set to zero (linear plots only); 
after the first quantifiable concentration of the profile any NQ values will be 
set to missing.  
 
Plasma PK parameters such as mentioned below (if reportable) for each analyte 
separately  will be summarised for the PAS by dose level using the following 
descriptive statistics:  
 Cmax, Clast and AUC last, will present n, gmean, gmean+gSD, gmean -gSD, 
gCV(%), mean, SD, CV%, median, min and max.  
 tmax and t last will present only n, median, min and max.  
 t1/2 (if reported) will present n, mean, SD, CV%, median, min and max . 
It should be noted that not all PK parameters are applicable to all study drugs. For 
the calculation of summary statistics of PK parameters, all not reportable (NR) and 
not calculated (NC) values or parameters flagged for exclusion by the 
pharmacokineticist (eg. due to con comitant medication , dose modification, etc ) will 
be set to missing. Three reportable values are required as a minimum for a PK 
parameter to be summarised. Two values are p resented as a minimum and 
maximum with the other summary statistics as NC. If one or more values for a 
given parameter is zero (or imputed with zero), then no geometric statistics will be 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 44 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 calculated for that parameter and the results for geometric statisti cs will be set to 
“NA”, not applicable.PK concentration and parameter data from patients excluded 
from the PK analysis set will be included in the data listings, but not in the 
descriptive statistics or in mean figures or combined individual figures. Extra  
measurements (such as unscheduled or repeat assessments) will also not be 
included in summary tables, but will be included in patient listings.  
Individual plasma concentrations versus actual elapsed time after dose will be 
plotted on both the linear and s emi-logarithmic scales for  each analyte  (each 
analyte will have a different timeframe) . 
Combined individual plasma concentration versus actual elapsed times after dose 
will be plotted on both the linear and semi -logarithmic scale for each analyte 
separatel y. Plots will be grouped by dose level.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 45 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  
 
 
 
 
 
 
   
7.7 Safety  
 
The overall observation period will be divided into three mutually exclusive segments:  
 Pre-treatment period:  from day of subject’s informed consent to the day before 
first dose of study treatment  
 On-treatment period:  from day of first dose of study medication to 30 days after 
last dose of study treatment  
 Post-treatment period:  starting at day 30+1 after last dose of study treatment  
Safety summaries (tables, figures) will include only data from the on -treatment 
period with the exception of baseline data which will also be summarized where 
appropriate (e.g. change from baseline summaries)  and deaths, which will be 
presented for the on -treatment  and post -treatment period.  AE data will be 
summarised separately for the on -treatment and post -treatment period.  
 
7.7.1  Secondary Safety Analysis  
7.7.1.1  Adverse Events  
 
All adverse events (AEs) recorded on the eCRF will be coded using the MedDRA 
dictionary Version 23.1 (or a later version if updated during the study).  
Assessment of AE severity  will be based on the National Cancer Institute -Common 
Terminology Criteria for Adverse Events (NCI -CTCAE, version 5.0).  
The number of patients experiencing TEAEs (as defined in section 3.3.1.1 ) by 
MedDRA system SOC  (sorted alphabetically)  and or MedDRA PT  (sorted by 
descending overall total)  will be presented  for each dose level  and overall , with 
further splits by CTCAE  5.0 severity grade, causal relationship to study medication 
and type of adverse event . TEAE data will be summarised separately for the on -
treatment and post -treatment period   

Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 46 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 The relationship between an AE and each of study drugs is assessed as suspected 
or not suspect ed. A study drug -related AE is an AE considered by the investigator 
as related to study drug or with unknown/missing relationship to study drug. (AEs 
with unknown/missing relationship to study drug  will be summarized along with 
study drug related AEs and se parately). An overview table will summarize the 
number and percentage of patients with at least one of the following T EAEs by dose 
level, where patients with more than one T EAE in a particular category are counted 
only once in that category:  
 Any TEAEs ; 
 Any TEAEs causally related to treatment ; 
 Any TEAEs by maximum CTCAE severity  (Grade 1,  Grade 2 , Grade 3 , Grade 
4 [life-threatening ], Grade 5 [ death ]); 
 Any TEAEs of CTCAE grade 3 or higher causally related to any study 
treatment ; 
 Any TEAEs with outcome of death;  
 Any TEAEs with outcome of death causally related to treatment ; 
 Any TESAEs;  
 Any TESAEs causing discontinuation of each of the study medications ; 
 Any TESAEs causing discontinuation of each of the study medications ; 
causally related to treatment ; 
 Any TEAEs leading to dose interruption  (or to dose interval modified for 
canakinumab) of each of the study medications ; 
 Any TEAEs causing discontinuation of each of the study medications;  
 Any TEAEs causing discontinuation of each of the study medications; causa lly 
related to treatment;  
 Any AESIs  
 
The number and percentage of patients reporting each AE will be summarized by 
System Organ Class (SOC ), Preferred  Term (PT) and dose level  for the SAF.  Tables 
will be sorted alphabetically by SOC.  PTs will be sorted by descending overall total.  
The following summaries will be produced:  
 TEAEs, by SOC and PT;  
 TEAEs by PT;  
 TEAEs causally related to treatment, by SOC and PT;  
 TEAEs causally related to treatment, by PT;  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 47 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
   TEAEs by maximum severity  (mild, moderate, severe, l ife-threatening, 
death);  
 TEAEs of CTCAE grade 3 or higher , by SOC and PT; 
  TEAEs of CTCAE grade 3 or higher causally related to treatment, by  SOC 
and PT;  
  TEAEs with outcome of death , by SOC and PT;  
  TEAEs with outcome of death causally related to treatment , by SOC and PT;  
 TESAEs leading  discontinuation of each of the study medications , by SOC 
and PT;  
  TESAEs leading to  discontinuation of each of the study medications causally 
related to treatment,  by SOC and PT;  
  TEAEs leading to discontinuation of each of the study medications , by SOC 
and PT;  
 TEAEs leading to discontinuation of each of the study medications  causally 
related to treatment, by SOC and PT;  
  TEAEs leading to dose modification/ reduction  of nab-paclitaxek and 
gemcitabine , by SOC and PT;  
  TEAEs leading to dose interruption  (or to dose interval modified for 
canakinumab)  of each of the study medications , by SOC and PT;  
 AESIs by SOC and PT  
A summary of deaths  with associated primary reason fo r death  by dose level will be 
provided during the on -treatment and post -treatment  period separately . 
A separate summary will be produced that presents any adverse  events that occur 
prior to dosing (Pre-treatment period ) or starting more than 30 days after 
discontinuing therapy  (Post-treatment period ); 
The number and percentage of patients who reported treatment -emergent adverse 
events of  special interest will be summarized by SOC, preferred term and dose 
level. 
SOC names will be sorted alphabetically and, within each risk name, the preferred 
terms will  be sorted in descending order of frequency in the overall dose level . If a 
patient reported more than one adverse event with the same preferred term, the 
adverse even t will be counted only once. If a patient reported more than one 
adverse event within the same system organ class , the patient will be counted only 
once at that SOC. 
 
All AE data will be listed by dose level.  In addition, corresponding listings of serious 
AEs , deaths, SAEs, AESIs, AEs leading to discontinuation of study drug, AEs resulting 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 48 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 in death, AEs that led to dose reduction, discontinuation of treatment or death, and 
treatment -related AEs  will be produc ed and those starting during the pre -treatment 
and post -treatment period will be flagged.  Dose Limiting Toxicity AEs will be flagged 
as well. Deaths will also be listed and post -treatment deaths will be flagged.  
No statistical comparisons of AEs between dose levels  will be performed.  
7.7.1.2  Clinical Laboratory Evaluations  
 
Laboratory data ( biochemistry, hematology, and urinalysis) will be summarized by  
dose level and listed  as described below:  
Shift tables will be provided for select tests, where shift from base line to the worst 
on-treatment value will be summarized  using  CTCAE grades (for tests where grades 
are not defined by CTCAE , laboratory normal ranges will be used). Laboratory data 
outside the reference ranges will be indicated in the listings.  
Laboratory d ata absolute and change from baseline values for biochemistry, 
hematology and urinalysis will be summarized  at each scheduled assessment time  
by dose level .  
Continuous laboratory parameters will be summarized  with descriptive statistics. If 
a patient has multiple results for a particular test at a particular time window , the 
first non -missing scheduled value will be used for the summary  
Listings of all laboratory values for each patient will be presented with abnormal 
values flagged.  Abnormal lab values wh ich qualify as DLT will be flagged as well.  
Shift tables for laboratory values by worst common toxicity criteria (CTC) grade will 
be produced. For parameters with no CTCAE grading, shift tables from baseline to 
worst value on -treatment will be provided . 
For all laboratory variables included in the current version of CTCAE, the CTCAE grade 
will be summarized .    
Raw values and changes from baseline for laboratory data at each timepoint will 
presented using box  and whiskers  plots and any data not included b etween the 
whiskers should be plotted as outliers.  
Liver function parameters of interest are total bilirubin (TBL), ALT, AST, and alkaline 
phosphatase (ALP). The number (%) of participants with worst post -baseline values 
as per Novartis Liver Toxicity guid elines will be summarized:  
 ALT or AST > 3xULN  
 ALT or AST > 5xULN  
 ALT or AST > 8xULN  
 ALT or AST > 10xULN  
 ALT or AST > 20xULN  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 49 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
  TBL > 2xULN  
 TBL > 3xULN  
 AST and ALT =< ULN at baseline  
 ALT or AST >3x ULN & BILI >2x ULN  
 ALT or AST >3x ULN & BILI >2x ULN & ALP >=2x ULN  
 ALT or AST >3x ULN & BILI >2x ULN & ALP <2x ULN  
 AST and ALT > ULN at baseline  
 Elevated ALT or AST (*) & BILI (>2x Bsl and 2x ULN)  
 Elevated ALT or AST (*) & BILI (>2x Bsl and 2x ULN) & ALP >=2x ULN  
 Elevated ALT or AST (*) & BILI (>2x Bsl and 2x  ULN) & ALP <2x ULN  
* Elevated AST or ALT defined as: >3x ULN if =< ULN at baseline, or (>3x Bsl or 
8x ULN) if > ULN at baseline  
In addition, a listing of all TBILI, ALT, AST and ALP values for patients with a post -
baseline TBILI > 2xULN, ALT> 3xULN or AST  > 3xULN will be provided.    
A plot of maximum (worst)  post-baseline total bilirubin  vs maximum (worst) post -
baseline ALT , both relative to the ULN will be provided  with different symbols for 
different dose level  groups . This eDISH plot (evaluation of drug-induced 
hepatoxicity) will have reference lines at 3xULN for ALT and at 2xULN for total 
bilirubin. An additional eDISH plot might be considered of peak total bilirubin versus 
peak AST” if there are potential cases based on AST rather than ALT . 
Data for  the following hematology, biochemistry, and urinalysis analytes as presented 
in the below table  will be provided : 
 
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 51 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 The duration of (total or intended) exposure (in days) as well as dose intensity 
(percentage dose intensity and relative dose intensity) , as defined in sections 
3.3.2.1  and 3.3.2.2  will be listed and summarized separate for e ach study drug 
using descriptive statistics for each dose level  group  and by cycle  for the SAF.  
The number and percentage of patient s with duration of exposure in the following 
categories will also be summarized for the SAF:  
 ≤2 months  
 >2 and ≤6 months  
 >6 and ≤10 months  
 >10 months  
Total exposure will be summarized by  the following: mean, standard deviation, 
minimum, maximum, median and number of observations.    
Dose intensity data will be summarised using means, standard deviation, medians, 
and quartiles as  well as the minimum and maximum values  and number of 
observations . 
In addition, the number and percentage of patients with  neither dose interruption nor 
dose reduction , at one dose interruption or dose reduction,  at least one dose 
interruption, at least one dose reduction along with their associated reasons  where 
applicable  will be presented by dose level  and study drug . 
All dosing data will be listed.  
 
7.7.2.2  Vital Signs  
Vital signs as described in 3.3.2.3  will be listed by dose level, patient  and visit/time 
and summarized by dose level  and visit  and normal range groups   Vital sign values 
measured outside of on -treatment  period will flagged.  
Vital signs data and changes from baseline in vital signs will be summarized by visit 
and dose level using standard descriptive statistics for the SAF.   
 
7.7.2.3  Physical Examination  
Physical examination will be  summarised by dose level and listed  by dose level, 
patient  and visit/time . 
7.8 Interim Analysis  
No interim analysis will be performed for this study .  
Statistical Analysis Plan  
Sponsor Name: Pancreatic Cancer Action Network  
Sponsor Protocol ID: PanCAN -SRI  Labcorp  Study ID: 000000203412  
 
 CONFIDENTIAL  Page 53 of 53 
Document Date: 21Jul20220   ST-AD-008 version 05 
 11. Appendices  
Appendix 1: Document History  
Document Version, Status, Date  Summary/Reason for Changes  
Version 1.0, Final, ”16Sep  2022 Include revisions of Version 1.0  of 02Oct 
2020 and 18 Feb2022  (inclusive of updated 
definition  for exposure ) , 21Jul2022  & 
29Aug   
Version 1.0, Final, 02Oct 2020 Include revisions of Version 0. 2 
Version 0. 2, Draft, 04 Sep 2020 Include revisions of Version 0.1  
Version 0.1, Draft, 31 Jul 2020  Not applicable; the first version  
 
 
 